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Abstract 
Cancer has long been a global health concern and the recent resurgence of resistant 
microbial infections has led to the prediction that both of these issues will become the 
leading causes of death worldwide. As a result, there has been a push towards 
developing novel cytotoxic and antimicrobial agents. In this investigation, 14 different 
N4-Tetradentate Ligands (N4-TLs) and their respective copper(II) complexes were 
successfully synthesised and characterised. NMR and UV spectroscopy was used to 
characterise the ligands before coordination to copper(II). ESI-MS, UV spectrometry, 
and X-ray crystallography were used to characterise the copper(II) complexes, while 
CD spectroscopy was used to confirm chirality. The antimicrobial properties of the 
complexes were determined to be relatively poor in comparison with ampicillin and 
streptomycin, against S. aureus, K. pneumoniae and C. krusei microbial strains. 
However, several ligands and complexes demonstrated cancer potency with IC50 
values comparable to cisplatin. QDNA binding studies revealed that Cu1 and Cu2 
bound to QDNA at a ratio of 1:5 of metal complex to QDNA.  
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1.!Introduction 
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1.1.!Background  
While there are many health challenges that the global population faces, cancer is the 
second leading cause of death in the world.2 Antibiotic overuse and increasing 
microbial resistance to current antibiotics could overtake cancer as the leading cause 
of death, if novel antibiotics are not developed.3 Therefore, developing new cytotoxic 
and bacteriostatic drugs are crucial to improve global health. The term ‘superbug’ has 
been widely used in the media to report on the threat of increasing antibiotic 
resistance,4 which predicts a future where current antibiotics are no longer effective 
against microbial infections.5 The World Health Organisation (WHO) considers this 
issue as “the biggest threat to global health today”3 as the last decade saw an increase 
in the incidences of bacterial resistance,6 with 480,000 cases of multi-drug resistant 
tuberculosis, Shigella and Salmonella infectious strains, alone in 2014.7  
 
Each year, over 8 million people die globally of cancer.2 This number is expected to 
increase to around 13.6 million over the next 20 years. Current cancer treatments are 
similar to those used over 50 years ago and as a result, there is a need to develop 
effective, new treatments to ensure a healthy future for subsequent generations. As the 
cancer mortality rate increases, different strategies for anticancer treatments need to 
be explored.2 The increasing threat of bacterial resistance and deaths as a result of 
cancer, make research in these areas vital in increasing the life expectancy and quality 
of the global population. The necessity to develop both antibacterial and anticancer 
compounds that are potent and have a different mechanism of action, has compelled 
researchers to look beyond simple organic molecules for inspiration.   
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1.2.!Antibiotic Development 
Initial antibiotic development saw a drastic drop in deaths caused by bacterial 
infections. The first class of antibiotics, the !-lactams were developed in the 1930s 
following Alexander Fleming’s accidental discovery of penicillin (Figure 1.1 and 
1.2).8 Beta-lactam antibiotics are characterised by the presence of the beta-lactam ring, 
which binds irreversibly to serine/lysine residues on the active site, preventing cell 
wall synthesis in cell division and results in cell lysis.9,!10 Since the introduction of 
antibiotics into medicine, bacteria have had an increased exposure to !-lactams and 
over time, through natural selection, they have developed resistance by changing a 
single amino acid residue in the target enzyme to prevent drug binding.11, 12 In 
response, new antimicrobials were identified and synthesised to combat the developed 
resistance of microbes. They incorporate different structural design elements, which 
contribute to their altered mechanism of action and were classed accordingly. These 
new antimicrobials include aminoglycosides, tetracyclines and quinolones (Figure 1.1 
and 1.2). Aminoglycosides are structurally characterised by their amine and glycoside 
bonds. They act, by selectively binding to bacterial ribosomes to impeding protein 
synthesis.12 They were first synthesised in the early 1940s to combat the penicillin 
resistant tuberculosis causing bacterium, mycobacterium tuberculosis.13 However, 
within 10 years, resistance to the aminoglycosides was observed. This combined with 
the side-effects, such as impaired hearing upon administration, initiated the search for 
more antibiotic compounds.14  
 
 
!!! 4!
 
Figure 1.1 βeta-lactams (1), aminoglycosides (2), tetracyclines (3), quinolones (4), 
chloramphenicol (5) and erythromycin (6).  
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Tetracyclines were also introduced in the early 1940s and were found to be effective 
against Vibrio cholera, however when used in combination with chloramphenicol, 
their activity increased significantly against resistant strains.15 In the 1950s, the 
erythromycin class of antibiotic was developed. Erythromycin is characterised by the 
presence of a lactone ring and it was found to be effective against intestinal 
amoebiasis.16 These antibiotics act by preventing peptide elongation, which inhibits 
protein synthesis and cell division.12 Resistance to these antibiotics was subsequently 
observed in streptococci and staphylococci strains through methyl transfer by 
dimethylases.12, 17 As a result, several other classes of antibiotics, such as 
glycopeptides, rifampicins18 and quinolones (Figure 1.2),19 were synthesised to 
combat the various resistance mechanisms developed, but resistance was observed to 
these antibiotics as well.20, 21!As bacteria have been exposed to organic antibiotics for 
over 70 years, microorganisms have become adept at developing mechanisms to resist 
each antibiotic class .12 Current antibiotics on the market are organic compounds and 
researchers are now looking at introducing a metal, to thwart microbial resistance but 
profoundly changing the three dimensional structure and oxidation potential. 
!!! 6!
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Figure!1.2!Timeline!of!antibiotic!development.!
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1.3. Development of Cytotoxic Chemotherapeutic Agents 
Potential treatments for cancer have been around since the origin of formal medical 
practice, with reports of tumour patients being operated on without anaesthesia to 
excise the growth.22 Only in the middle of the nineteenth century could these 
operations be performed under anaesthetic, yet the lack of antibiotics contributed to a 
high number of post-operative wound infections.22 The introduction of gamma 
radiation therapy in the early twentieth century, reduced the incidences of sepsis as a 
result of tumour excision, however, all tumours did not respond to this type of 
treatment.22 The mid twentieth century led to the introduction of hormones and 
chemical compounds to act as chemotherapeutic agents, which utilised different 
mechanisms to destroy cancer cells or inhibit replication.22  
 
The development of modern anticancer chemotherapeutic agents began after World 
War II, when the effects of chemical weapons were discovered and investigated.22 
Researchers reported that nitrogen mustard gases inhibited cell division and resulted 
in these compounds being active against leukaemia and lymphomas.22 In the 1950s, 
the antibacterial compounds of the time were found to be cytotoxic, with 5-fluorouracil 
and 5-fluorouridine having ID50 values of 0.8 and 0.008, respectively (Figure 1.3).23 
These drugs were later deployed as chemotherapeutic agents, with 5-fluorouracil used 
to treat colorectal, breast, head and neck cancers24 and 5-fluorouridine for pancreatic 
cancer, acute myeloid leukaemia and non-Hodgkin’s lymphoma.25 Researchers 
hypothesised that by administering these compounds directly in the bloodstream close 
to the tumour site, they could reduce the adverse side effects that result from overall 
!!! 8!
systemic cytotoxicity.26 As the adverse effects remained unchanged, more compounds 
were developed to combat cancer.26  
 
Figure 1.3 Development of current chemotherapeutic agents.27 
 
Around the same time, researchers also developed metal complexes that demonstrated 
cytotoxic activity. In 1954, F.P Dwyer co-authored a paper which reported on the 
biological activity of 1,10-phenanthroline and 2,2′-bipyridine chelates of iron(II) and 
ruthenium(II) against mouse cell lines.28 Copper(II) and ruthenium(II) with 3,4,7,8-
tetramethyl-1,10-phenanthroline significantly inhibited the tumour growth observed 
with a single dose of 5 mg per kilogram per animal.29 However, as the cytotoxic dose 
for this complex is high, excess toxins had to be excreted from the body, causing renal 
toxicity.29 Therefore, similar compounds with a lower active dose were explored.30 
 
The current methods of cancer treatment include radiation and chemotherapeutic 
agents, however these methods also cause significant adverse side-effects and are not 
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always successful.31 Patients undergoing radiation therapy are often subjected to 
treatments from 3-7 weeks. Depending on the type of tumour, it utilizes ionizing 
radiation to damage DNA and prevent replication and cell division.32 
Chemotherapeutic agents were first introduced in the 1960s when Rosenberg and 
fellow researchers discovered that E.coli grew three times larger when exposed to a 
platinum electrode, which led to the development of cisplatin.30 Upon entering the cell, 
the 2 chloride groups of cisplatin are replaced by 2 aqueous groups, which facilitate 
binding to the adenine and guanine on each DNA strand, causing a cross-link that leads 
to apoptosis (Figure 1.4).30 As cisplatin treatment results in nephrotoxicity and 
neurotoxicity, there is a search for chemotherapeutic agents with less severe side-
effects.33  
 
 
Figure 1.4 Mechanism of cisplatin binding to DNA.34  
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Carboplatin was the second generation platinum anticancer drug introduced in 1973, 
with a structure comparable to that of cisplatin, as the chloride ligands were replaced 
with a bidentate cyclobutane-1-1-dicarboxylate ligand.33 While carboplatin is 
significantly less toxic compared to cisplatin, it causes a reduction in the white blood 
cell count of patients and makes them more susceptible to infections.33 Oxaliplatin 
gained clinical approval in 1999, and was found to be effective against colorectal 
cancers in combination with 5-fluorourcil.33 Oxaliplatin is similar to cisplatin and 
carboplatin as it is a square planar platinum(II) drug, however both its ligands, 1R,2R-
diaminocyclohexane, and oxalate are bidentate.33 Oxaliplatin is significantly less toxic 
compared to either cisplatin or carboplatin, however it is peripherally neurotoxic 
affecting the sensation of touch and cold in patients.33  
 
Nedaplatin was developed in 1983 by Japanese scientists, who reported that the 
complex exhibited a mode of action similar to cisplatin, while side effects such as 
nausea and vomiting were reduced.35 It also demonstrated increased potency in 
comparison with cisplatin, as well as reduced gastrointestinal and renal toxicity. It was 
used to treat head, neck, lung and cervical cancers.36 Heptaplatin was developed by 
Korean researchers in the 1990s and has been used to treat gastric cancers, it has also 
shown activity against cisplatin resistant leukaemia cells.37 It has proven to be more 
stable, less toxic and equally as active as cisplatin, but with a similar mechanism of 
action.37 Lobaplatin was first introduced to the market in 2003, and was reported to be 
10 times more active against cisplatin-resistant testicular cancer, and 20 times more 
active against cisplatin-resistant ovarian cancer cell lines (see Figure 1.5).38 However, 
it contributed to a number of adverse side-effects, including nausea and vomiting, 
although serious side-effects such as CNS and renal toxicity was not observed.38 The 
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side-effects of current anticancer agents as well as the lack of malignant tumour 
response to normal dosages, call for the development of new antimicrobial agents.  
 
 
Figure 1.5 Approved platinum chemotherapeutic drugs: cisplatin (PtII-1), carboplatin 
(PtII-2), oxaliplatin (PtII-3), nedaplatin (PtII-4), heptaplatin(PtII-5) and lobaplatin(PtII-
6).  !
1.4. Government Response  
The Australian Government, and its agencies, have identified microbial resistance and 
cancer as the biggest threats to the health and life-expectancy of Australians. The 
Australia Government’s Department of Health 2015 report39 into antimicrobial 
resistance investigated the significance of this issue and the implications on the future 
health of the country. The stated goal of this study was to “minimise the development 
and spread of antimicrobial resistance”, as well as ensure the continuous availability 
of effective antimicrobial agents. The report developed a series of objectives; which 
centred around increasing the awareness of the issue, better management of prescribing 
antimicrobials, infection prevention and control. It also set up a national research 
agenda to nurture international research relations. It found that Australia had one of 
the highest daily doses of antibiotics per capita in comparison to other developed 
!!! 12!
countries, such as Germany and the UK (Figure 1.6). Therefore, reducing the number 
of daily doses was another specified objective.  
 
Figure 1.6: Volume of antibiotics prescribed in different countries.39  
 
Similarly, Cancer Australia’s 2016-2017 report highlighted the importance of 
anticancer research by establishing a dedicated budget, guiding scientific 
improvements of cancer prevention/treatment and providing financial assistance for 
research.40 It was also reported that both incidences and mortality were projected to 
increase in the next 2 years.40 Researchers in 2012 reported that earlier diagnosis of 
metastatic cancers, preventative measures and more cancer research progress were the 
top priorities for Australians,41 therefore it remains a government research focus.  
 
1.5. Antimicrobial Metal Complexes 
While most antibiotics on the market are organic compounds (see Figure 1.2), metal 
complexes have also demonstrated bactericidal activity. The Australian inorganic 
chemist, Frank Dwyer synthesised various Ru(II), Co(III) and Cu(II) complexes 
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throughout his career and reported on their biological activity.42 Co(III) and Ru(II) 
complexes coordinated to phenanthroline and bipyridine ligands demonstrated 
bacteriostatic activity against Escherichia. coli and Staphylococcus haemolyticus.43 
These complexes showed significant topical activity against bacteria in mice and when 
they were administered intraperitoneally, it was excreted more quickly than absorbed 
by the digestive tract. Therefore these complexes were ineffective against internal 
bacterial infections and as a consequence, the development of this type of antibiotic 
was abandoned due to narrow activity target range.44 However, with the emergence of 
biofilms and resistant bacteria, researchers are compelled to re-investigate topical 
treatments against biofilms as they grow on epithelial and tissue surfaces.45  
 
Iridium and cobalt complexes are active against Staphylococcus aureus bacterial 
strains and gram-positive resistant bacteria that are often contracted in hospitals.46 
Ruthenium complexes have also shown antimicrobial activity against Bacillus subtilis 
and S. aureus strains.47 In 2014, researchers reported that complexes containing copper 
were effective in reducing the formation of biofilms and could potentially be 
developed into new drugs to combat resistance.48, 49 Researchers have also reported 
that silver and its complexes demonstrate anti-biofilm properties.50, 51 Recently in 
2016, researchers reported that metal oxide complexes of vanadium exhibited 
significant bactericidal activity against 10 strains of microbes compared to the [(3-
methoxy-2-oxidobenzylidene)benzohydrazidato] ligand alone.52, 53 Derivatives of 
1,10-phenanthroline (phen) displayed cytotoxic properties when coordinated to 
platinum(II),54 however when co-ordinated to copper(II) they were more bactericidal 
activity than the ligand alone (Table 1.1).49 Recent efforts have focused on developing 
tetradentate ligands with nitrogen donor atoms (N4-TLS) to coordinate to Cu(II).55 
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Once coordinated to Cu(II), complexes had greater antimicrobial properties than the 
ligand alone.56 In particular, Cu(II) coordinated to Schiff bases exhibited a lower 
minimum inhibitory concentration (MIC) and were reported to be more antibacterial 
(see Figure 1.7).57-59 
 
Table 1.1: MIC of 1,10-phenanthroline and derivative ligands together with the Cu(II) 
complexes after 25 min of exposure at 37 °C.20  
 S. aureus E. coli P. aeruginosa S. cerevisiae 
Ligands     
1,10-Phenanthroline(phen) >20 >20 >20 >20 
4,7-diphenylphenanthroline (DIP) 5-10 >20 >20 >20 
5-chloro-1,10-phenanthroline >20 >20 >20 >20 
Complexes     
[Cu(DIP)(SS-dach)](ClO4)2 1.25-2.5 10-20 >20 >20 
[Cu(phen)(SS-dach)](ClO4)2 10-20 >20 >20 >20 
[Cu(5Clphen)(SS-dach)](ClO4)2 5-10 >20 >20 >20 
 
!
Figure 1.7: Structure of antimicrobial Schiff base in metal complexes.60 
 
The polypyridyl-ruthenium(II) complex of [{Ru(2,2:6,2-terpyridine)Cl}2{bis-[4(4-
methyl-2,2-bipyridyl)]] (Figure 1.8) demonstrated increased antibacterial activity 
against E. coli and B. subtilis.61 Researchers reported that the presence of a coordinated 
chloride, as well as increased chain length contributed to increased antimicrobial 
activity.61 In 2011, Keene and Collins investigated mono-, di-, tri- and tetranuclear 
ruthenium(II) complexes and found the dinuclear complexes to be active against both 
Gram positive, and negative bacteria (see Figure 1.8).62 They reported that the 
complexes have a low MIC value of 1 µg/mL against MRSA and S.aureus and that 
!!! 15!
the presence of methyl groups on phen ligands increased their bacteriostatic activity.62 
They also were active at a slightly higher concentration against E.coli (2-4 µg/mL) and 
P.aeruginosa (8-16 µg/mL).62 
 
Figure 1.8: Dinuclear polypyridylruthenium(II) complexes (n=2,5,7, 10, 12, 14 or 
16)62 
 
In 2015, researchers investigated the antibacterial activity of an asymmetrical 
tetradentate ligand as well as its chromium, iron, cobalt, nickel, copper, and zinc 
complexes (Figure 1.9).63 They utilised the disk diffusion method and reported that the 
metal complexes were more bactericidal than the ligand alone.63 They reported that 
the complexes were active against S.aureus, E.coli, B.subtilis and K.pneumoniae.63 
The reason for this increased activity is still unknown but could be attributed to the 
metal adding charge and allowing the complex to partition into cells.64 The unique 
geometry of the complex could also yeild a favourable binding interaction.65 
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Researchers in 2014, investigated complexes of Ni(II), Cu(II) and Co(II) coordinated 
to fluoroquinolones and reported that metal complexes of ternary ligands were more 
stable and exhibited greater antimicrobial activity in comparison to complexes of 
bidentate ligands.65 Hence, when developing new antimicrobials, the choice of metal, 
the resulting geometry of the complex, and its solubility all need to be taken into 
consideration. Recently, the N4-TL, N',N'-dimethyl-N',N'-bis(2-pyridylmethyl)-1,2-
ethanediamine, was synthesised and coordinated to manganese(II) and iron(II),66 
although no antibacterial activity was determined.66 There is potential that these N4-
TLs (both Schiff base and reduced) and their metal complexes could be bactericidal, 
therefore, assessing their biological activity would provide a new dimension to the 
development of new antibacterial agents. 
!
Figure 1.9: Asymmetric Schiff base ligand that was co-ordinated to different metals.63 
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1.6. Cytotoxic Metal Complexes 
With the release of cisplatin and other platinum complexes into the clinic, research 
interest increased to improve platinum anticancer drug design.67 Ruthenium, gold, 
titanium and palladium complexes have all been reported to  exhibit anticancer 
activity.33 Octahedral ruthenium(II) complexes have a different mechanism of action 
to cisplatin and its square-planar analogues, which allows them to target cisplatin 
resistant cell lines.68 The majority of anticancer ruthenium(II) complexes contain 
nitrogen or sulphur donor atoms, which is indicative of the significance of these 
coordinate bonds on the mechanism of action (see Figure 1.10).68 While ruthenium 
complexes are active against cisplatin resistant cell lines, they are still toxic and 
therefore studies to refine and produce an active but less toxic product is ongoing.68  
Gold(I) and (III) complexes have been reported to be anti-proliferative in vitro for 
ovarian and leukaemia cancer cells (see Figure 1.10).69 Evidence suggests that their 
mechanism of action is through “protein metalation”, where the gold complex modifies 
selected proteins, which lose their function and prevent tumour growth.70 Gold 
complexes coordinated to nitrogen or sulphur were reported the most cytotoxic.70 
There is still ongoing research to design and synthesise ligands that coordinate to gold 
to increase the in vitro activity.70 
 
Titanium(IV) complexes are also octahedral but the highly charged ion makes 
complexes unstable in water and blood.33 In the 1970s, was reported, titanocene 
dichloride (Figure 1.10) was reported to demonstrate anticancer activity against 
Ehrlich ascites tumour cells and to be less cytotoxic than cisplatin, with no observed 
myelotoxicity or nephrotoxicity.33 The lack of stability of this complex led researchers 
to develop more stable chemotherapeutic agents.33 Recently, Ti(IV) coordinated to the 
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tetradentate ligands, salen, and salan, were found to have cytotoxicity in liver and 
cervical cancer cell lines, yet with higher IC50 values than for cisplatin.71  
 
Following the development of cisplatin, palladium(II) was also investigated because it 
is isostructural with platinum.33 Like cisplatin, PdCl2 is a covalent groove binder and 
utilizes the same cell pathway to cause apoptosis. The cytotoxicity against breast 
cancer (MCF7) and leukemia (CCRF-SB) was determined for [PdCl2] and 
[Pd(pyridine)Cl2] with the pyridine complex found to be cytotoxic (see Figure 1.10).72 
Despite the reported cytotoxicity, it also induces similar side effects to cisplatin.33  
!
Figure 1.10 Ruthenium (1)68, gold (2)69, titanium (3)33 and palladium (4)72 cytotoxic 
metal complexes. !!
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1.7. N4-Tetradentate Ligands (N4-TLs) 
N4-TLs are organic ligands characterised by the presence of four nitrogen donor atoms, 
which enable them to coordinate to either single or multiple metal centres. The ligands 
are synthesised via Schiff base intermediates and many have been reported to have 
antibacterial potency.73 Complexes of these ligands have also been reported to exhibit 
bacteriostatic activity.73, 74 In 2015, researchers investigated the antimicrobial activity 
of a hydrazone hesperetin Schiff base (HHSB) ligand and the resulting copper(II) 
complex (see Figure 1.11).75 They reported that though the Schiff base ligand did not 
exhibit any antibacterial activity, when coordinated to Cu(II) the complex was 
bacteriostatic against E. coli and S. typhimurium.75 While this Schiff base ligand 
contained both nitrogen and oxygen donor atoms, a similar ligand with only a single 
nitrogen donor also exhibited an increase in biological activity.60 The Co(II), Cu(II), 
Mn(II) and Zn(II) complexes of [2-(bis-2-hydroxyl phenylidene)diimmine] were 
investigated and all exhibited activity, apart from Mn(II).60 While there has been some 
research into the antimicrobial activity of Schiff base ligands and the complexes they 
form, a systematic comparison with the reduced ligands and the resulting copper(II) 
complexes has not been explored.66  
!
Figure 1.11 Cu(II) HHSB complex.75 
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In 2007, researchers investigated the IC50 values of [Cu(2-(2-(2-hydroxyethylamino)-
(ethylimino)methyl)phenol)Cl2] and [Cu(2-(2-bydroxyethylamino)-
((ethylimino)methyl)phenol)(phen)]Cl2 (Figure 1.12).1 They discovered that when 
copper(II) coordinated to this N4-TLs the IC50 value lowered from 54.54 ± 1.00 to 0.29 
± 0.05 µM after 48 hours of treatment.1 This suggested that N4-TLs were more 
cytotoxic than a N2-bidentate ligand and hence investigation into copper(II) N4-TLs is 
warranted. In 2013, researchers at the Massachusetts! Institute of Technology, 
developed a platinum(II) complex with a N4-TL, β-diketiminate quinolone, and 
reported that the cytotoxicity in A549 cancer cell lines (of 1.2 ± 0.2 µM) was better 
than for cisplatin (5.2 ± 1.0 µM).76 Another N4-TL  , N-benzyl-N’,N’-bis(3,5-dimethyl-
1H-pyrazol-1-yl)-2-methy]-1,2-ethylenediamine,  was reported to demonstrate 
activity against A549 lung cancer cell lines with an impressive IC50 value of 1.71 µM. 
However, upon coordination to Cu(II) this value improved to 0.107 µM. Hence, these 
N4-TLs exhibit improved chemotherapeutic potential when coordinated to a metal (see 
Figure 1.12).77    
 
 
 
 
 
 
Figure 1.12: Cytotoxic N-donor Cu(II) complexes; 2007 Cu(II) complex (left),1 Cu(II) 
complex active against A549 lung cancer cell lines (right).77 
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1.8. Biological Activity of Copper(II) 
Simple copper(II) salts exhibit antimicrobial properties78 and as a result are used 
prominently in hospital equipment.79 Copper coated surfaces in hospitals contain 90-
100% fewer microorganisms than non-copper coated surfaces.80 Therefore, there has 
been a proliferation of copper coated/based equipment in recent years. However, some 
bacterial strains have developed resistance, therefore copper(II) complexes are been 
reinvestigated to thwart this resistance.81 While Dwyer’s work in the 1960s reported 
that Cu(II) complexes were active against M. tuberculosis, S. aureus and S. 
pneumonia, there has since been little investigation of the antimicrobial potential of 
these complexes.43 In 1994, researchers investigated the antibacterial activity of Cu(II) 
coordinated to sulfacetamide (see Figure 1.13) and found it to be more effective than 
the sulfacetamide ligand alone, particularly against S.aureus.82 In 2004, researchers 
investigated the anti-fungal activity of Cu(II) coordinated to bidentate nitrogen donor 
ligands (see Figure 1.14)83 and reported that they were active against many species 
including E.coli, S.aureus and P.aeruginosa.83       
!
Figure 1.13: Antimicrobial Cu(II) sulfacetamide complex.82 
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More recently in 2012, [Cu(4,7-di-phenyl-1,10-phenanthroline)(glycine)H2O]NO3 
was reported to be effective against S. aureus (see Figure 1.14).84 In 2013,57 the 
biological activity of [Cu(phen)(SS/RR-dach)]2+ was assessed against E. coli, S. 
aureus, P. aeruginosa and S. cerevisiae with both enantiomeric Cu(II) complexes 
demonstrating significant bacteriostatic activity. !
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: New bacteriostatic Cu(II) complexes developed recently.  
 
 
While copper is known to exhibit antimicrobial properties, it also demonstrates 
cytotoxic properties. In the late 1960s, cytotoxic copper complexes were reported to 
also bind strongly to DNA. Later it was reported that [Cu(phen)2]2+ cleaved DNA in 
vitro, which led to the formation of oxyradicals.88 Oxyradicals react with DNA to form 
adducts, which leads to mutation and apoptosis.89 Copper also has a broad range of 
activity and lower toxicity, making it a viable metal to use in the development of new 
chemotherapeutic agents.86 Previously, Dwyer’s work had also revealed that 
[Cu(3,4,7,8-tetramethyl-1,10-phenanthroline)2Cl2] was cytotoxic against Landschutz 
ascites tumour cells.29 In the late 1970s, researchers investigated the effect of 
copper(II) on the cytotoxicity of bleomycin. They reported that in combination they 
2012 2013 2004 
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were more cytotoxic than bleomycin alone, while the toxic side-effects associated with 
chemotherapy did not increase.87  
 
1.9. Characterisation Techniques 
1.9.1. Nuclear Magnetic Resonance (NMR) 
Nuclear Magnetic Resonance (NMR) spectroscopy utilises two external magnetic 
fields to ascertain the magnetic field responsible for energy level splitting within 
compounds. It measures the difference between the ground and excited nuclear spin 
states, which is unique to each compound.90 NMR samples can be liquids or solutions 
yielding spectra with unique chemical shifts.91 NMR experiments (1H, 13C, 1H-1H 
HMQC, 2D correlation (COSY) allow various chemical shifts to be expressed in the 
overall spectra and this provides information about the structure.91,92 NMR 
Spectroscopy observes the nuclear spin present in nuclei that contain an odd number 
of protons or neutrons.91 Different nuclei have different nuclear spin, which is a 
characteristic of specific isotopes, however if a nucleus has both an even number of 
protons or neutrons it is “NMR silent”.91 NMR silent nuclei, do not exhibit nuclear 
spin and therefore cannot be characterised using NMR spectroscopy.91 
Characterisation of the N4-TLs will be conducted using 1H, 13C experiments and when 
required 2D correlation NMR spectroscopy (COSY) experiments. As copper(II) is 
paramagnetic, its complexes are only weakly attracted to external magnets and its large 
shielding affects other nuclei in the compound.93, 94 Therefore, 1H, 13C and COSY 
NMR spectroscopy could not be used to characterise the complexes.95 !!!
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1.9.1.1. 1H NMR spectroscopy 
Proton NMR spectroscopy distinguishes between different chemical environments of 
protons within a N4-TL and it displays (on a ppm scale) different chemical shifts to 
produce a spectrum.91 Hydrogens are characterised by the atom and functional groups 
they are attached to. If multiple hydrogens are the same, then the integral of that 
particular hydrogen peak increases with respect to the number of hydrogens of that 
type. This type of NMR analysis is useful to quickly ascertain product purity when 
evaluating products of intermediate reactions. When different types of hydrogens are 
in close proximity and have the same spin-spin coupling constant, the conformation of 
compounds can be understood better by using 1H-1H COSY experiments. 
 
1.9.1.2. 13C NMR spectroscopy92 
13C NMR spectroscopy was not developed till 1951 and only in the early 1960s was 
the first 13C-NMR spectra recorded and this increased the use of this type of NMR. 
With the introduction of Fourier transform (Ft) NMR spectrometers in the 1970s, this 
enabled better resolution and 13C spectra to be obtained more quickly.96 13C nuclei are 
around 5700 times more sensitive than protons and are also particularly useful for 
biological testing.97 This type of spectroscopy coupled with proton NMR has provides 
better structure elucidation as it elucidates the relationships of each type of hydrogen 
to the carbon spectra.98 It is useful in characterising amino acid bonds and therefore 
can be used to identify protein binding.96  
 
1.9.1.3. 2D Correlation NMR spectroscopy (COSY) 
COSY or correlation spectroscopy is a two dimensional spectroscopy which 
characterises how each proton type is coupled to each other.91 COSY can be used to 
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ascertain how different proton types correlate to each other (1H-1H ) as well as how 
the protons within a molecule correlate to the carbons (1H-13C).99 Therefore, this type 
of spectroscopy can also provide confirmation of the location of different protons in 
relation to others within the molecule, providing information on the three dimensional 
structure of a compound.99 Both 1H and 13C NMR are particularly useful in 
ascertaining the structure of the N4-TL, however the intensities of some peaks can 
overlap, which can hinder structure elucidation.99  
1.9.2. Circular Dichroism Spectroscopy (CD) 
CD spectroscopy utilises an oscillating magnetic field to form a propagating sinusoidal 
electromagnetic wave.100 As this wave generates a left and right handed circularly 
polarized light, it can be used to distinguish between different chiral compounds.101 
CD spectra are obtained over a wavelength range for chiral compounds.102 For achiral 
molecules, the difference between left- and right-handed absorbance equals zero, 
hence the spectral absorbance would equal zero and no spectrum would be evident.102 
It is often used to determine secondary protein folding structure,101 as well as DNA 
binding affinity.103  
1.9.3. Electrospray Ionization Mass Spectrometry (ESI-MS) 
ESI-MS is a characterisation method which characterises compounds using their mass 
to charge ratio (m/z).91 The m/z is ascertained through an electrical signal, which yields 
a peak upon ionization.104 The abundance of a particular sample is represented by the 
intensity of the peak.104 Once a sample is introduced to a mass spectrometer, it is 
ionised through rapid evaporation of the solvent (electrospray) yielding the naked ions 
of the sample.91 These ions are then separated by their mass and detected, the time of 
flight (TOF) is used to measure the mass of different ions based on the time required 
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by each ion to travel a fixed distance.91 Different types of mass spectrometers can be 
used to obtain data with different specifications and combing different instrument 
types in tandem can provide more accurate spectra.104 The Quadrupole Time of Flight 
(QToF) utilizes four parallel poles opposite each other, with opposite pairs electrically 
connected. The sample is then introduced through the quadrupole before collision 
induced dissociation and the TOF is analysed (see figure 1.15).104 This type of 
instrument is useful as it selects ions with a particular m/z to pass through a collision 
induced dissociation cell for the TOF to be measured.104 
 
Figure 1.15: QTOF mass spectrometry.104 
1.9.4. Ultraviolet-Visible Spectroscopy (UV-Vis)91 
Ultraviolet-visible (UV-Vis) spectroscopy is a type of absorbance spectroscopy that 
refers to the region of light within the electromagnetic spectrum, between 200-800 nm. 
To obtain an absorbance spectrum, light is emitted through the sample over a 
wavelength range. The spectrum is displayed as absorbed energy verses wavelength, 
with peaks corresponding to absorption minimums. The UV spectrometer functions by 
passing light from a radiation source through a sample. Light then passes through a 
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dispersing device and slit before reaching the detector, which measures the amount of 
light that remains and calculates the amount of light absorbed (see Figure 1.16). UV 
spectroscopy can be used to obtain the molar extinction coefficient, which is a 
characteristic of a compound. It is a measure of how a particular species attenuates 
light at different wavelengths and provides useful characterisation information. The 
UV spectrum of each N4-TL and Cu(II) complex produces characteristic peaks of 
different intensities, and the molar extinction coefficient is determined for each. 
Figure 1.16: UV-vis Spectroscopy.91  
 
1.9.5. X-Ray Crystallography  
X-ray diffraction crystallography of compounds are obtained when a beam of light hits 
a crystal and the structure within diffracts the light.105 This can then be measured to 
obtain bond angles of different parts of the molecule to provide an accurate 
representation of the structure.105 This characterisation method is useful as individual 
atoms can be seen through the X-ray beam scattering in different patterns and it 
provides information on the location of atoms within the crystal.105 Once data is 
collected, the intensities and direction of the reflections are measured in a 
diffractometer to provide a 3D structural model.105 This structure is then resolved into 
one of 230 space groups in crystallographic software based on the electron density 
map produced by x-ray interactions.105 This type of characterisation is essential to 
obtain structures of synthesised copper complexes.  
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1.10. Biological testing 
Synthesised N4-TLs/complexes need to be tested against different biological species, 
either microorganisms or cell lines to ascertain their potential as effective 
treatments.106 Investigating the bacteriostatic activity and cytotoxicity provides key 
information as to how the different components and structures of a complex affects the 
interaction with the organisms.107 There are specific types of testing that can be used 
to determine if a compound could also act as an antibacterial, antifungal or anticancer 
agent. Further testing is required to determine how compounds are metabolised, the 
potential side-effects, as well as stability in different biological environments.108 For 
this reason antibacterial and anticancer testing is an important part of preliminary 
investigation, as it identifies compounds/complexes that are worthy of further 
investigation. When investigating the antibacterial activity of inorganic compounds, 
Minimum inhibitory concentration testing(MIC) will be used.  
 
1.10.1. Minimum Inhibitory Concentration Testing (MIC) to assess Antibacterial 
Activity  
The MIC is the lowest concentration of an antimicrobial agent that will inhibit the 
growth of organisms after incubation for a specific period of time.109 It is used in 
diagnostic laboratories to identify the presence of antibiotic resistance and to evaluate 
the antimicrobial activity of the prepared complexes.109 Samples are always evaluated 
against proven antibiotics, to confirm activity.109 Typically overnight cultures of 
different types of microorganisms would need to be sub-cultured and the optical 
density measured to calculate the colony forming units (CFUs). A uniform 
concentration of cells in each strain are added to the 96-well plate containing different 
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compounds/antibiotics and incubated overnight. The plates are read before and after 
incubation to measure the bacteriostatic activity. This provides an assessment of 
antimicrobial activity, however it cannot determine the amount of the antimicrobial 
agent entering the cell.  
 
1.10.2. Cell Line Testing to assess cytotoxicity 
Cell culturing technique refers to the process by which cells are grown outside of the 
body and it has been in use since 1885, when a chicken embryo in saline solution was 
maintained for eight days.110 Over the next 80 years, cell culturing techniques have 
progressed with the development and use of a variety of cell lines.110 Cells require 
specific nutritional and environmental specifications to grow in vivo. Different types 
of media containing amino acids, sugars, salts and vitamins are used to promote cell 
growth upon sub-culturing.110 Once cells are successfully sub-cultured, IC50 values can 
be obtained after incubation with a potential cytotoxic agent. IC50 values are defined 
as the lowest concentration required to kill 50% of cells in the assay, therefore the 
lower the IC50 value the more potent the anticancer agent.110  
 
1.10.3. G-Quadruplex DNA (Q-DNA) Binding Studies 
Deoxyribonucleic acid (DNA) form various structures, from double helices to triplexes 
and quadruplexes.111 G-Quadruplex DNA (Q-DNA) occurs when guanine(G) rich end 
regions of a DNA strand (telomeres) fold to form G-tetrad structures.112 G-tetrads form 
when four G-residues align in a square planar formation by Hoogsteen hydrogen 
bonds.112 Q-DNA can form various structures, with parallel, antiparallel, and single 
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strand intramolecular quadruplexes.111 Telomeres protect chromosomal ends, however 
they shorten after each mitotic cell cycle and lead to apoptosis.111 The maintenance of 
telomeric length has been associated with cancer,113 therefore developing complexes 
that bind to Q-DNA can stabilise its structure and prevent it from unfolding. This 
would then stop unchecked cell division.114 Recent binding studies have reported that 
large planar molecules interact with Q-DNA and stabilise the folded structure.114 Here 
binding experiments will use the c-MYC oncogene, because it regulates cell 
proliferation, arrest, differentiation and death, is responsible for accelerating cells 
through the cell cycle and through overriding checkpoints, it causes tumour growth 
(see Figure 1.17).115 Binding studies are useful to identify compounds that bind to Q-
DNA and could potentially interfere with telomerase activation to stop unchecked cell 
replication.114 ESI-MS can be utilised to assess Q-DNA binding.112 In these 
experiments an example of the c-MYC oncogene from the Protein data bank (ID: 
1XAV) will be used. The mass of 1XAV and metal complex is used to identify binding 
at different ratios to Q-DNA112 The change in m/z peaks in the spectra of the Q-DNA 
alone and that with added metal complex are compared to evaluate at which specific 
ratios the copper complex forms a stable association. It is a useful tool to analyse the 
binding affinity.112 
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Figure 1.17: Structure of the human oncogene, c-MYC promoter, a monomeric 
parallel –stranded quadruplex. (1XAV).116 
 
1.11. Project Aims 
The aims of this project were to synthesise and characterise a series of Schiff base 
(red), and reduced (blue) N4-tetradentates (N4-TLs, Figure 1.18) and subsequently 
coordinate them to copper(II). The resulting complexes were characterised, using 
NMR, UV, CD, and ESI mass spectrometry, as well as X-ray crystallography, where 
crystals were obtained. The antimicrobial and anticancer activity of the N4-TLs and 
Cu(II) complexes was assessed to determine their potency. Antibacterial activity will 
be ascertained against S. aureus, K. pneumoniae and C. krusei, whereas the anticancer 
activity will be determined using A2780 ovarian cancer cell lines. The DNA binding 
affinity was assessed against QDNA as the planar structure of the copper complexes 
should enable them to effectively end-stack. The insights gained from this work will 
inform the design of drugs to more successfully treat bacterial resistant infections or 
cancer.45 
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Figure 1.18: 14- N4-TLs that will be coordinated to copper(II) in this project. 
!!
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2.!Materials and Methods
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2.1. Materials 
All reagents that were commercially available were used without further purification. 
MilliQ™ water was used throughout. Copper(II) perchlorate (CuClO4), 2-pyridine 
carboxaldehyde, 1,2-diaminoethane, ethyl acetate, sodium carbonate (anhydrous), 
sodium borohydride, formaldehyde, formic acid, dichloromethane and sodium 
hydroxide were obtained from Sigma-Aldrich. Organic solvents ethanol, diethyl ether, 
acetonitrile and methanol were of analytical grade and purchased from Chem-supply 
and DMSO-D6 and deuterated chloroform was purchased from Cambridge Isotope 
Laboratories.  
2.2. Instrumentation  
2.2.1. NMR Spectroscopy  
Spectral data were obtained using a 400 MHz Bruker Avance spectrometer and 
acquired at 298 K, using 10 mM samples prepared in chloroform. 1H NMR spectra 
were obtained using a spectral width of 8250 Hz and 65536 data points. COSY spectra 
were obtained using a spectral width of 3443 Hz for both 1H nucleus (F1 and F2 
dimension) with 256 data points for F1 and 2048 for F2. Chemical shifts are reported 
in parts per million (ppm) with J coupling reported in Hz. Spin multiplicity is reported 
as: s (singlet), d (doublet), dd (doublet of doublets) and m (multiplet). 
2.2.2. CD Spectroscopy 
Circular dichroism spectra was obtained using a Jasco J-810 spectropolarimeter at 
room temperature in a 1 cm quartz cuvette. Samples were prepared in acetonitrile and 
measured between 250-400 nm (20 accumulations) at a scan speed of 200 nm/min, a 
sensitivity setting of 100 mdeg, a response of 1 s, a spectral bandwidth of 1 nm and 
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data pitch of 1 nm. An acetonitrile blank, obtained under the same conditions was 
subtracted from the spectra. 
2.2.3. ESI-MS 
Mass Spectrographs for characterisation and the Q-DNA titrations were obtained using 
the Xevo QToF HR Mass Spectrometer and scans were carried out at a m/z range of 
50-2000 in positive ionisation scanning mode for the copper complexes and a range of 
1000-3000 for QDNA titrations. Data for copper(II) complex characterisation was 
obtained at a desolvation temperature of 450 °C, capillary voltage of 1.0 kV, cone 
voltage of 20 V, and desolvation gas flow rate of 5 L/min. First analyser LM resolution 
was set to 4.70 and HM resolution to 15.00. Collision Energy was set 4.0 and Collision 
gas flow was set to 0.20 mL/min. Data for QDNA titrations was obtained at a 
desolvation temperature of 150 °C, capillary voltage of 2.3 kV, cone voltage 25 V and 
desolvation gas flow rate of 250 L/min. First analyser LM resolution was set to 4.70 
and HM resolution as well as Collision Energy was set to 15.00 and Collision gas flow 
was set to 0.20 mL/min.  
2.2.4. UV-Vis Spectroscopy 
Absorption spectra were recorded on a Cary Varian 300 (version 9.00) Bio UV-Vis 
double beam spectrophotometer, at room temperature from 240 – 500 nm with the 
baseline corrected, using the Scan Version 3.00 software. A 1 cm path length stoppered 
cuvette was used, with 3 mL of acetonitrile as a reference for the copper complexes 
and 3 mL of chloroform for the ligands. A 5-10 mg of sample was dissolved in 1.5 mL 
of acetonitrile (complex) or chloroform (ligand) and 2-10 µL portions of sample 
solution was added to 3 mL of the blank. 
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2.3. Synthesis of N4-Tetradentate ligands 
2.3.1. Schiff Base Ligands 
General method for the synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-
diiminoethane (L1(in))66  
To a solution of 1,2-diaminoethane (7.75 mg, 0.1289 mmol) in methanol (15.0 mL), 
3-methylpyridine-2-carboxyaldehyde (24.8 mg, 0.2050 mmol) was added and left to 
stir for two days. The volume of the resulting solution was reduced and the isolated 
product dried in the desiccator overnight (Figure 2.1). Yield: 27.4 mg (98.6%) 3-
methylpicen(IN)(L1in) 1H-NMR (400 MHz, DMSO-d6) δ: 8.53 (s, 2H, H16), 8.44 (d, 
2H, J1 = 4.44 Hz, H11), 7.42 (d, 2H, J1 = 7.68 Hz, H13), 7.01 (t, 2H, J1 = 12.36, H12), 
4.02 (s, 4H, H1), 2.44 (s, 6H, CH3-py). 13C-NMR (400 MHz, DMSO-d6) δ: 163.1 
(C16), 151.4 (C15), 147.1 (C11), 139.2 (C13), 133.8 (C14), 123.8 (C12), 62.3 (C1), 
19.5 (CH3-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 279 (7.3 ± 0.5 !103). !!
!
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Figure 2.1: Synthesis of Schiff base ligands. 
 
Synthesis of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diiminoethane (L2(in))  
The above method was used to synthesize L2(in) using 4-methylpyridine-2-
carboxyaldehyde (24.8 mg, 0.2050 mmol) in the reaction instead of 3-methylpyridine-
2-carboxyaldehyde. Yield: 27.5 mg (98.9 %). 4-methylpicen(IN)(2in) 1H-NMR (400 
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MHz, DMSO-d6) δ: 8.39 (d, 2H, J1 =4.96 Hz, H11), 8.32 (s, 2H, H16), 7.74 (s, 2H, 
H14), 7.04 (d, 2H, J1 =4.68, H12), 3.97 (s, 4H, H1), 2.29 (s, 6H, CH3-py). 13C-NMR 
(400 MHz, DMSO-d6) δ: 163.7 (C16), 154.1 (C15), 149.1 (C11), 147.8 (C13), 125.8 
(C12), 121.9 (C14), 61.4 (C1), 20.9 (CH3-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, 
CHCl3): 272 (5.9 ± 0.4 !103). 
 
Synthesis of N,Nʹ-bis(5-chloro-2-pyridylmethyl)-1,2-diiminoethane (L3(in))  
The general method was used to L3(in) using 5-chloropyridine-2-carboxyaldehyde 
(25.6 mg, 0.1810 mmol) in the reaction instead of 3-methylpyridine-2-
carboxyaldehyde. The mass of 1,2-diaminoethane (6.16 mg, 0.1023 mmol) was also 
reduced. Yield: 27.6 mg (98.63 %). 5-chloropicen(IN)(3in) 1H-NMR (400 MHz, 
DMSO-d6) δ: 8.57 (s, 2H, J1 =2.64 Hz, H11), 8.57 (s, 2H, H16), 7.94 (d, 2H, J1 =8.44 
Hz, H13), 7.70 (d, 2H, J1 =10.72 Hz, H14), 4.06 (s, 4H, H1). 13C-NMR (400 MHz, 
DMSO-d6) δ: 162.2 (C16), 152.4 (C15), 148.2 (C11), 136.3 (C13), 133.3 (C12), 121.9 
(C14), 61.12 (C1). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 248 (27.1 ± 1.2 !103). 
 
Synthesis of N,Nʹ-bis(6-bromo-2-pyridylmethyl)-1,2-diiminoethane (L4(in))  
The general method was used to synthesize L4(in) using 6-bromopyridine-2-
carboxyaldehyde (25.8 mg, 0.1390 mmol) in the reaction instead of 3-methylpyridine-
2-carboxyaldehyde. The mass of 1,2-diaminoethane (4.71 mg, 0.0782 mmol) was 
reduced. Yield: 22.07 mg (80.0 %). 6-bromopicen(IN)(4in) 1H-NMR (400 MHz, 
DMSO-d6) δ: 8.33 (s, 2H, H16), 7.96 (d, 2H, J1 =7.60 Hz H13), 7.60 (m, 2H, J1 =15.48 
Hz, H12), 7.51 (t, 2H, J1 =7.8 Hz, H14), 4.03 (s, 4H, H1). 13C-NMR (400 MHz, 
DMSO-d6) δ: 162.1 (C16), 155.4 (C15), 141.5 (C11), 138.8 (C13), 129.2 (C12), 119.8 
(C14), 61.1 (C1). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 284 (12.3 ± 0.3 !103). 
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Synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1R,2R,-diiminocyclohexane 
(L5(in)) 
The general method was used to synthesise L5(in) using 1R,2R-diaminocyclohexane 
(11.7 mg, 0.1025 mmol) in the reaction instead of 1,2-diaminoethane. Yield: 30.8 mg 
(93.26 %) RR-dach-3-methylpicen(IN)(5in) 1H-NMR (400 MHz, DMSO-d6) δ: 8.42 
(d, 2H, J1 =4.8 Hz, H11), 8.37 (s, 2H, H16), 7.60 (d, 2H, J1 = 7.76 Hz, H13), 7.25 (m, 
2H, J1 =2.64, H12), 3.38 (m, 2H, H1), 2.49 (s, 6H, CH3-py), 1.80 (d, 4H, J1 =10.8 Hz, 
H6), 1.49 (t, 4H, J1 =8.8 Hz, H5). 13C-NMR (400 MHz, DMSO-d6) δ: 162.6 (C15), 
151.60 (C16), 147.0 (C11), 139.8 (C14), 133.6 (C13), 124.0 (C12), 75.2 (C1), 32.8 
(C6), 24.4 (C5), 20.2 (CHx-Py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 279 (10.3 
± 0.5 !103). CD/λmax  (nm)(mdeg.L.mol-1!104, acetonitrile): 265(-2.8); 287(-13.1); 
 
Synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1S,2S-diiminocyclohexane 
(L6(in)) 
The general method was used to synthesise L6(in) using 1S, 2S-diaminocyclohexane 
(11.7 mg, 0.1025 mmol) in the reaction instead of 1,2-diaminoethane. Yield: 19.5 mg 
(59.04%) SS-dach-3-methylpicen(IN)(5in) 1H-NMR (400 MHz, DMSO-d6) δ: 8.42 (d, 
2H, J1 =4.0 Hz, H11), 8.38 (s, 2H, H16), 7.59 (d, 2H, J1 = 7.52 Hz, H13), 7.25 (m, 2H, 
J1 =6.4, H12), 3.39 (m, 2H, H1), 2.51 (s, 6H, CH3-py), 1.77 (d, 4H, J1 =10.0 Hz, H6), 
1.48 (t, 4H, J1 =8.4 Hz, H5). 13C-NMR (400 MHz, DMSO-d6) δ: 162.9 (C15), 151.7 
(C16), 147.1 (C11), 139.7 (C14), 133.7 (C13), 124.1 (C12), 75.0 (C1), 32.9 (C6), 24.5 
(C5), 20.2 (CHx-Py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 279 (9.3 ± 0.3 
!103).!CD/λmax (nm)(mdeg.L.mol-1 !104, acetonitrile): 265(2.1); 287(13.7); 
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Synthesis of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diiminoethane (L7(in)) 
The general method was followed to synthesise L7(in) using 4-ethylpyridine-2-
carboxyaldehyde (24.9 mg, 0.1850 mmol) in the reaction instead of 3-methylpyridine-
2-carboxyaldehyde. Yield 25.6 mg (93.6%). 4-ethylpicen(IN)(7in) 1H-NMR (400 
MHz, DMSO-d6) δ: 8.42 (d, 2H, J1 =5.0 Hz, H11), 8.34 (s, 2H, H16), 7.76 (s, 2H, 
H14), 7.07 (t, 2H, J1 =5.0, H12), 3.98 (s, 4H, H1), 2.60 (m, 4H, J1 =7.62 Hz, CH3-py), 
1.18 (t, 6H, J1 =7.62 Hz, C2H5-py). 13C-NMR (400 MHz, DMSO-d6) δ: 163.8 (C15), 
154.23 (C13), 153.7 (C16), 149.26 (C11), 124.6 (C14), 120.79 (C12), 61.46 (C1), 
28.20 (CH3-py), 14.27 (C2H5-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 272 
(5.9 ± 0.4 !103). 
 
2.3.2.! Reduced Ligands 
General method for the synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-
diaminoethane (L1)  
Sodium borohydride (523.8 mg, 13.8 mmol) was added to a solution of L1(in) (35.0 
mg, 0.1304 mmol) in of methanol (20.0 mL) and stirred overnight (Figure 2.2). The 
volume was reduced, water (2.00 mL) was added and the product extracted into 
chloroform.66 The chloroform layer was dried with sodium carbonate and filtered. The 
volume was reduced and the final product dried in a desiccator. Yield: 26.6 mg (75.43 
%). (L1) 1H-NMR (400 MHz, DMSO-d6) δ: 8.35 (d, 2H, J1 = 4.68 Hz, H11), 7.75 (d, 
2H, J1 = 7.48 Hz, H13), 7.16 (m, 2H, J1 = 14.32 Hz, H12), 3.77 (s, 4H, H16), 2.69 (s, 
4H, H1), 2.29 (d, 6H, J1 = 4.72 Hz, CH3-py). 13C-NMR (400 MHz, DMSO-d6) δ: 158.1 
(C15), 146.2 (C11), 137.8 (C13), 131.4 (C14), 122.3 (C12), 52.5 (C16), 49.3 (C1), 
17.9 (CH3-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 266 (6.16 ± 0.4 !103). !
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Figure 2.2: Synthesis of reduced ligands. 
Synthesis of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diaminoethane (L2)  
The above method was used to synthesize this product using L2(in) (39.2 mg, 0.1461 
mmol) in the reaction instead of L1(in). Yield: 27.7 mg (70.14 %). (L2) 1H-NMR (400 
MHz, DMSO-d6) δ: 8.33 (d, 2H, J1 = 4.96 Hz, H11), 7.25 (s, 2H, H14), 7.06 (d, 2H, 
J1 = 4.84 Hz, H12), 3.73 (s, 4H, H16), 2.63 (s, 4H, H1), 2.29 (s, 6H, CH3-py). 13C-
NMR (400 MHz, DMSO-d6) δ: 160.7 (C15), 148.9 (C11), 147.3 (C13), 123.1 (C12), 
122.9 (C14), 54.9 (C16), 49.1 (C1), 20.9 (CH3-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-
1, CHCl3): 260 (4.36 ± 0.4 !103). 
 
Synthesis of N,Nʹ-bis(5-chloro-2-pyridylmethyl)-1,2-diaminoethane (L3)  
The general method was used to synthesize this product using L3(in) (27.6 mg, 0.0893 
mmol) in the reaction instead of L1(in). Yield: 17.9 mg (64.41 %). (L3) 1H-NMR (400 
MHz, DMSO-d6) δ: 8.52 (d, 2H, J1 = 2.32 Hz, H11), 7.87 (m, 2H, J1 = 10.92 Hz, H13), 
7.48 (t, 2H, J1 = 8.32 Hz, H14), 3.77 (s, 4H, H16), 2.60 (s, 4H, H1). 13C-NMR (400 
MHz, DMSO-d6) δ: 159.9 (C15), 147.6 (C4), 136.6 (C13), 129.4 (C12), 123.6 (C14), 
54.3 (C16), 48.9 (C1). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 272 (6.3± 0.4 
!103). 
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Synthesis of N,Nʹ-bis(6-bromo-2-pyridylmethyl)-1,2-diaminoethane (L4)  
The general method was used to synthesize this product using L4(in) (34.4 mg, 0.0864 
mmol) in the reaction instead of L1(in). Yield: 19.6 mg (56.41 %). (L4) 1H-NMR (400 
MHz, DMSO-d6) δ: 7.71 (t, 2H, J1 = 15.4 Hz, H13), 7.49 (t, 2H, J1 = 7.72 Hz, H12), 
7.47 (t, 2H, J1 = 7.72 Hz, H14), 3.76 (s, 4H, H16), 2.61 (s, 4H, H1). 13C-NMR (400 
MHz, DMSO-d6) δ: 163.3 (C15), 141.0 (C11), 140.3 (C13), 126.3 (C12), 122.2 (C14), 
54.3 (C16), 48.9 (C1). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 269 (8.6 ± 0.2 
!103). 
 
Synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1R,2R-diaminocyclohexane 
(L5) 
The general method was used to synthesise this product using L5(in) (27.5 mg, 0.0853 
mmol) in the reaction instead of L1(in). Yield: 24.8 mg (89.56 %) (L5) 1H-NMR (400 
MHz, DMSO-d6) δ: 8.32 (m, 2H, J1 =5.6 Hz, H11), 7.53 (m, 2H, J1 = 8.4 Hz, H13), 
7.15 (m, 2H, J1 = 6.4 Hz, H12), 4.57 (s, 4H, H16), 3.35 (t, 2H, J1 = 12.0 Hz, H1), 2.50 
(s, 6H, CH3-py), 1.66; 1.92 (t, 4H, J1 =12.0 Hz, H6), 1.22 (m, 4H, J1 =6.0 Hz, H5). 
13C-NMR (400 MHz, DMSO-d6) δ: 158.2 (C15), 146.2 (C11), 138.1 (C13), 132.8 
(C14), 123.0 (C12), 79.9 (C1), 61.6 (C16), 31.4 (C6), 24.9 (C5), 18.4 (CHx-Py). UV-
Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 265 (4.7 ± 0.4 !103). CD/λmax 
(nm)(mdeg.L.mol-1 !104, acetonitrile): 291(-2.9); 263(1.9); 253(1.3) 
 
Synthesis of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1S,2S-diaminocyclohexane (L6) 
The general method was used to synthesise this product using L6(in) (19.5 mg, 0.0605 
mmol) in the reaction instead of L1(in). Yield: 18.1 mg (92.24 %) (L6) 1H-NMR (400 
MHz, DMSO-d6) δ: 8.29 (m, 2H, J1 =6.4 Hz, H11), 7.55 (m, 2H, J1 = 8.8 Hz, H13), 
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7.19 (m, 2H, J1 = 5.2 Hz, H12), 4.57 (s, 4H, H16), 3.34 (t, 2H, J1 = 8.8 Hz, H1), 2.52 
(s, 6H, CH3-py), 1.71; 1.93 (m, 4H, J1 =8.8 Hz, H6), 1.20; 1.01 (m, 4H, J1 = 8.8 Hz, 
H5). 13C-NMR (400 MHz, DMSO-d6) δ: 158.5 (C15), 146.2 (C11), 137.9 (C13), 131.8 
(C14), 123.1 (C12), 80.0 (C1), 61.7 (C16), 31.5 (C6), 24.9 (C5), 18.2 (CHx-Py). UV-
Vis λmax nm (ε mol-1 dm-3 cm-1, CHCl3): 265 (4.7 ± 0.4 !103). CD/λmax 
(nm)(mdeg.L.mol-1 !104, acetonitrile): 291(2.9); 263(-1.6); 253(-1.2) 
 
Synthesis of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diaminoethane (L7) 
The general method was followed to synthesise this product using L7(in) (25.0 mg, 
0.1850 mmol) in the reaction instead of L1(in). Yield 30.2 mg (84.88%) (L7) 1H-NMR 
(400 MHz, DMSO-d6) δ: 8.35 (d, 2H, J1 =4.96 Hz, H11), 7.27 (s, 2H, H14), 7.08 (d, 
2H, J1 = 4.8 Hz, H12), 3.74 (s, 4H, H16), 2.62 (t, 4H, J1 = 7.84, CHx-CH2-Py), 2.57 
(d, 4H, J1 =7.6 Hz, H1), 1.17 (t, 6H, J1 =7.58 Hz, CH3-py). 13C-NMR (400 MHz, 
DMSO-d6) δ: 160.8 (C15), 153.2 (C13), 149.0 (C11), 121.8 (C14), 121.6 (C12), 55.0 
(C16), 49.1 (C1), 27.9 (CH3-py), 14.8 (C2H5-py). UV-Vis λmax nm (ε mol-1 dm-3 cm-1, 
CHCl3): 260 (6.3 ± 0.5 !103). 
 
2.3.3.! Synthesis of Copper(II) Complexes 
General method for the synthesis: [Cu (N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-
diiminoethane)](ClO4)2 (Cu1(in)) 
To a solution of 3-methylpicen(in) (38.8 mg, 0.1447 mmol) in acetonitrile, Copper(II) 
perchlorate hexahydrate (53.6 mg, 1.1447 mmol) was added and stirred for 1 hour at 
55°C. The solution was then left to crystallise by diffusion in diethyl ether. (Figure 
2.3) Yield 35.6mg (73.5%). MS C16H18CuN4 calc. for [M+] 329.08, found [M+] m/z 
329.08. UV-Vis λmax nm (ε mol-1 dm-3 cm-1, ACN): 300 (6.2 ± 0.1 !103). The synthesis 
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of the rest of the copper(II) complexes followed this general method, with 3-
methylpicen(in) replaced by each different N4-TLs. The amounts of each reagent were 
changed according to Table 2.1. 
 
 
 !
Figure22.3:!Synthesis!of!Cu(II)!complexes!!!
2.4. Biological Testing 
2.4.1.! Materials and equipment 
Sterile agar plates and kanamycin were purchased from Oxoid. A Ratek metering 
pump was used to dispense on the agar plates. Nutrient broth agar was purchased from 
Sigma-Aldrich and bacterial strains were purchased from the University of New South 
Wales (UNSW). The 96-well plates were incubated in a Labec incubator and an Innova 
400 New Brunswick Scientific shaking incubator was utilized to incubate microbial 
strains. Reference antibiotics, ampicillin, streptomycin, 5-fluorocytosine and L-
glutamine were purchased from Sigma Aldrich. Penicillin, fetal bovine serum (FBS) 
and RPMI media 1640 were purchased from Life Technologies (Carlsbad, US). 
Microtitre and multiwall plates were purchased from Interpath (Heidelberg West, AU). 
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Table 2.1. Synthesis of Cu(II) complexes. !
!
Copper(II) 
Complex  16BLigand Name 
Ligand mass 
& moles 
(mg; mmol) 
Cu(ClO4)2 
mass and 
moles 
(mg; mmol) 
Yield  
(mg; %) 
Molecular 
weight 
(g/mol) 
ESI-MS 
(Molecular Ion) 
(m/z) 
UV/ λmax (nm) 
(ε/mol-1.dm3cm-1) 
CD/λmax (nm) 
(mdeg.L.mol-1 X104) 
Cu2(in) 4-methylpicen(in) 35.2; 0.1314 48.6; 0.1312 38.6; 89.2 329.08 328.07 [M-1H] 287 (8.4 ± 0.3) - 
Cu3(in) 5-chloropicen (in) 30.5; 0.0986 36.6; 0.0988 25.0; 68.4 370.97 369.07 [M-1H] 297 (5.2 ± 0.3) - 
Cu4(in) 6-bromopicen(in) 28.0; 0.0703 26.1; 0.0704 19.2; 59.4 459.63 458.87 [M-1H] 276 (4.8 ± 0.3) - 
Cu5(in) RR-3-methylpicchxn(in) 34.3; 0.1065 39.4; 0.1063 31.7; 77.8 383.13 382.12 [M-1H] 299 (8.2 ± 0.4) 
317(-39.3); 307(-
34.3); 285(-1.8); 
254(-17.3) 
Cu6(in) SS-3-methylpicchxnn(in) 30.6; 0.0950 35.2; 0.0950 27.3; 74.8 383.13 382.12 [M-1H] 299 (14.3 ± 0.7) 317(40.2); 307(37.9); 285(1.7); 254(18.0.3) 
Cu7(in) 4-ethylpicen(in) 82.8; 0.2793 103.5; 0.2793 76.5; 77.3 357.11 356.11 [M-1H] 286 (4.1 ± 0.1) - 
Cu1 3-methylpicenH 25.0; 0.0925 34.3; 0.0926 25.3; 82.0 331.10 332.10 [M+1H] 261 (8.5 ± 0.3) - 
Cu2 4-methylpicenH 25.1; 0.0928 34.6; 0.0934 23.7; 77.0 331.10 332.10 [M+1H] 261 (7.1 ± 0.2) - 
Cu3 5-chloropicenH 28.7; 0.0923 34.3; 0.0926 29.3; 85.0 372.99 373.99 [M+1H] 268 (8.1 ± 0.5) - 
Cu4 6-bromopicenH 37.1; 0.0927 34.4; 0.0926 31.9; 74.6 461.64 462.90 [M+1H] 261 (9.1 ± 0.4) - 
Cu5 RR-3-methylpicchxnH 27.6; 0.0851 31.6; 0.0853 27.5; 83.7 385.15 386.15 [M+1H] 262 (2.4 ± 0.3) 276(-9.9); 255(3.6) 
Cu6 SS- 3-methylpicchxnH 30.3; 0.0934 34.3; 0.0926 29.1; 81.4 385.15 386.15 [M+1H] 264 (7.2 ± 0.1) 276(9.4); 255(-3.0) 
Cu7 4-ethylpicenH 24.9; 0.0834 30.9; 0.0834 25.6; 85.3 359.13 358.12 [M+1H] 257 (6.8 ± 0.2) - 
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All! microbial! and! cell! culture! experiments! were! conducted! in! sterile!environments! and measurement! of! the!microtitre plates was performed using a 
Biorad 300 plate reader. The Q-DNA TGA GGG TGG GTA GGG TGG GTA A 
(1XAV) was purchased from DNA Technology, Denmark and HPLC was utilised to 
purify further. Ammonium acetate was purchased from APS and HPLC grade 
acetonitrile, methanol, and DMSO were purchased from Merck chemicals. 
2.4.2.! Microbial cultures and media 
Microbial cultures of S. aureus, K. pneumoniae and C. krusei were purchased from 
ATCC or UNSW and used without alterations or transformations to the species. 
Glycerol stocks were stored at -80 °C and those with bacterial cultures were inoculated 
to nutrient agar petri dishes to accommodate for working subcultures. Plate cultures 
were stored at 4 °C and sub-cultured again after a course of 30 days. Pipette tips, 
prepared liquid media (TSB) and water were sterilized using a Centenary Atherton 
autoclave for 20 minutes at 121 °C.  
2.4.3.! MIC Assays 
These assays were carried out in accordance with the European Committee on 
Antimicrobial Susceptibility Testing’s (EUCAST) protocol. Copper samples (2 mg) 
were dissolved in 10% DMSO (1 mL) and diluted down to a range of different 
concentrations, from 2-64 µg/mL (0.006-0.139 mM). Bacterial and yeast cultures were 
inoculated from Nutrient Broth agar cultures in 40 mL of Tryptic Soy Broth, incubated 
and shaken overnight at 37 °C. The optical densities (OD) of each culture was 
determined and diluted down based on the colony forming units (CFUs) at OD595 nm. 
These diluted cultures were then incubated with different concentrations (2-64 µg/mL 
in 99.75% media and 0.25% DMSO) of different samples (Cu1-Cu7(In)) in 96-well 
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plates as were solvent-media, ampicillin (Gram-positive), streptomycin(Gram-
negative) and 5-fluorocytosine(yeast) as controls. Samples were pipetted into wells on 
the plate prior to microbial inoculation. Prior to incubation, the absorbance was read 
at time(T)=0 and then incubated at 37 °C for 24 hours. The absorbance at T = 24 (after 
24 hours) was read and the assays were performed in duplicates at the same range of 
concentrations each time. 
2.4.4.! Cytotoxicity Assays 
Cytotoxicity assays of L1(in)-L4(in); L7(in) were determined against Colon (HY29), 
Glioblastoma (U87), Breast (MCF-7), Ovarian (A2780), Lung (H460), Skin (A431), 
Prostate (Du145), Neuroblastoma (BE2-C), Glioblastoma (SJ-G2), Pancreas (MIA) 
and Breast (MCF10A) cell lines at the Calvary Mater Newcastle Hospital, Waratah, 
NSW, Australia. Test agents were prepared as 30 mM stock solutions in DMSO and 
stored at -20 °C. All cell lines were cultured at 37 °C in a 5% CO2 humidified 
atmosphere and maintained in Dulbecco’s modified Eagle’s medium (Trace 
Biosciences, Australia) supplemented with 10% foetal bovine serum, sodium 
bicarbonate (10 mM), penicillin (100 µg/mL), streptomycin (100 µg/mL) and 
glutamine (4 mM). Cytotoxicity was ascertained by planting cells in duplicate in 100 
mL media at a density of 2500-4000 cells/well in 96-well plates. 24 hours (day 0) after 
cell planting (logarithmic growth), media (100 mL) was added to each test well. After 
72-hour drug exposure, the growth inhibitory effects were evaluated using MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay and absorbance 
read at 540 nm. The IC50 value was obtained from an 8-point dose response curve and 
this value is the concentration at which cell growth is inhibited by 50% based on the 
difference optical density values of day 0 and the end of drug exposure. Cell line 
testing of the copper(II) complexes and ligands were conducted against A2780cisR 
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cell lines at the School of Medicine WSU, Campbelltown, NSW, Australia. Stock 
solutions were made up to 3 mM concentration in 50% DMSO solution and then 
diluted with media to the desired concentration. A2780cisR cell lines were maintained 
in RPMI-1640 and supplemented with 10% FBS, L-glutamine (1 g/L) and penicillin 
and streptomycin (100 mg/L). All cell lines were negative for mycoplasma, when 
tested following 20 passages from initial subcultures (Garvan Molecular Genetics, 
PCR). The passage number was below 10 for each experiment.117 The A2780cisR 
assays were conducted using an adapted reazurin-based method.118 in 96-well plates.  
 
2.4.5. Q-DNA ESI-MS Binding Studies  
The 1XAV oligomer was purified on a Waters HPLC system using a reverse-phase 
C18 column and a UV detector at 260nm. 1XAV was dissolved in ammonium acetate 
(1mL, 10mM) and the concentration was determined by UV analysis, using the 
extinction coefficient(ε) provided by DNA Technology (ε260 =  76 x103 M-1.cm-1), in a 
1 cm path length quartz cuvette. 1XAV was dissolved in ammonium acetate buffer 
(150 mM) to obtain a stock solution (1mM), which was confirmed by UV.112  The 
stock solution was then heated to 95 °C in a water bath for 15 minutes and was cooled 
to room temperature over several hours. The resulting solution was then divided by 4 
equal amounts to yield a final concentration of 0.25 mM. The 1XAV solution was 
stored at 4 °C before use. The 5 copper complex samples (1 mg/mL) were dissolved 
in 30% acetonitrile and water solution, which were diluted down to 10 µL in 1 mL for 
Q-DNA titrations. The final concentration of each Q-DNA: copper complex solution 
was 100 µM at ratios of 1:0, 1:1, 1:2, 1:3, 1:4, 1:5, 1:7 and 1:9 that were analysed on 
the QToF HR-MS using the specified parameters.  
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Figure 2.4. Steps to prepare samples for Q-DNA ESI-MS binding studies.112 
2.5. X-Ray Crystallography 
Single X-ray diffraction measurements of the copper complexes were obtained on the 
MX2 beamline at the Australian Synchrotron by Dr. Yingjie Zhang. The diffraction 
data was collected using a Si<111> monochromated synchrotron with X-ray radiation 
(λ=0.71073) at 293(2) K using the Blu-Ice interface software. Structures were solved 
using SHELXL and the full matrix refinements were carried out on SHELXL-2014/7 
via the OLEX2 interface. All non-H atoms with occupancy greater than 0.5 were 
refined anisotropically and H atoms associated with Cu(II)-C/N/O bond were added in 
idyllic position using the riding model.  
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3.X-ray Crystallography 
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3.1.! X-ray Crystallography and structure resolution 
Crystal structures obtained of the copper(II) complexes were acquired by x-ray single 
crystal diffraction at the Australian Synchrotron. The copper complexes adopted 4 
different types of orthorhombic and monoclinic space groups, P212121, Pbca, P21/c and 
Cc. Monoclinic space groups contain twofold rotational symmetry and therefore the 
α° and γ° are equal at 90° but the β° can range between 90° and 120°. Orthorhombic 
space groups contain unit cells that are orthogonal to each other, hence α, β and γ angle 
all equal 90°. The Cc monoclinic space group is a polar group, while P21/c is 
centrosymmetric. The P212121 Orthorhombic space group is enantiomorphic, while the 
Pbca group is centrosymmetric. The polar point group incorporates structures that have 
one fixed point in each different rotation and the centrosymmetric group refers to 
structures that are inversely symmetrical as they have symmetry around the centre of 
the structure. The enantiomorphic group refers to structures that are have left and right 
handed enantiomers and as a result there are no unsuitable rotations. The summarized 
crystallographic data of these complexes are represented in Tables 3.1 and 3.2 and the 
full crystallographic tables of the 7 crystal structures obtained (Cu1(in), Cu2, Cu4, 
Cu5(in), Cu6, Cu6(in) and Cu7) are included in Appendix A.7. 
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Table 3.1 Crystallographic data of Cu1(in), Cu2, Cu4 and Cu5(in) 
 
[Cu(3-
methylpicen(in))](ClO4)2 
(H2O) 
Cu1(in) 
[Cu(4-
methylpicenH)](ClO4)2 
Cu2 
[Cu6-
bromopicenH)ACN](ClO4)2  
Cu4 
[Cu(R,R-dach-3-
methylpicen(in))H2O](ClO4)2  
Cu5(in) 
Empirical formula C16H20Cl2CuN4O9 C16H22Cl2CuN4O8 C16H19Br2Cl2CuN5O8 C20H26Cl2CuN4O9 
Formula weight 546.83 532.81 670.88 600.89 
Temperature/K 293(2) 293(2) 293(2) 293(2) 
Crystal system Monoclinic Orthorhombic Monoclinic Orthorhombic 
Space group Cc (no.9) Pbca (no.62) P21/c (no.14) P212121 (no.19) 
a/Å 13.620(3) 13.218(3) 13.448(3) 7.0750(14) 
b/Å 11.831(2) 15.967(3) 12.230(2) 12.274(3) 
c/Å 13.980(3) 20.104(4) 15.302(3) 28.007(6) 
α/° 90 90 90 90 
β/° 110.21(3) 90 110.64(3) 90 
γ/° 90 90 90 90 
Volume/Å3 2114.0(8) 4243.0(15) 2355.2(9) 2432.1(8) 
Z 4 8 4 4 
ρcalcg/cm3 1.718 1.668 1.892 1.641 
µ/mm-1 1.344 1.333 2.964 1.176 
F(000) 1116.0 2184 1349 1236.0 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data 
collection/° 11.386 to 51.994 4.052 to 49.974 3.236 to 55.000 2.908 to 52 
Index ranges -16 ≤ h ≤ 16, -14 ≤ k ≤ 14, -17 ≤ l ≤ 17 
-15 ≤ h ≤ 15, -18 ≤ k ≤ 18, -
23 ≤ l ≤ 23 
-17 ≤ h ≤ 17, -15 ≤ k ≤ 15, -19 ≤ 
l ≤ 19 -8 ≤ h ≤ 8, -15 ≤ k ≤ 15, -34 ≤ l ≤ 34 
Reflections collected 12395 43092 34345 29378 
Independent reflections 3846 [Rint = 0.0389, Rsigma = 0.0404] 
3684 [Rint = 0.0817, Rsigma = 
0.0464] 
5363 [Rint = 0.0469, Rsigma = 
0.0290] 4642 [Rint = 0.0312, Rsigma = 0.0200] 
Data/restraints/parameters 3846/2/295 3648/0/283 5363/0/309 4642/0/329 
Goodness-of-fit on F2 1.055 1.158 1.145 1.291 
Final R indexes [I>=2σ (I)] R1 = 0.0316, wR2 = 0.0839 R1 = 0.0902, wR2 = 0.0862 R1 = 0.0446, wR2 = 0.1216 R1 = 0.0371, wR2 = 0.0919 
Final R indexes [all data] R1 = 0.0317, wR2 = 0.0840 R1 = 0.0905, wR2 = 0.1863 R1 = 0.0447, wR2 = 0.1217 R1 = 0.0371, wR2 = 0.0919 
Largest diff. peak/hole / e 
Å-3 0.377/-0.244 1.057/-2.379 2.222/-1.587 0.765/-1.169 
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Table 3.2 Crystallographic data of Cu6, Cu6(in) and Cu7  
 [Cu(S,S-dach-3-methylpicenH)](ClO4)2  Cu6 
[Cu(S,S-dach-3-methylpicenin)](ClO4)2  
Cu6(in) 
[Cu(4-ethylpicenH)](ClO4)2  
Cu7 
Empirical formula C20H26Cl2CuN4O8 C20H26Cl2CuN4O9 C18H25Cl2CuN4O8 
Formula weight 612.90 600.89 559.86 
Temperature/K 293(2) 293(2) 293(2) 
Crystal system Orthorhombic Orthorhombic Orthorhombic 
Space group P212121 (no.19) P212121 (no.19) Pbca (no.61) 
a/Å 8.7200(17) 7.0820(14) 13.565(3) 
b/Å 11.078(2) 12.288 (3) 16.144(3) 
c/Å 28.953(6) 27.986 (6) 20.191(4) 
α/° 90 90 90 
β/° 90 90 90 
γ/° 90 90 90 
Volume/Å3 2796.9(10) 2435.4(8) 4421.7(15) 
Z 4 4 8 
ρcalcg/cm3 1.456 1.639 1.682 
µ/mm-1 1.025 1.175 1.284 
F(000) 1260 1236 2304 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.63 to 51.996 3.62 to 51.996 4.034 to 50 
Index ranges -10 ≤ h ≤ 10, -13 ≤ k ≤ 13, -35 ≤ l ≤ 35 -8 ≤ h ≤ 8, -15 ≤ k ≤ 15, -32 ≤ l ≤ 32 -16 ≤ h ≤ 16, -19 ≤ k ≤ 19, -24 ≤ l ≤ 24 
Reflections collected 34980 30067 44480 
Independent reflections 5476 [Rint = 0.0573, Rsigma = 0.0300] 4623[Rint = 0.0437, Rsigma = 0.0296] 3836[Rint = 0.0507, Rsigma = 0.0249] 
Data/restraints/parameters 5476/0/337 4623/0/329 3836/0/301 
Goodness-of-fit on F2 1.065 1.293 1.065 
Final R indexes [I>=2σ (I)] R1 = 0.0898, wR2 = 0.2598 R1 = 0.0464, wR2 =0.1049 R1 = 0.01064, wR2 = 
Final R indexes [all data] R1 = 0.0900, wR2 = 0.2604 R1 =0.0465 , wR2 = 0.1049 R1 = , wR2 = 0.3050 
Largest diff. peak/hole / e Å-3 1.895/-0.612 0.0717/-1.278 1.909/-0.716 
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3.2.! [Cu(N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-
diiminoethane)](ClO4)2 (Cu1(in)) 
The crystalline structure of [Cu(N,N’-bis(3-methyl-2-pyridylmethyl)-1,2-
diiminoethane)](ClO4)2 was investigated by single crystal x-ray diffraction. The 
crystals obtained were blue and small in appearance and data was obtained at 19.85 
°C. This structure was resolved in the monoclinic crystal lattice structure and the Cc 
space group. The intensities were calculated within 11°< 2θ < 52° using MoKα 
radiation at λ = 0.71073. A total of 3846 independent reflections with an R-factor of 
3.16%. The complex adopts a square planar geometry with 4 symmetric units, which 
stack within the unit cell. An example of the packing can be seen in Figure 3.1. This 
monoclinic crystal lattice structure is part of the Cc group has symmetry in 2 planes x, 
y, z and x, ȳ, ½ + z + (½, ½, 0).119 As this type of unit cell does not contain mirror 
planes, the structure does not contain any special positions.119 This crystal system is 
polar and its cell angles a and c are equal to 90° while b is 110.21°; its resolutions are 
specified as a = 13.620, b = 11.831 and c = 13.980 Å. The copper ion is identified as 
Cu1 and the 4 donor nitrogen atoms from the ligand form a bond angle with copper 
ion at 81° (N2-Cu1-N1 and N3-Cu1-N4) and 162° (N2-Cu1-N4 and N3-Cu1-N1). A 
slight distortion was observed in N4-Cu1-N1 as it formed an angle of 116°, a 
difference of 46. The bond lengths for Cu1-N1, Cu1-N2, Cu1-N3 and Cu1-N4 are 
2.031, 1.950, 1.954 and 2.022 Å, respectively (see Table 3.3). The π- π interactions are 
parallel displaced as the cationic metal centre creates a partial dipole, which causes 
each individual structure to stack in parallel within the unit cell.120 The rest of the bond 
angles and lengths were resolved to form a stable geometry of the complex and were 
between 80°-125° and 1.268-2.031 Å.  
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Figure 3.1 Crystal structure of Cu1(in) and the π- π interactions within unit cell. 
Table 3.3 Selected bond angles and lengths of Cu1(in) 
 
3.3.! [Cu(N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-
diaminoethane)](ClO4)2 (Cu2) 
The crystals of this complex were blue and small in appearance and data was collected 
at 19.85 °C. This complex formed an orthorhombic crystal lattice structure, with a 
space group of Pbca. The intensities were calculated within 4° < 2θ < 50° using MoKα 
radiation at λ = 0.71073 and a total of 3684 independent reflections with a R1 of 9.02%. 
The complex also adopts a square planar geometry and contains 8 structures (Z=8) 
within each unit cell, which π- π interactions and an example can be seen in Figure 
3.2. This orthorhombic space group contains 8 different planes of symmetries and 
therefore, 6 reflections. This crystal system is centrosymmetric and its cell angles a, b 
Bond  
Angle (º) 
Bond  
Length 
(Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N2 Cu1 N1 81.02 Cu1 N1 2.031 
N2 Cu1 N3 81.68 Cu1 N2 1.950 
N2 Cu1 N4 162.45 Cu1 N3 1.954 
N3 Cu1 N1 162.62 Cu1 N4 2.022 
N3 Cu1 N4 81.11    
N4 Cu1 N1 116.26    
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and c are equal to 90°; its resolutions are specified as a =13.218 Å, b=15.967 Å and c 
=20.104 Å. The copper ion is identified as Cu1 and the 4 donor nitrogen atoms from 
the ligand form different bond angles with the copper ion. These angles are reported 
in Table 4.4 and range from 81°-168°. The bond lengths for Cu1-N1, Cu1-N2, Cu1-
N3 and Cu1-N4 are 2.005, 1.996, 2.004 and 1.982 Å, respectively. The π- π 
interactions for this unit cell are in a T-shape as the cationic metal centre creates a 
dipole, which causes each individual structure to stack almost perpendicular to each 
other. The rest of the bond angles and lengths were resolved to form a stable geometry 
of the complex and were between 82°-124° and 1.346-2.005 Å (see table 3.4).  
  
Figure 3.2 Crystal structure of Cu2 and the π- π interactions within unit cell. 
 
Table 3.4 Selected bond angles and lengths of Cu2 
 
 
Bond Angle (º) Bond Length (Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N2 Cu1 N1 81.57 Cu1 N1 2.005 
N2 Cu1 N3 85.66 Cu1 N2 1.996 
N3 Cu1 N1 166.16 Cu1 N3 2.004 
N4 Cu1 N1 110.62 Cu1 N4 1.982 
N4 Cu1 N2 167.66    
N4 Cu1 N3 82.36    
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3.4.! [Cu(N,Nʹ-bis(6-bromo-2-pyridylmethyl)-1,2-
diaminoethane)](ClO4)2 (Cu4) 
The crystalline structure of [Cu(N,N’-bis(6-bromo-2-pyridylmethyl)-1,2-
diiminoethane)](ClO4)2 (Cu4) was investigated by single crystal x-ray diffraction. The 
crystals obtained were blue and small in appearance and data was obtained at 19.85 
°C. This data was resolved in the monoclinic crystal lattice structure and the P21/c 
space group. The intensities were calculated within 3°< 2θ < 55° using MoKα radiation 
at λ = 0.71073. A total of 5363 independent reflections with a R-factor goodness of fit 
of 4.46%. The complex adopts a trigonal bipyramidyl geometry as acetonitrile 
coordinates with the copper ion and it stacks with 4 symmetric units within the unit 
cell. An example of the packing can be seen in Figure 3.3 This monoclinic crystal 
lattice structure is a centrosymmetric group, as it has symmetry in 4 planes X, Y, Z; -
X, -Y, -Z; -X, ½ + Y, ½ -Z and X, ½ -Y, ½ +Z. This crystal system is polar and its cell 
angles a and c are equal to 90° while b is 110.64°; its resolutions are specified as a 
=13.448 Å, b=12.230 Å and c =15.302 Å. The copper ion is identified as Cu1 and the 
5 donor nitrogen atoms from the ligand and acetonitrile form bond angles with the 
copper ion ranging from 76°-166°. The bond lengths for Cu1-N1, Cu1-N2, Cu1-N3, 
Cu1-N4 and Cu1-N5 are 2.338, 2.036, 2.002, 2.076 and 1.989 Å, respectively (Table 
3.5). The π- π interactions cause the aromatic groups to stack in a T-shape within the 
unit cell. The rest of the bond angles and lengths were resolved to form a stable 
geometry and were between 76°-166° and 1.329-2.338 Å and are reported in Table 
3.5.  
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Figure 3.3 Crystal structure of Cu4 and the π- π interactions within unit cell. 
Table 3.5 Selected bond angles and lengths of Cu4 
 
3.5.! [Cu (N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1R,2R-1,2-
diiminocyclohexane) (H2O)] (ClO4)2 (Cu5(in)) 
The crystals of this complex were blue and small in appearance and data was collected 
at 19.85 °C. This complex formed an orthorhombic crystal lattice structure, with a 
space group of P212121. The intensities were calculated within 2° < 2θ < 52° using 
MoKα radiation at λ = 0.71073 and a total of 4642 independent reflections, with a 
goodness of fit R-factor of 3.71%. The complex also adopts a square pyramidal 
geometry and contains 4 structures (Z=4) within each unit cell, and an example of the 
Bond Angle (º) Bond Length (Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N2 Cu1 N1 76.83 Cu1 N1 2.338 
N2 Cu1 N4 165.83 Cu1 N2 2.036 
N3 Cu1 N1 97.65 Cu1 N3 2.002 
N3 Cu1 N2 84.79 Cu1 N4 2.076 
N3 Cu1 N4 82.17 Cu1 N5 1.989 
N4 Cu1 N1 110.38    
N5 Cu1 N1 99.01    
N5 Cu1 N2 90.48    
N5 Cu1 N3 161.15    
N5 Cu1 N4 100.11    
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π- π interactions can be seen in Figure 3.4. This orthorhombic space group contains 4 
different planes of symmetries and 3 asymmetries. This crystal system is 
enantiomorphic and its cell angles a, b and c, are equal to 90°; its resolutions are 
specified as a = 7.0750, b = 12.274 and c = 28.007 Å. The copper ion is identified as 
Cu1, and the 4 donor nitrogen atoms from the ligand, and an oxygen, form different 
bond angles with the copper ion. These angles are reported in Table 3.6 and range from 
81°-164°. The bond lengths for Cu1-N1, Cu1-N2, Cu1-N3, Cu1-N4 and Cu1-O1W are 
2.026, 1.944, 1.956, 2.037 and 2.263 Å, respectively. The π- π interactions for this unit 
cell are parallel displaced and the rest of the bond angles and lengths were resolved to 
form a stable geometry between 81°-124° and 1.267-2.263 Å.  
 
 
Figure 3.4 Crystal structure of Cu5(in) and the π- π interactions within unit cell. 
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Table 3.6 Selected bond angles and lengths of Cu5(in) 
 
3.6.! [Cu (N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1S,2S-1,2-
diaminocyclohexane)](ClO4)2 (Cu6) 
The crystal of this complex were blue and small in appearance and data was collected 
at 19.85 °C. This complex formed an orthorhombic crystal lattice structure, with a 
space group of P212121. The intensities were calculated within 4° < 2θ < 52° using 
MoKα radiation at λ = 0.71073 and a total of 5476 independent reflections with an R-
factor as a goodness of fit of 8.98%. The complex also adopts a square pyramidal 
geometry with the 4 nitrogen donor atoms of the ligand and an oxygen from a 
perchlorate ion. The complex contains 4 structures (Z=4) within each unit cell, and an 
example of the π- π interactions can be seen in Figure 3.5. This orthorhombic space 
group contains 4 different planes of symmetries and 3 asymmetries, hence the crystal 
system is enantiomorphic and its cell angles a, b and c are equal to 90°; its resolutions 
are specified as a =8.7200, b=11.078 and c =28.953 Å. The copper ion is identified as 
Cu1 and the 4 donor nitrogen atoms from the ligand and an oxygen from the counter 
ion form different bond angles with the copper ion. These angles are reported in Table 
3.7 and range from 81°-164°. The bond lengths for Cu1-N1, Cu1-N2, Cu1-N3, Cu1-
Bond Angle (º) Bond Length (Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N1 Cu1 O1W 99.39 Cu1 O1W 2.263 
N1 Cu1 N4 114.54 Cu1 N1 2.026 
N2 Cu1 O1W 94.90 Cu1 N2 1.944 
N2 Cu1 N1 81.25 Cu1 N3 1.956 
N2 Cu1 N3 82.00 Cu1 N4 2.037 
N2 Cu1 N4 163.13    
N3 Cu1 O1W 103.73    
N3 Cu1 N1 152.43    
N3 Cu1 N4 81.14    
N4 Cu1 O1W 88.53    
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N4 and Cu1-O1W are 2.026, 1.944, 1.956, 2.037 and 2.263 Å, respectively. The π- π 
interactions for this unit cell are parallel displaced and the rest of the bond angles and 
lengths were resolved to form a stable geometry of between 81°-166° and 2.006 -2.367 
Å.  
 
 
Figure 3.5 Crystal structure of Cu6 and the π- π interactions within unit cell. 
 
Table 3.7 Selected bond angles and lengths of Cu6 
 
 
 
 
3.7.! [Cu (N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1S,2S-1,2-
diiminocyclohexane) (H2O)](ClO4)2 (Cu6(in)) 
The crystals of this complex were blue and small in appearance and data was collected 
at 19.85 °C. This complex formed an orthorhombic crystal lattice structure, with a 
Bond Angle 
(º) 
Bond Length 
(Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N1 Cu1 O9 97.6 Cu1 O9 2.367 
N1 Cu1 N2 81.4 Cu1 N1 2.019 
N1 Cu1 N3 165.9 Cu1 N2 2.003 
N2 Cu1 O9 99.7 Cu1 N3 2.033 
N3 Cu1 O9 79.9 Cu1 N4 2.006 
N3 Cu1 N2 85.3    
N3 Cu1 O9 91.9    
N4 Cu1 N1 112.2    
N4 Cu1 N2 160.9    
N4 Cu1 N3 81.8    
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space group of P212121. The intensities were calculated within 3° < 2θ < 52° using 
MoKα radiation at λ = 0.71073 and a total of 4623 independent reflections with a 
goodness of R-factor of 4.64%. The complex also adopts a square pyramidal geometry 
with the 4 nitrogen donor atoms of the ligand and an aqueous oxygen. It contains 4 
structures (Z=4) within each unit cell, and an example of the π- π interactions can be 
seen in Figure 3.6. This orthorhombic space group contains 4 different planes of 
symmetries and 3 asymmetries and its cell angles a, b and c are equal to 90°; its 
resolutions are specified as a = 7.0820, b = 12.288 and c = 27.986. The copper ion is 
identified as Cu1 and the 4 donor nitrogen atoms from the ligand and an aqueous 
oxygen form different bond angles with the copper ion. These angles are reported in 
Table 3.8 and range from 81°-164°. The bond lengths for Cu1-N1, Cu1-N2, Cu1-N3, 
Cu1-N4 and Cu1-O1W are 2.025, 1.944, 1.957, 2.034 and 2.264 Å, respectively. The 
π- π interactions for this unit cell are parallel displaced, to accommodate the aqueous 
ligand and the rest of the bond angles/lengths were resolved to form a stable geometry 
between 81°-164° and 1.264-2.264 Å.  
 
 
Figure 3.6 Crystal structure of Cu6(in) and the π- π interactions within unit cell. 
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Table 3.8 Selected bond angles and lengths of Cu6(in) 
 
3.8.! [Cu(N,Nʹ-bis(4-ethyl-2-pyridylmethyl)-1,2-
diaminoethane)](ClO4)2 (Cu7) 
The crystals of this complex were blue, small in appearance and data was collected at 
19.85 °C. This complex formed an orthorhombic crystal lattice structure, with a space 
group of Pbca. The intensities were calculated within 4° < 2θ < 50° using MoKα 
radiation at λ = 0.71073 and a total of 3836 independent reflections with an R1 of 
10.64%. The complex also adopts an octahedral geometry and contains 8 structures 
(Z= 8) within each unit cell, an example of the π- π interactions can be seen in Figure 
3.7. This orthorhombic space group contains 8 different planes of symmetry and 
therefore 6 reflections. This crystal system is centrosymmetric and its cell angles a, b 
and c are equal to 90° ° and its resolutions are specified as a = 13.565, b = 16.144 and 
c = 20.191 Å. The copper ion is identified as Cu1 and the 4 donor nitrogen atoms from 
the ligand and 2 oxygen atoms from the counter ion form different bond angles with 
the copper ion. These angles are reported in Table 3.9 and range from 81°-168°. The 
bond lengths for Cu1-N1, Cu1-N2, Cu1-N3 and Cu1-N4 are 2.007, 1.986, 2.018 and 
1.989 Å, respectively (Table 3.9). The π- π interactions for this unit cell are parallel 
Bond Angle (º) Bond Length (Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N1 Cu1 O1W 99.33 Cu1 O1W 2.264 
N1 Cu1 N4 114.52 Cu1 N1 2.025 
N2 Cu1 O1W 94.85 Cu1 N2 1.944 
N2 Cu1 N1 81.31 Cu1 N3 1.957 
N2 Cu1 N3 82.02 Cu1 N4 2.034 
N2 Cu1 N4 163.05    
N3 Cu1 O1W 103.78    
N3 Cu1 N1 152.47    
N3 Cu1 N4 81.04    
N4 Cu1 O1W 88.66    
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displaced due to the presence and polarity of the counter ions. The rest of the bond 
angles and lengths were resolved to form a stable geometry and were between 81°-
169° and 1.327-2.018 Å.  
 
 
Figure 3.7 Crystal structure of Cu7 and the π- π interactions within unit cell. 
 Table 3.9 Selected bond angles and lengths of Cu7  
Bond Angle (º) Bond Length (Å) Atom 1 Atom2 Atom3 Atom1 Atom2 
N2 Cu1 N1 166.1 Cu1 N1 2.007 
N2 Cu1 N3 81.7 Cu1 N2 1.986 
N3 Cu1 N1 85.5 Cu1 N3 2.018 
N4 Cu1 N1 168.2 Cu1 N4 1.989 
N4 Cu1 N2 110.1    
N4 Cu1 N3 82.90    
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4.!Results and Discussion 
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4.1.! Synthesis of N4-TLs 
Synthesis of the 14 N4-TLs was achieved by adapting the published methods.66 Schiff 
base N4-TLs were generally obtained as yellow-white powders while the reduced 
ligands formed brown-yellow oils (Figure 4.1). Both were obtained in yields > 50% 
(Table 3.1).  In general, the yields of the Schiff base N4-TLs were greater than the 
reduced N4-TLs as they require isolation extraction using chloroform and drying with 
anhydrous Na2CO3, which produces smaller quantities but purer products. L4 was 
obtained in significantly lower amounts (56.4%) and this was attributed to the high 
molecular mass, compared with the other N4-TLs. This effect is also evident in L3 and 
L6, which also had relatively higher molecular masses. (see Figure 4.1). 
 
 
Figure 4.1 Appearance of N4-TLs (L5, L7) and copper(II) complexes (Cu5, Cu3) 
 
 
 
!!! 66!
Table 4.1 Yields of ligands and copper(II) complexes. 
 
4.2.! Synthesis of Copper(II) Complexes 
The overall yield of the copper(II) complexes was better than that obtained for the N4-
TLs synthesis, which is most likely due to less synthetic steps required. In general 
there were no observable differences in yield between the coordinated Schiff base or 
reduced N4-TLs complexes. However, complexes of the halogenated N4-TLs, with 
substitution in positions close to the coordinating pyridyl nitrogen (CuL3(in) and 
CuL4(in)) yielded less than other N4-TLs, 68.4 and 59.4% respectively. It is 
hypothesised that the structural constraints of the Schiff base N4-TLs affect 
coordination (see Figure 4.1). Although the resulting Schiff base complexes formed 
deep blue crystal-gel products in acetonitrile and powders in methanol, over time 
CuL3(in) and CuL4(in), changed to a green-yellow product, indicating decay.  
 Yield, mg (%)  Yield, mg (%) 
Schiff 
base Ligand Complex Reduced Ligand Complex 
1(in) 27.4 (98.6%) 35.6 (73.5%) 1 26.6 (75.4%) 25.3 (82.0%) 
2(in) 27.5 (98.9%) 38.6 (89.2%) 2 27.7 (70.1%) 23.7 (77.0%) 
3(in) 27.6 (98.6%) 25.0 (68.4%) 3 17.9 (64.4%) 29.3 (85.0%) 
4(in) 22.07 (80.0%) 19.2 (59.4%) 4 19.6 (56.4%) 31.9 (74.6%) 
5(in) 30.8 (93.3%) 31.7 (77.8%) 5 24.8 (89.6%) 27.5 (83.7%) 
6(in) 19.5 (59.0%) 27.3 (74.8%) 6 18.1 (92.2%) 29.1 (81.4%) 
7(in) 25.6 (93.6%) 76.5 (77.3%) 7 30.2 (84.9%) 25.6! (85.3%) 
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4.3.! Characterisation 
NMR spectroscopy and UV analysis were used to characterise the synthesised ligands 
to ensure the structure of the compound before coordination to copper(II). The 
paramagnetic properties of copper(II) prevented the use of NMR spectroscopy to 
characterise the resulting complexes, however mass spectrometry, UV analysis and 
single beam X-ray crystallography were used to confirm the structure of the different 
copper(II) complexes. The chirality of the N4-TLs (L5(in), L5, L6(in) and L6) and 
their resulting complexes (CuL5(in), CuL5, CuL6(in) and CuL6) was confirmed by 
Circular Dichroism (CD).  
 
4.3.1.! NMR 
1H NMR Spectroscopy 
NMR spectroscopy was used to characterise the synthesised ligands and confirm purity 
before coordination to copper(II). As all synthesised N4-TLs were symmetrical, as the 
hydrogens on the left side of the compound are chemically equivalent to those on the 
right producing 1H peaks at the same ppm (see Tables 4.2 and 4.3).91 The spectrum of 
L1(in) yielded 6 proton peaks, ranging from 2.44-8.53 ppm. The presence of a methyl 
group on the 3rd position of the pyridine ring is indicated by a shift at 2.44 ppm (Figure 
4.2). The peak for H1 was recorded at 4.02 ppm and was more deshielded than CH3-
Py, due to its proximity to the nitrogen atom. The rest of the peaks were also more 
deshielded and therefore correspond to protons on the pyridine ring. The most shielded 
proton on the pyridine ring is H12, as it is the furthest away from all the nitrogen atoms 
and the Schiff base. H13 is also shielded and therefore produces a peak at 7.42 ppm. 
H11 and H16 are the most deshielded due to their proximity to the N-donor atoms, as 
well as an imine group, therefore they exhibit similar peaks at 8.44 and 8.53 ppm, 
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respectively.91 The coupling constants also reveal that H12 and H13 are coupled. 
Although spectra of the Schiff base ligands, show impurities present, they were not 
further purified before coordination, as these impurities did not affect coordination, as 
revealed by the X-ray crystallography and ESI-MS data. The percentage of these 
impurities was calculated to produce accurate coordination ratios to Cu(II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 1H NMR of L1(in)  
 
The spectra of both L1(in) and L1 are similar, however the chemical shift of H16 has 
moved upfield in comparison to the Schiff ligand with a chemical shift of 3.77 ppm 
for L1(Figure 4.2 and 4.3). The presence of a Schiff base, can be attributed to a peak 
at around 8.5 ppm.121 A similar pattern can be seen for the remaining N4-TLs, L2-L7 
and L2(in)-L7(in), to confirm the Schiff base and reduced nature of each ligand. The 
presence of a methyl group in L1, L1(in), L2 and L2(in) is indicated by the lack of a 
H14(in L1,L1(in)) and H13 (in L2, L2(in)) peak as well as the presence of a CH3-Py 
peak in all four around 2.29  ppm and confirming that a methyl group is attached to 
pyridine.91 The presence of a chloride and bromide group in L3/L3(in) and L4/L4(in), 
respectively are indicated by the lack of a peak for H12 and H11. The peaks for H1 in 
L5(in), L6(in), L5 and L6 are around 1.0 ppm upfield, at around 3.38 ppm for the N4-
H11!H16! H13!H12!
H1!
CHx/Py!
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TLs, without the 1,2-diaminocyclohexane group,91 which confirm the structural 
difference between N4-TLs L1(in)/L1 and L5(in)/L6(in)/L5/L6. The spectra of L5, 
L6, L5(in) and L6(in) have similar chemical shifts with the main difference between 
the compounds occurring at H16. 
 
 
 
 
of the presence/absence of a Schiff base 
group.91 
 
 
Figure 4.3 1H NMR of L1.  
 
The H16 peaks for L5(in) and L6(in) are located around the 8.37 ppm, however the 
corresponding peaks in L5 and L6 appear upfield at 4.57 ppm. The spectra of L5(in)/5 
and L6(in)/6 contained more peak splitting due to the presence of the 
diaminocyclohexane ring.91 The spectra of L5 and L6 also contained additional peaks 
at 3.50-4.00 ppm, which are indicative of chloroform and methanol, as the product is 
an oil, traces of the solvent used in synthesis can be seen on the spectra.122 The 
presence of an additional peak at around 1.18 ppm in the spectra of L7 (Figure 4.4) 
and L7(in) indicates the presence of an ethyl carbonyl group, as there is an additional 
H11!H13!H12! H16!
H1!
CHx-Py 
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peak downfield around 1-2 ppm.91 The individual proton spectra of each ligand can be 
found in Appendix A2.! 
 
Figure 4.4: 1H NMR of L7.  
 
 
13C NMR 
The 13C NMR spectra also supports the information provided by the 1H NMR and 
highlights the effect on carbon chemical shift by the different substitutions on the 
pyridine ring and the 1,2-diaminoethane/1,2-diaminocyclohexane bridge. The 13C 
NMR spectra of L1 yielded 8 peaks and the CH3-Py peak was the most shielded at 
17.9 ppm and C1 and C16 were also shielded, at 49.3 and 52.5 ppm respectively. 
Their proximity to a nitrogen makes their chemical shift downfield from the CH3-Py 
peak. The rest of the peaks correspond to carbons on the pyridine ring, with C12, 
C13 and C14 more shielded (122.3-137.8 ppm) than C15 and C11 (146.2-158.1 
ppm), which is due to the different proximities to a nitrogen atom.91 
H11 H14 
H12 
H16 
H1 
CHx-CH2-Py!
CHx-Py 
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Table 4.2: NMR chemical shifts of Schiff base ligands in ppm. (Numbered according to Talib, 2008)111    
    
Label 3-methylpicenIN, 
L1(in) 
4-methylpicenIN, 
L2(in) 
5-chloropicenIN, 
L3(in) 
6-bromopicenIN, 
L4(in) 
RR-dach-3-methylpicenIN 
L5(in) 
SS-dach-3-methylpicenIN 
L6(in) 
4-ethylpicenIN, 
L7(in) 
1H-NMR        
CHx-Py 
 
2.44(s, 6H) 2.29(s, 6H) - - 2.49 (s, 6H) 2.51 (s, 6H) 2.60(m, 4H) 
J1 =7.62 Hz 
CHx-CH2-Py - - - - - - 1.18(t, 6H) 
J1 = 7.62 Hz 
H3/6a,b - - - - 1.80 (d, 4H) 
J1 = 10.8 Hz 
1.77 (d, 4H) 
J1 = 10.0 Hz 
- 
H4/5a,b - - - - 1.49 (t, 4H) 
J1 = 8.8 Hz 
1.48 (t, 4H) 
J1 = 8.4 Hz 
- 
H1/2a,b 4.02(s, 4H) 3.97(s, 4H)   4.06(s, 4H) 4.03(s, 4H) 3.38 (m, 2H) 
J1 = 7.68 Hz 
3.39 (m, 2H) 
J1 = 4.8 Hz 
3.98(s, 4H) 
H16/26a,b 8.53(s, 2H) 8.32(s, 2H) 8.57 (s, 2H) 8.33(s, 2H) 8.37 (s, 2H 8.38 (s, 2H) 8.34(s, 2H) 
H14/24 - 7.74 (s, 2H) 
 
7.70(d, 2H) 
J1 = 10.72 Hz 
7.51(t, 2H) 
J1 = 7.8 Hz 
- - 
 
7.76(s, 2H) 
H13/23 7.42(d, 2H) 
J1 = 7.20 Hz 
- 7.94(d, 2H) 
J1 = 8.44 Hz 
7.96(d, 2H) 
J1 = 7.6 Hz 
7.60 (d, 2H) 
J1 = 7.76 Hz 
7.59 (d, 2H) 
J1 = 7.52 Hz 
- 
H12/22 7.01 (t, 2H) 
J1 = 7.20 Hz 
7.04(d, 2H)  
 J1 = 4.68 Hz 
 
- 7.60(m, 2H) 
J1 = 15.48 Hz 
7.25 (m, 2H) 
J1 = 2.64 Hz 
7.25 (m, 2H) 
J1 = 6.4 Hz 
7.07(t, 2H) 
J1 = 5.04 Hz 
H11/21 8.44(d, 2H) 
J1 = 5.20 Hz 
8.39(d, 2H)  
J1 = 4.76 Hz 
8.57(s, 2H) 
J1 = 2.64 Hz 
- 8.42 (d, 2H) 
J1 = 4.8 Hz 
8.42 (d, 2H) 
J1 = 4.0 Hz 
8.42(d, 2H) 
J1 =5.04 Hz 
13C-NMR        
CHx-py 19.5 20.9 - - 20.2 20.2 28.20 
CHx-CH2-Py - - - - - - 14.27 
C3/6 - - - - 32.8 32.9 - 
C4/5 - - - - 24.4 24.5 - 
C1/2 62.3 61.4 61.12 61.1 75.2 75.0 61.46 
C16/26 163.1 163.7 162.2 162.1 151.6 151.7 153.7 
C15/25 151.4 154.1 152.4 155.4 162.6 162.9 163.80 
C14/24 133.8 121.9 121.9 119.8 139.8 139.7 124.60 
C13/23 139.2 147.8 136.3 138.8 133.6 133.7 154.23 
C12/22 123.8 125.8 133.3 129.2 124.0 124.1 120.79 
C11/21 147.1 149.1 148.2 141.5 147.0 147.1 149.26 
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Table 4.3: NMR chemical shifts of reduced ligands in ppm. (Numbered according to Talib, 2008)111    
Label 3-methylpicenH, 
L1 
4-methylpicenH, 
L2 
5-chloropicenH, 
L3 
6-bromopicenH, 
L4 
RR-dach-3-methylpicenH 
L5 
SS-dach-3-methylpicenH 
L6 
4-ethylpicenH, L7 
1H-NMR        
CHx-Py 
 
2.29(d, 6H) 
J1 = 4.72Hz 
2.29 (s, 6H) - - 2.50 (s, 6H) 2.52 (s, 6H) 1.17(t, 6H) 
J1 =7.58 Hz 
 
CHx-CH2-Py - - - - - - 2.62(t, 4H) 
J1 =7.84 Hz 
 
H3/6a,b - - - - 1.66; 1.92 (t, 4H) 
J1 =12 Hz 
1.93; 1.71 (m, 4H) 
J1 = 8.8 Hz 
- 
H4/5a,b - - - - 1.22 (m, 4H) 
J1 = 6.0 Hz 
1.20; 1.01(m, 4H) 
J1 = 8.8 Hz 
- 
H1/2a,b 2.69 (s, 4H) 2.59(s, 2H)  2.49(s, 4H) 2.61 (s, 4H) 3.35 (t, 2H) 
J1 = 12 Hz 
3.34 (t, 2H) 
J1 = 8.8 Hz 
2.57(d, 4H) 
J1 =7.6 Hz 
H16/26a,b 3.77 (s, 4H 3.65(s, 2H) 3.77 (s, 4H) 3.76 (s, 4H) 4.57(s, 4H) 4.57 (s, 4H) 3.74(s, 4H) 
H14/24 - 
 
7.25 (s, 2H) 
 
7.48 (t, 2H)  
J1 = 8.32 Hz 
7.47 (t, 2H)  
J1 = 7.72 Hz 
- 
 
- 7.27(s, 2H) 
H13/23 7.75 (d, 2H)  
J1 = 7.48Hz 
- 
 
7.87 (m, 2H)  
J1 = 10.92 Hz 
7.71 (t, 2H)  
J1 = 15.4 Hz 
7.53 (m, 2H) 
J1 = 8.4 Hz 
7.55 (m, 2H) 
J1 = 8.8 Hz 
- 
H12/22 7.16 (m, 2H)  
J1 = 14.32 Hz 
7.06 (d, 2H)  
J1 = 4.84 Hz 
- 7.49 (t, 2H)  
J1 = 7.72 Hz 
7.15 (m, 2H) 
J1 = 6.4 Hz 
7.19 (m, 2H) 
J1 = 5.2 Hz 
7.08(d, 2H) 
J1 = 4.8 Hz 
H11/21 8.35 (d, 2H)  
J1 = 4.68 Hz 
8.33 (d, 2H) 
 J1 = 4.96 Hz 
8.52 (d, 2H) 
J1 = 2.32 Hz 
- 8.32 (m, 2H) 
J1 = 5.6 Hz 
8.29 (m, 2H) 
J1 = 6.4 Hz 
8.35(d, 2H) 
J1 = 4.96 Hz 
13C-NMR        
CHx-py 17.9 20.9 - - 18.4 18.2 27.94 
CHx-CH2-Py - - - - - - 14.82 
C3/6 - - - - 31.4 31.5 - 
C4/5 - - - - 24.9 24.9 - 
C1/2 49.3 49.0 48.9 48.9 79.9 80.0 49.09 
C16/26 52.5 54.9 54.3 54.3 61.6 61.7 55.01 
C15/25 158.1 160.7 159.9 163.3 158.2 158.5 160.83 
C14/24 131.4 122.8 123.5 122.2 132.8 131.8 121.83 
C13/23 137.8 147.3 136.6 140.3 138.1 137.9 153.19 
C12/22 122.3 123.1 129.4 126.3 123.0 123.1 121.57 
C11/21 146.2 148.9 147.6 141.0 146.2 146.2 149.05 
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Similar to the proton NMR, the C16 shift was higher in the Schiff base ligands than 
the reduced ligands, which confirms the presence of a C=N as this is shifted is more 
downfield.91 Similarly the chemical shifts of C1 are lower in the reduced ligands 
(around 49.0 ppm) compared with the Schiff base ligands (around 61.0 ppm).91 The 
chloride and bromide substituted ligands lack downfield peaks below 50 ppm, 
indicating no ethyl or methyl substitution.91 L1, L1(in), L2 and L2(in) all contain a 
peak around 18-20 ppm indicative of a CH3 group (see Figure 4.5) while L7 and L7(in) 
contain two (CHx) shifts below 30 ppm, which indicates the presence of an ethyl 
group.91 L3(in), L4(in), L3 and L4 all lack the presence of a CH3 or a CH2-CH3 peak 
although the rest of the peaks are relatively similar in chemical shift in the other N4-
TLs. The spectra for L5(in), L6(in), L5 and L6 all lack an ethyl group, however they 
contain two additional peaks (C6 and C5), which confirm the presence of a RR/SS-
diaminocyclohexane.91 The C14 peak in the spectra of these ligands was shifted 
downfield compared with other ligands, which indicates the presence of a methyl 
group was influenced by the SS-/RR-dach group. The remaining carbon chemical shifts 
occurred around the same for almost all of the ligands, i.e. C12 values in all ligands 
are around 125 ppm, which only varies slightly as a result of the 
methyl/chloride/bromide/SS-/RR-dach/ethyl group substitution.91 The individual 13C 
NMR spectra of each ligand can be found in Appendix A2. 
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Figure 4.5 13C Spectrum of L1. 
 
COSY  
The COSY spectra (see Figure 4.5) confirm the structures synthesised were of the 
desired ligand, with H11, H12, H13 and H14 all correlated, supported by similar 
coupling constants and the presence of 2 pyridine rings in each N4-TLs. N4-TLs with 
SS-/RR-dach rings, such as L5(in), L6(in), L5 and L6 had peaks H6 and H5 correlating 
with each other, confirming the presence of the RR-/SS-dach groups (Figure 4.6). As 
L3(in), L4(in), L3 and L4 had Cl- and Br- substitutions on the pyridine rings, no 
additional correlations were observed. The coupling constants for the different ethyl 
hydrogens in the spectra of L7(in) and L7, each had similar values and the coupling 
was also supported by the COSY spectra. The full correlation spectra can be found in 
Appendix A2. 
C15 C13 C12 C16 
CHx-Py C11 
C14 C1 
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Figure 4.6 COSY of L
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4.3.2.! UV-Vis Spectroscopy 
UV-Vis analysis was performed on both the N4-TLs as well as the copper(II) 
complexes and the observed peaks were in the wavelength range of 240-350 nm. While 
each yielded peaks at wavelengths lower than 240 nm, they were omitted from analysis 
because the solvents, chloroform (ligands) and acetonitrile (complexes) absorb in that 
region. The presence of peaks above 200 nm, confirm the presence of aromatic systems 
(Figure 4.6) and the log of the extinction coefficient also confirms the presence of 
conjugations of different groups with values between 3.5 and 4.5.91 Each N4-TL and 
complex yielded a different ε value (see Table 4.3), however the complexes and their 
related ligands yielded peaks at similar wavelengths and Log10(ԑ) values. The 
structurally similar L1(in), L2(in), L7(in), L1, L2 and L7, had similar ԑ values, 
although there are methyl and ethyl groups in different positions on the pyridine ring. 
The coordinated copper(II) complexes also had similar log10(ԑ) values to their related 
ligand with the reduced ligands and complexes yielding peaks at a lower wavelength 
compared to the Schiff base form. As expected, N4-TLs with differing SS- or RR- 
groups produced peaks at a similar wavelength and extinction coefficients. As the 
log10(ԑ) values for L3(in) and L4(in) are both above 4.0, this suggests that the Schiff 
base as well as the halogenated pyridine contributes to a higher extinction coefficient.  
 
The copper(II) complexes have a different extinction coefficient and this together with 
the introduction of a shoulder of peaks suggest Cu(II) complex formation. Although 
the spectra of Cu4(in) produced a shoulder peak at around 315 nm, this peak does not 
correlate with the wavelength of the peak in the corresponding N4-TLs, which suggests 
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Figure 4.7 UV-vis spectra of L2 and Cu2 (n=3). 
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Table 4.4: UV and CD analysis of ligands and Copper(II) complexes. 
 
LIGAND 
UV/ ΛMAX (nm) 
(ε/×103mol-
1.dm3cm-1) 
LOG10(Ԑ) 
CD/ΛMAX (NM) 
(MDEG.L.MOL-1 
X104) 
COPPER(II) 
COMPLEXES 
UV/ ΛMAX (nm) 
(ε/mol-1.dm3cm-
1) 
LOG10(Ԑ) 
CD/ΛMAX (NM) 
(MDEG.L.MOL-1 
X104) 
Δ OF Ԑ. 
(ε/×103mol-
1.dm3cm-1) 
L1(IN) 279 (7.3 ± 0.5) 3.8 - Cu1(in) 300 (6.2 ± 0.1) 3.8 - - 1.1 
L2(IN) 272(5.9 ± 0.4) 3.8 - Cu2(in) 287 (8.4 ± 0.3) 3.9 - + 2.4 
L3(IN) 248 (27.1 ± 1.2) 4.4 - Cu3(in) 297 (5.2 ± 0.3) 3.7 - - 21.9 
L4(IN) 284 (12.3 ± 0.3) 4.1 - Cu4(in) 276 (4.8 ± 0.3) 3.7 - - 7.5 
L5(IN) 279 (10.3 ±  0.5) 4.0 
265(-2.8); 287(-
13.1) Cu5(in) 299 (8.2 ± 0.4) 3.9 
317(-39.3); 307(-
34.3); 285(-1.8); 
254(-17.3) 
- 2.1 
L6(IN) 279 (9.3 ± 0.3) 4.0 265(2.1); 287(13.7) Cu6(in) 299 (14.3 ± 0.7) 4.1 317(40.2); 307(37.9); 285(1.7); 254(18.0) + 5.0 
L7(IN) 272 (5.9 ± 0.4) 3.8 - Cu7(in) 286 (4.1 ± 0.1) 3.6 - - 1.8 
L1 266 (6.0 ± 0.4) 3.8 - Cu1 261 (8.5 ± 0.3) 3.9 - + 2.5 
L2 260 (4.2 ± 0.4) 3.6 - Cu2 261 (7.1 ± 0.2) 3.8 - + 2.9 
L3 272 (6.1 ±0.4) 3.8 - Cu3 268 (8.1 ± 0.5) 3.9 - + 2.0 
L4 269 (8.5 ± 0.2) 3.9 - Cu4 261 (9.1 ± 0.4) 4.0 - + 0.6 
L5 265 (4.7 ± 0.4) 3.7 291(-2.9); 263(1.9); 253(1.3) Cu5 262 (2.4 ± 0.3) 3.4 
276(-9.9); 255(3.6) - 2.3 
L6 265 (4.7 ± 0.4) 3.7 291(1.9); 263(-1.6); 253(-1.2) Cu6 264 (7.2 ± 0.1) 3.9 
276(9.4); 255(-3.0) + 2.5 
L7 260 (6.3 ± 0.5) 3.8 - Cu7 257 (6.8 ± 0.2) 3.8 - + 0.5 
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that fragmentation of the product, as the wavelength corresponds with that of 
bromine.123 The f extinction coefficients change upon coordination of the Schiff base 
ligands with the exception of Cu2(in) and Cu6(in). Cu3(in) had a larger decrease in ԑ 
upon coordination, and it could be hypothesised that the presence of a halogen on the 
pyridine ring. As halogens are electron withdrawing, the lone electron pair from the 
N-donor atoms could move to the chlorines, causing 2 of the Cu(II) coordination bonds 
to be weaker.124 Similarly Cu4(in) also had a larger decrease in ԑ upon coordination. 
The extinction coefficients mostly increased upon coordination with copper(II) for the 
reduced ligands, apart from L/Cu5. This suggests that the different SS and RR-dach 
groups affect coordination and influences the extinction coefficient.  
 
4.3.3.! CD Spectroscopy 
The spectra of the 4 chiral ligands (L5, L6, L5(in) and L6(in)) and complexes (Cu5, 
Cu6, Cu5(in) and Cu6(in)) confirmed the synthesis of the different chiral compounds 
(see Table 4.3). The Schiff base ligands, L5(in) and L6(in) both yielded peaks at 265 
and 287 nm and L5(in) had L6(in) were inversely correlated. L5 and L6 both yielded 
three complementary peaks at 291, 263 and 253 nm. Cu5(in) and Cu6(in) both yielded 
4 complementary peaks at 254, 285, 307 and 317 nm (Figure 4.8). Cu5 and Cu6 
yielded complementary peaks at 255 and 276 nm.  
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Figure 4.8 The enantiomeric spectra of Cu5(in) and Cu6(in).  
 
4.3.4.! ESI-MS 
ESI-MS was used to analyse and characterise the copper(II) complexes. The samples 
(1-2 mg) were dissolved in acetonitrile (1 mL) and diluted 1000 times before analysis. 
The spectra confirmed the presence of the complexes and the peaks ranged between 
100-1000 m/z, the complete spectra of the complexes is shown in Appendix A.4. The 
Schiff base complexes (Cu1(in)-Cu7(in)) produced molecular ion peaks that had lost 
a proton, while the reduced complexes (Cu1-Cu7) produced molecular ion peaks that 
gained a proton (Figure 4.9). The spectra of the Schiff base complexes produced more 
fragmentation than the reduced complexes, with similar fragmentation peaks of 
Cu1(in) and Cu2(in). However, the abundance of the molecular ion peak in Cu2(in) 
was greater than Cu1(in), which suggests a more stable structure. Cu3(in) and Cu4(in) 
produced peaks at comparatively low abundances, which is due to the more rigid 
structure of the Schiff base, as well as halogens on the pyridine rings.125 This is shown 
by fragmentation observed in both spectra, as Cu3(in) breaks down into 2 peaks 
(153.02 and 215.95) equivalent to the [M-1H] peak, while Cu4(in) loses 2 bromine 
ions from the molecular ion at the peak at 390.88 m/z.
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Figure 4.9 Mass spectra, monoisotopic mass analysis and structure of Cu1.
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The low abundance of Cu3(in) and Cu4(in), could be due to the presence of halogens, 
which are electron withdrawing and hence the lone electron pairs of the nitrogen donor 
atoms move towards the halogen, making the coordination to Cu(II) weaker.124 
Similarly, Cu5(in) and Cu6(in) presented evidence of fragmentation and the 
abundance of the molecular ion peak in Cu7(in), was relatively low in comparison to 
all the other complexes, which indicates the lack of stability of this structure.126 The 
reduced complexes all exhibited the [M+1] peak. The complexes Cu4, Cu5 and Cu7 
had relatively low abundance in comparison with Cu1-Cu3 and Cu6. Overall the 
reduced complexes had a higher abundance than the Schiff base complexes.126 As the 
Schiff base N4-TLs have a rigid structure, a low abundance of the Cu(II) complex is 
expected.127  
 
4.4.!Biological Testing 
The synthesised copper(II) complexes and ligands were assessed to ascertain if they 
exhibited antimicrobial or anticancer activity. Initially MIC testing was performed on 
the copper(II) complexes in duplicates, however none exhibited activity against Gram-
negative, Gram-positive or fungal strains. So further antibacterial testing on other 
bacterial and fungal strains as well as biofilms was not pursued. A single concentration 
investigation of the anticancer activity of all the copper(II) complexes and 
hydrogenated ligands was performed at 30 µM and subsequently the active ligands 
were assessed at different concentrations to obtain IC50 values. ESI-QDNA binding 
experiments were conducted with the Cu(II) complexes that had been isolated as 
crystals and their structure confirmed. 
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4.4.1.! MIC Assays 
The copper(II) complexes were incubated overnight at different concentrations (2 - 64 
µg/mL) against S. aureus, K. pneumoniae and C. krusei and compared with 
antimicrobial reference agents such as ampicillin (S. aureus), streptomycin (K. 
pneumoniae) and 5-fluorocyctosine (C. krusei). None of the synthesised copper(II) 
complexes inhibited bacterial growth with the microbial growth similar to or larger 
than the blank after incubation. In the assays against Gram-negative bacteria, the 
complexes promoted growth in comparison with the blanks, particularly at higher 
concentrations. These complexes did not exhibit antimicrobial properties against the 
tested Gram-negative, Gram-positive or fungal strains as all complexes had 100% or 
greater bacterial growth after 24-hour incubation in comparison with a water blank, 
while ampicillin eradicated microbial growth >95%. (see Figure 4.10) 
 
4.4.2.! Cytotoxicity Assays 
Cell-line testing was conducted to ascertain activity against cancer cells.29 Preliminary 
screening of 5 Schiff base ligands (L1(in)-L4(in) and L7(in)) was conducted against 
11 cancer cell lines. L1(in), L2(in), L3(in) and L7(in) exhibited IC50 values below 20 
against all the cell lines. Whereas L4(in) had relatively high value in comparison with 
the other ligands and therefore was not tested further. L1(in), L2(in) and L7(in) had 
IC50 values comparable to cisplatin (1.0 ± 0.1 µM) and better than carboplatin (9 ± 3 
µM) in A2780 cancer cell lines (Table 4.5). As a result, a single concentration assay 
at 30 µM against A2780 ovarian cancer cells was run with both the Schiff base and 
reduced copper(II) complexes. All the copper complexes except Cu1, Cu1(in), Cu4 
and Cu4(in) killed more than 50% of cells after 72 hrs of incubation. (Appendix A.7)
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Figure 4.10 MIC Cu1-Cu6 and ampicillin at different concentrations (2-64 µg/mL) against S. aureus. (n=2)
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Table 4.5 IC50s (µM) of L1(in)-L4(in) and L7(in). (n=3)  
Cell lines L1(in) L2(in) L3(in) L4(in) L7(in) Cisplatin 
Colon (HY29) 3.0 ± 0.2 4.7 ± 0.8 18 ±1 >50 3.0 ± 0.1 11.3 ± 1.9 
Glioblastoma (U87) 2.9 ± 0.2 6.1 ± 0.4 19 ± 1 63 ± 7 4.8 ± 0.2 3.8 ± 1.1 
Breast (MCF-7) 3.2 ± 0.3 3.6 ±0.2 17 ± 1 60 ± 13 3.5 ± 0.2 6.5 ± 0.8 
Ovarian (A2780) 3.0 ± 0.3 2.4 ± 0.2 14 ± 1 29 ± 3 3.0 ± 0.1 1.0 ± 0.1 
Lung (H460) 2.8 ± 0.1 3.5 ± 0.2 9.7 ± 1.1 >50 2.6 ± 0.0 0.9 ± 0.2 
Skin (A431) 2.7 ± 0.1 3.5 ± 0.2 13 ± 0 60 ± 14 2.6 ± 0.0 2.4 ± 0.3 
Prostate (Du145) 2.3 ± 0.1 3.7 ± 0.3 8.0 ± 2.0 63 ± 7 2.8 ± 0.3 1.2 ± 0.1 
Neuroblastoma (BE2-C) 2.5 ± 0.1 2.8 ± 0.2 2.7 ± 0.3 46 ± 7 1.6 ± 0.2 1.9 ± 0.2 
Glioblastoma (SJ-G2) 2.4 ± 0.1 3.0 ± 0.1 3.3 ± 0.4 >50 2.4 ± 0.1 0.4 ± 0.1 
Pancreas (MIA) 3.2 ± 0.4 3.1 ± 0.4 14 ± 1 41 ± 3 3.3 ± 0.2 7.5 ± 1.3 
Breast (MCF10A) 2.9 ± 0.1 4.1 ± 0.5 15 ± 0 >50 2.9 ± 0.1 Not determined 
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Table 4.6 IC50s of copper(II) complexes against an A2780 cancer cell line (n=2). 
(Green=IC50s lower than cisplatin) 
 
Complex IC50 Value (µM) IC50 of N4-TLs* 
Cu1 >30 - 
Cu2 16.5 ± 0.02 - 
Cu3 2.2 ± 0.02  - 
Cu5 3.4 ± 0.1 - 
Cu6 5 ± 0.02 - 
Cu7 6.9 ± 0.1 - 
Cu1(in) >30  3.0 ± 0.3 
Cu2(in) 13.6 ± 1.2 2.4 ± 0.2 
Cu3(in) 1.9 ± 0.1 17 ± 1 
Cu5(in) 3.3 ± 0.4 - 
Cu6(in) 4.8 ± 0,4 - 
Cu7(in) 6.7 ± 0.2 3.0 ± 0.1 
Cisplatin 2 ± 0.04 1.0 ± 0.1 
*Conducted at the Calvary Mater Newcastle Hospital, Waratah, NSW, Australia. 
 
 
Based on the results from the single concentration assay, (Cu1 - Cu7 and Cu1(in), -
Cu7(in)), were assessed against A2780 cancer cell line to obtain their IC50 values, 
compared with cisplatin. The Schiff base complexes (Cu1(in), Cu2(in), Cu3(in), 
Cu5(in) and Cu6(in)) exhibited similar IC50 values to the reduced complexes, however 
the majority had higher IC50 values than cisplatin. Both Cu3 and Cu3(in) 
demonstrated cytotoxic activity, however these complexes include halogens 
substituted on the pyridyl ring. This destabilises the coordination to Cu(II) and could 
be responsible for the observed activity.124 A comparison of the IC50 values of L1(in)-
L3(in), and L7(in), and their Cu(II) complexes, reveal that Cu(II) coordination reduces 
cytotoxicity (Table 4.5 and 4.6). Cu1(in), Cu2(in), Cu1 and Cu2, were the least 
cytotoxic and the inclusion of an SS and RR-dach group in the bridge or ethyl and 
chloride substitution on the pyridyl ring increased cytotoxicity. It was noted that the 
IC50 value obtained for cisplatin at the Calvary Mater Newcastle Hospital, was 
different to those obtained in the A2780 cell lines at WSU. It would be useful to repeat 
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this assay with the N4-TLs and their complexes together to be able to ascertain if 
cytotoxicity reduced upon coordination to Cu(II).  
 
4.4.3.! Q-DNA Binding Studies 
Q-DNA binding studies require stable folded structures for mass spectrometry analysis 
as it is chiral and can be additionally characterised using CD spectrometry to confirm 
its structure and undertake melting experiments. Initial CD investigations revealed that 
the structure of the c-MYC oncogene (Protein data bank ID: 1XAV),116 had a high 
melting point and therefore it was theorised that it would be stable in QToF mass 
spectrometric analysis.114 Similarly, investigation by molecular modelling using the 
published protein data bank crystal structure allowed for better understanding of the 
potential binding of Cu(II) complexes (Figure 1.17). The negative ion mass spectrum 
of the free 1XAV (TGA GGG TGG GTA GGG TGG GTA A) yielded an abundance 
of 100% at 1396.4 m/z, which corresponds to a charged state of 5- and another peak at 
1749.8 m/z at an abundance of 30% corresponding to a 4- charged state of 1XAV (see 
Figure 4.11). The peaks were used to reference spectra when investigating binding 
ratios of the different copper(II) complexes. While the reported uncharged state 1XAV 
mass is equal to 7086.7 m/z,116 the experimentally calculated mass was 6985.0 m/z, 
this loss of 101 m/z can be attributed to interactions with the ammonium buffer.112 
 
 
 
 
 
Figure 4.11 Negative ion mass spectrum of free 1XAV.!  = 5- charged state;   =4- 
charged state. 
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Different ratios of Cu1 were mixed with 1XAV with the 1:5 experiment exhibiting a 
100% abundance at 1462 m/z, which is indicative of one Cu(II) complex binding to 
1XAV. As the difference between the two 5- charged states of free DNA and Cu1 1:5 
is 66.273 m/z, when multiplied by 5 it equals 331.36 and this is the equivalent mass of 
Cu1. A 1XAV + Cu1 complex is produced from a 1:5. At a ratio of 1:3, the abundance 
of the 1XAV and Cu1 is relatively low (50%) compared to the free 1XAV, however, 
at a ratio of 1:7 the complex and QDNA break down into fragments and no free 1XAV 
or bound complex peaks are visible (see Figure 4.12). Therefore, this complex has a 
strong binding affinity when it is introduced to 1XAV at a ratio of 1:5. Cu1(in) 
exhibited some activity at the same ratio as Cu1, however the m/z difference between 
the free 1XAV5- charged state and complex peak was 12.50, which when multiplied 
by 5 yielded a difference of 63.0 m/z (see Figure 4.13). Indicating that only the Cu(II) 
ion bound to 1XAV and the N4-TLs Schiff base does not stay coordinated when titrated 
into 1XAV, instead free Cu2+ binds.  
 
 
 
 
 
 
 
Figure 4.12 Relative abundances of ions in ESI mass spectra of 1:3, 1:5 and 1:7 
binding of Cu1 to 1XAV.!  = Free 1XAV5-;  = 1XAV5- + Cu1 and = 1XAV4- 
+ Cu1. 
 
 
 
 
 
1:7 
1:5 
1:3 
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Figure 4.13 Relative abundances of ions in ESI mass spectra of 1:5 and 1:7 binding 
of Cu1(in) to QDNA 1XAV. = 1XAV5- + Cu2+ 
 
Cu2 also bound to 1XAV but at a ratio of 1:4. The complex + 1XAV peak was 
expressed at 100%, however at 1:5 the abundance of this peak decreased to 60% and 
at a ratio of 1:7 fragmentation was observed (see Figure 4.14). Binding was also 
observed at 1:3 and 1:1, however in much smaller abundance. As it binds at a smaller 
ratio than Cu1, this indicates that Cu1 is stable and binds effectively. Peaks for this 
complex and 1XAV are expressed in a charged state of 5- and 4- at 1462.70 and 
1750.28, respectively. There are no peaks at 1408.91 m/z or 1450.44 m/z and the 
complex does not breakdown, as there is no evidence of free Cu2+ or L2 binding. Both 
Cu5(in) and Cu6 did not bind to 1XAV and this revealed that both the hydrogenated 
and Schiff base ligands containing 1,2-diaminocyclohexane were not stable in these 
experiments. The smaller square planar complexes, Cu1 and Cu2, exhibited binding 
to 1XAV. The remaining 3 complexes only exhibited the Cu2+ binding to the 1XAV 
molecule, indicating breakdown of the complex under the experimental conditions of 
ESI-MS.  
 
1:7 
1:5 
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Figure 4.14 Relative abundances of ions in ESI mass spectra of 1:1, 1:3, 1:4, 1:5 and 1:7 (bottom to top) binding of Cu2 to 1XAV. ! != Free 
1XAV5- charged state; =1XAV5- + Cu2 and = 1XAV4- + Cu2.
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5. Conclusions and 
Future Work 
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5.1.! Conclusion 
The 14 proposed N4-tetradetate ligands investigate the influences of bridging ligand 
flexibility and pyridyl rings substitution on the resulting biological activity of the 
ligands and the copper(II) coordinated complexes. This research project confirmed that 
the proposed N4-TLs and their respective copper(II) complexes could be successfully 
synthesised, through characterisation by NMR, UV, CD, ESI mass spectroscopy and 
in seven instances crystals were isolated that were suitable for x-ray crystallography. 
The yield of both the N4-TLs and the complexes was good with >50% yield for all 
products. NMR spectroscopy was utilized to characterise Schiff base and reduced N4-
TLs and in each case the 1H NMR was consistent with the chemical shifts observed 
for previously synthesised ligands. UV and ESI mass spectroscopy were also used to 
characterise the ligands and where 1R,2R- and 1S,2S-diaminocyclohexane was used in 
the synthesis, CD was employed to confirm chirality of the resulting N4-TL. These 
isolated ligands were coordinated to copper(II) where UV, ESI-MS and where 
appropriate, CD and X-ray crystallography was used to confirm the synthesis of the 
desired complex.  
 
N4-TLs and their complexes were assessed for antibacterial activity and compared with 
antimicrobial reference compounds ampicillin (S. aureus), streptomycin (K. 
pneumoniae) and 5-fluorocyctosine (C. krusei) however, none of the N4-TLs or copper 
complexes exhibited any antibacterial activity. The cytotoxicity for N4-TLs: L1(in), 
L2(in), L3(in), L4(in) and L7(in) was determined against Breast (MCF10A) cell lines 
and Colon (HY29), Glioblastoma (U87), Breast (MCF-7), Ovarian (A2780), Lung 
(H460), Skin (A431), Prostate (Du145), Neuroblastoma (BE2-C), Glioblastoma (SJ-
G2) and Pancreas (MIA) cancer cell lines. N4-TLs: L1(in), L2(in) and L7(in) were 
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more cytotoxic than cisplatin in Colon (HY29), Breast (MCF-7) and Pancreas (MIA) 
cancer cell lines and exhibited comparable activity in Ovarian (A2780), Lung (H460), 
Skin (A431), Prostate (Du145) and Neuroblastoma (BE2-C) cell lines. Copper 
complexes, in general where less cytotoxic than the N4-TLs they were made from. 
Only copper complexes, Cu3 and Cu3(in) were as potent than cisplatin in the Ovarian 
(A2780) cell line.  
 
The structure of the copper complexes that were observed using X-ray crystallography, 
and this showed that the N4-TL coordinated in a relatively corrugated fashion around 
the copper with water molecules in the axial positions (as seen in Figure 4.1.) It was 
hypothesized that this type of structure would be a suitable size and shape to associate 
with Q-DNA by end-stacking. The c-MYC oncogene from the Protein data bank (ID: 
1XAV) was used for these experiments. This Q-DNA had not been evaluated by ESI-
Ms before. 1XAV was determined to be stable under the experimental conditions used 
for ESI-MS and copper complexes, Cu1 and Cu2 formed stable associations with 
1XAV. The ratio with the highest binding abundance for both these complexes was 
1:4 and 1:5. Cu1(in), Cu5(in) and Cu6, were more labile, resulting in only Cu2+ bound 
to the 1XAV.!!
5.2.!  Future Work 
5.2.1.! Synthesis, purification and characterisation 
As a better understanding of which N4-TLs have cytotoxic activity was ascertained, 
this will help inform design modification to the N4-TLs to form more stable complexes. 
As the 3-methyl, 4-methyl and 4-ethyl groups produced the most stable complexes, it 
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would be worthwhile to lengthen the bridge, to see if cytotoxicity improves. Modelling 
suggests that adding flexible and longer groups to replace the 3-methyl, 4-methyl and 
4-ethyl groups may improve QDNA binding affinity. Although the inclusion of 
chlorine and bromine in the 5th and 6th position of the pyridine ring lowered the 
cytotoxicity, it may be useful to add groups that can coordinate such as hydroxyl or 
carboxylic acid groups to see if stability and cytotoxicity are influenced.75  
 
While the copper complexes reported here exhibited minimal antimicrobial activity, 
[Ru(2,9-dimethyl-1,10-phenanthroline)2(dipyrido[3,2-α:2,3-c]phenazine)] has been 
reported to demonstrate antimicrobial potential, with activity against MRSA strains 
(see Figure 5.1).128 Other metal centres, such as ruthenium(II) and cobalt(II), could be 
investigated, as the change in geometry will influence cytotoxicity.129 Similarly, as 
ruthenium complexes containing a 2-(2-pyridyl)indole ligand have been reported to 
exhibit impressive IC50 values, coordinating this ligand to ruthenium(II) could 
potentially increase cytotoxic activity (see Figure 5.1).130  
 
5.2.2.! Biological testing 
It was not possible in this work to undertake cytotoxic testing against the range of cell 
lines for both the N4-TLs and copper complexes. Future work should facilitate 
preliminary screening of both N4-TLs and complexes against the same cell lines. 
Antibacterial screening is warranted if other metals are used. While the complexes 
exhibited minimal activity against certain microbial strains, it would be useful to test 
against different strains to confirm a lack of activity against microbial strains. 
Inductively-coupled plasma mass spectrometry (ICP-MS) could also be utilized to 
analyse the amount of copper complex that is actually taken up by the microbial cells,   
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Figure 5.1 Potential cytotoxic (1) and antimicrobial (2) Ru(II) complexes with N4-
TLs. 128, 130  
1 
2 
!!! 96!
to ascertain if this is the reason for poor bacteriostatic activity.131 Similarly minimum 
biofilm eradication concentration (MBEC) assays could also be performed to ascertain 
if complexes exhibited greater activity against biofilms.106  
 
QDNA binding studies with Cu7, should be undertaken to determine if group and 
substitution position influences binding affinity to QDNA. As only one type of Q-
DNA (1XAV) was investigated, it would be useful to attempt titrations with other 
types (see Figure 5.2), despite few Q-DNAs being stable enough for ESI-MS 
experiments.132 Alternatively, CD melts could also be performed to ascertain thermal 
denaturation properties of various Q-DNAs with metal complexes.103 Modelling and 
docking software such as Avogadro and AutoDockVina could be used to optimise the 
ligand structure, improve binding affinities, compare different complexes and compare 
different QDNA structures. This could help to understand which types of structures 
have a better fit to specific QDNA structures,114 before “wet” binding studies are 
conducted.  
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Figure 5.2 Other QDNA structures that can be used for further binding studies, 
2KKA133 (top) and 1KF1134 (bottom).!  
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A.1. X-ray Crystallography Tables 
 
Table A.1.1 Cu1(in) Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu1(in). Ueq is defined as 1/3 of the trace of 
the orthogonalised UIJ tensor. 
Atom x  y z U(eq) 
Cu1 4889.0(3)  4309.7(4) 4544.9(3) 34.2(2) 
N1 5766(3)  2883(3) 4947(3) 34.6(7) 
N2 6221(3)  4993(4) 5351(3) 45.6(10) 
N3 4458(3)  5894(4) 4362(3) 40.5(8) 
N4 3355(3)  4088(3) 3731(3) 33.1(7) 
C1 5491(4)  1798(4) 4770(4) 40.3(10) 
C2 6205(5)  913(5) 5082(4) 45.5(11) 
C3 7243(4)  1178(5) 5615(4) 48.6(12) 
C4 7552(4)  2291(5) 5819(4) 44.2(10) 
C5 8685(4)  2602(7) 6396(5) 61.2(15) 
C6 6789(4)  3139(4) 5476(4) 37.9(10) 
C7 7003(4)  4337(5) 5670(4) 46.8(12) 
C8 6200(6)  6217(6) 5508(7) 83(2) 
C9 5292(5)  6729(5) 4732(6) 63.7(16) 
C10 3508(4)  6088(4) 3826(4) 39.8(10) 
C11 2841(3)  5092(4) 3463(3) 35.7(9) 
C12 1202(4)  6237(6) 2555(5) 55.4(13) 
C13 1767(4)  5143(5) 2901(4) 42(1) 
C14 1231(4)  4125(5) 2650(4) 45.4(11) 
C15 1742(4)  3108(5) 2928(4) 43.6(10) 
C16 2814(4)  3123(4) 3472(3) 38.2(10) 
Cl1 3852.8(8)  3203.3(9) 6393.1(7) 38.1(3) 
O1 2823(3)  3526(3) 6315(4) 59.1(10) 
O2 4396(4)  4166(4) 6161(3) 53.9(10) 
O3 3837(4)  2287(3) 5722(3) 57.2(9) 
O4 4412(4)  2852(5) 7420(3) 71.2(12) 
Cl2 8213.4(9)  4626.6(11) 3561.1(9) 47.1(3) 
O5 7485(5)  3742(5) 3103(6) 99(2) 
O6 8925(5)  4257(5) 4513(5) 94(2) 
O7 8774(5)  5074(8) 2973(5) 111(3) 
O8 7597(6)  5509(6) 3743(8) 113(3) 
O9 5337(3)  4373(3) 2989(3) 41.0(8) 
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Table A.1.2 Anisotropic Displacement Parameters (Å2×103) for Cu1(in). The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cu1 26.4(3) 24.1(3) 47.5(3) -0.4(2) 6.99(18) 0.2(2) 
N1 30.6(18) 30(2) 42.1(17) 0.9(14) 11.1(14) 0.0(14) 
N2 34(2) 33(2) 58(2) 3.2(16) 1.2(17) -8.1(15) 
N3 40.5(19) 30(2) 54(2) -3.9(15) 20.4(17) -0.8(15) 
N4 27.5(18) 29.4(18) 41.4(17) 5.0(13) 10.5(14) -0.4(14) 
C1 35(2) 34(3) 52(2) -4.4(18) 14.4(18) 1.2(17) 
C2 54(3) 33(3) 54(2) 1(2) 24(2) 7(2) 
C3 46(3) 45(3) 60(3) 12(2) 25(2) 17(2) 
C4 33(2) 48(3) 51(2) 12(2) 14.7(18) 6(2) 
C5 33(2) 72(4) 69(3) 26(3) 6(2) 13(2) 
C6 28(2) 40(3) 43(2) 9.6(18) 10.1(16) 3.9(18) 
C7 26(2) 46(3) 58(3) 5(2) 2(2) -9.0(19) 
C8 64(4) 31(3) 116(6) 4(3) -15(4) -12(3) 
C9 47(3) 26(3) 107(5) -10(3) 12(3) -8(2) 
C10 37(2) 25(2) 60(3) 5.5(19) 19.8(19) 6.6(18) 
C11 30(2) 39(3) 41(2) 4.2(16) 16.3(17) 5.5(16) 
C12 38(2) 55(4) 73(3) 20(3) 19(2) 15(2) 
C13 33(2) 49(3) 47(2) 12(2) 17.2(18) 8.0(19) 
C14 30(2) 58(3) 46(2) 10(2) 10.5(18) -1(2) 
C15 37(2) 48(3) 43(2) -0.3(18) 9.8(18) -12(2) 
C16 32(2) 37(3) 44(2) 4.3(17) 11.9(18) -0.1(17) 
Cl1 33.6(5) 36.2(6) 45.3(5) -3.6(4) 14.8(4) 0.0(4) 
O1 37.1(18) 37(2) 103(3) 5.7(19) 24.6(19) 3.2(15) 
O2 58(2) 51(2) 61(2) -13.4(16) 30.4(19) -20.9(17) 
O3 74(2) 41(2) 66(2) -15.7(16) 37.3(19) -8.4(17) 
O4 71(3) 90(4) 50.1(19) 10(2) 17.1(19) 19(2) 
Cl2 39.2(6) 30.6(6) 67.1(7) 5.7(5) 12.8(5) -2.3(4) 
O5 68(3) 47(3) 164(6) -28(3) 17(3) -11(2) 
O6 84(4) 98(5) 84(4) 39(3) 9(3) 1(3) 
O7 77(3) 178(7) 77(3) 14(4) 25(3) -53(4) 
O8 85(4) 55(3) 190(8) -11(4) 38(5) 15(3) 
O9 32.2(16) 40(2) 50.3(18) 5.5(12) 13.9(14) 2.6(12) 
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Table A.1.3 Bond Lengths for Cu1(in). 
Atom Atom Length/Å Atom Atom Length/Å 
Cu1 N1 2.031(4) C6 C7 1.454(7) 
Cu1 N2 1.950(4) C8 C9 1.465(10) 
Cu1 N3 1.954(4) C10 C11 1.468(7) 
Cu1 N4 2.022(4) C11 C13 1.403(6) 
N1 C1 1.337(6) C12 C13 1.497(7) 
N1 C6 1.366(6) C13 C14 1.389(8) 
N2 C7 1.268(7) C14 C15 1.376(8) 
N2 C8 1.466(9) C15 C16 1.394(7) 
N3 C9 1.459(7) Cl1 O1 1.420(4) 
N3 C10 1.272(7) Cl1 O2 1.454(4) 
N4 C11 1.364(6) Cl1 O3 1.429(4) 
N4 C16 1.339(7) Cl1 O4 1.434(4) 
C1 C2 1.393(7) Cl2 O5 1.431(6) 
C2 C3 1.387(9) Cl2 O6 1.418(6) 
C3 C4 1.382(9) Cl2 O7 1.404(5) 
C4 C5 1.519(8) Cl2 O8 1.417(7) 
C4 C6 1.405(7)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110!!
Table A.1.4 Bond Angles for Cu1(in). 
Atom Atom Atom Angle/˚
  
Atom Atom Atom Angle/˚ 
N2 Cu1 N1 81.02(17) C4 C6 C7 123.7(5) 
N2 Cu1 N3 81.68(19) N2 C7 C6 116.1(4) 
N2 Cu1 N4 162.45(17) C9 C8 N2 110.7(5) 
N3 Cu1 N1 162.62(16) N3 C9 C8 109.7(5) 
N3 Cu1 N4 81.11(17) N3 C10 C11 116.1(4) 
N4 Cu1 N1 116.26(15) N4 C11 C10 114.1(4) 
C1 N1 Cu1 130.3(3) N4 C11 C13 121.9(4) 
C1 N1 C6 118.8(4) C13 C11 C10 124.0(5) 
C6 N1 Cu1 111.0(3) C11 C13 C12 122.6(5) 
C7 N2 Cu1 116.8(4) C14 C13 C11 117.3(5) 
C7 N2 C8 127.5(5) C14 C13 C12 120.1(5) 
C8 N2 Cu1 115.7(4) C15 C14 C13 121.1(5) 
C9 N3 Cu1 116.2(4) C14 C15 C16 118.4(5) 
C10 N3 Cu1 116.7(3) N4 C16 C15 122.2(5) 
C10 N3 C9 126.5(5) O1 Cl1 O2 109.7(3) 
C11 N4 Cu1 111.9(3) O1 Cl1 O3 111.3(3) 
C16 N4 Cu1 128.9(3) O1 Cl1 O4 108.9(3) 
C16 N4 C11 119.1(4) O3 Cl1 O2 109.9(2) 
N1 C1 C2 122.9(5) O3 Cl1 O4 108.6(3) 
C3 C2 C1 118.0(5) O4 Cl1 O2 108.4(3) 
C4 C3 C2 120.5(5) O6 Cl2 O5 109.7(4) 
C3 C4 C5 121.5(5) O7 Cl2 O5 116.5(5) 
C3 C4 C6 118.2(5) O7 Cl2 O6 109.4(4) 
C6 C4 C5 120.3(5) O7 Cl2 O8 107.6(6) 
N1 C6 C4 121.5(5) O8 Cl2 O5 104.9(4) 
N1 C6 C7 114.7(4) O8 Cl2 O6 108.3(5) 
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Table A.1.5 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for Cu1(in) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Atom x y         z U(eq) 
H1 4791 1626 4424 48 
H2 5992 166 4938 55 
H3 7734 602 5836 58 
H5A 8972 2977 5943 92 
H5B 9079 1929 6658 92 
H5C 8719 3097 6950 92 
H7 7675 4607 6010 56 
H8A 6169 6365 6179 99 
H8B 6837 6553 5474 99 
H9A 5047 7369 5021 76 
H9B 5490 7000 4169 76 
H10 3251 6820 3672 48 
H12A 1448 6788 3089 83 
H12B 465 6123 2394 83 
H12C 1332 6501 1960 83 
H14 516 4130 2289 54 
H15 1381 2428 2756 52 
H16 3165 2439 3661 46 
H9C 5913 4222 2908 62 
H9D 5097 4938 2603 62 
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Table A.1.6 Cu2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu2. Ueq is defined as 1/3 of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Cu1 3750.8(3) 5387.6(3) 6409.4(2) 22.4(3) 
Cl2 6035.4(7) 4181.4(7) 6615.8(5) 26.9(4) 
O5 5168(2) 4337(2) 6196.1(17) 38.8(8) 
O6 6285(2) 4972(3) 6944(2) 48.6(11) 
O7 6887(2) 3928(2) 6219.0(15) 32.4(7) 
O8 5822(4) 3579(3) 7114(2) 70.5(15) 
N1 4454(2) 6395(2) 6032.7(16) 22.4(7) 
N2 4280(3) 5866(2) 7258.1(16) 26.0(8) 
N3 3046(3) 4547(2) 6986.9(18) 28.1(8) 
N4 3146(3) 4704(2) 5688.7(18) 24.0(7) 
C1 4760(3) 6570(3) 5406.7(19) 24.9(8) 
C2 5122(3) 7343(3) 5217(2) 29.7(9) 
C3 5537(5) 8859(3) 5495(3) 49.6(13) 
C4 5178(3) 7988(3) 5686(2) 33(1) 
C5 4887(3) 7802(3) 6336(2) 31(1) 
C6 4538(3) 7010(3) 6497.8(19) 24.3(9) 
C7 4209(3) 6781(3) 7192(2) 28.2(9) 
C8 3720(3) 5472(3) 7819(2) 29.2(10) 
C9 3580(3) 4562(3) 7639(2) 29.3(10) 
C10 3003(3) 3750(3) 6628(2) 32.3(10) 
C11 2866(3) 3930(3) 5893(2) 26.4(9) 
C12 2503(3) 3336(3) 5445(2) 31.6(10) 
C13 2066(4) 2898(3) 4276(3) 43.4(12) 
C14 2407(3) 3530(3) 4775(2) 31.9(9) 
C15 2657(3) 4344(3) 4580(2) 30.3(9) 
C16 3016(3) 4906(3) 5044(2) 27.6(9) 
Cl1 1332.4(8) 6312.9(8) 6569.8(6) 33.1(4) 
O1 556(3) 6821(3) 6289.1(18) 46.0(9) 
O2 1496(3) 6565(3) 7251.7(18) 48.6(9) 
O3 1043(3) 5440(3) 6551(2) 48.3(10) 
O4 2273(2) 6423(2) 6208.6(18) 40.3(8) 
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Table A.1.7 Anisotropic Displacement Parameters (Å2×103) for Cu2. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 
 
U23 U13 
 
U12 
Cu1 25.2(4) 24.7(5) 17.3(4) 3.06(16) -0.45(16) -3.34(17) 
Cl2 25.2(6) 33.8(7) 21.9(6) -1.2(4) -0.1(4) 4.2(4) 
O5 31.0(16) 48(2) 37.6(18) -8.3(15) -10.4(14) 6.0(14) 
O6 34.0(18) 53(3) 59(2) -31(2) -6.1(15) 5.7(14) 
O7 30.1(16) 37.4(17) 29.7(15) -8.5(13) 3.9(12) 6.7(12) 
O8 75(3) 75(3) 62(3) 40(2) 27(2) 25(2) 
N1 21.2(15) 25.9(17) 20.0(15) -1.0(12) 0.3(12) -0.1(12) 
N2 24.3(16) 34.0(19) 19.7(15) 2.1(13) 2.5(13) -0.3(13) 
N3 26.3(17) 33(2) 25.4(18) 6.1(14) 0.0(14) 0.5(13) 
N4 25.6(16) 21.3(17) 25.1(17) 2.9(12) -2.7(13) -1.3(12) 
C1 24.3(19) 30(2) 20.5(18) -1.0(15) 2.3(15) -0.5(15) 
C2 28(2) 37(2) 23.7(19) 5.5(17) 2.1(15) -3.5(17) 
C3 63(3) 39(3) 47(3) 7(2) -3(3) -21(2) 
C4 32(2) 32(2) 35(2) 4.9(18) -4.7(17) -10.0(17) 
C5 34(2) 29(2) 29(2) -4.6(16) -4.1(17) -6.4(17) 
C6 22.1(19) 30(2) 20.3(18) 0.0(15) -2.3(14) 0.6(16) 
C7 29(2) 36(2) 19.6(19) -2.9(16) -1.2(15) -0.1(17) 
C8 23(2) 46(3) 18(2) 6.4(17) 2.4(14) 1.4(16) 
C9 25.8(19) 40(3) 22(2) 12.4(17) 0.7(16) 2.3(15) 
C10 30(2) 33(2) 34(2) 8.6(18) 1.7(17) -4.1(17) 
C11 22.7(18) 23(2) 34(2) 4.6(16) -0.6(16) -1.6(15) 
C12 31(2) 21(2) 43(2) 1.7(17) 0.2(18) -3.7(16) 
C13 53(3) 33(3) 44(3) -8(2) -1(2) -11(2) 
C14 27(2) 31(2) 38(2) -5.3(18) 0.4(17) -2.8(16) 
C15 33(2) 31(2) 27(2) -0.8(17) -4.8(16) -3.5(18) 
C16 31(2) 25(2) 27(2) 2.8(16) -4.8(16) -3.9(15) 
Cl1 24.4(6) 38.0(7) 37.0(7) 13.7(5) 2.4(4) 5.2(4) 
O1 35.4(18) 64(2) 38.3(18) 16.4(17) 2.1(15) 20.9(17) 
O2 44.2(19) 67(3) 34.4(19) 4.2(17) -0.8(15) 3.7(18) 
O3 32.0(18) 48(3) 65(3) 7.8(17) 2.1(18) -4.2(15) 
O4 31.4(17) 39.3(19) 50(2) 9.1(15) 13.5(15) 3.7(13) 
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Table A.1.8 Bond Lengths for Cu2. 
Atom Atom Length/Å Atom Atom Length/Å 
Cu1 N1 2.005(3) C2 C4 1.398(6) 
Cu1 N2 1.996(3) C3 C4 1.519(6) 
Cu1 N3 2.004(4) C4 C5 1.395(6) 
Cu1 N4 1.982(3) C5 C6 1.386(6) 
Cl2 O5 1.445(3) C6 C7 1.507(5) 
Cl2 O6 1.462(4) C8 C9 1.510(7) 
Cl2 O7 1.438(3) C10 C11 1.516(6) 
Cl2 O8 1.418(4) C11 C12 1.394(6) 
N1 C1 1.351(5) C12 C14 1.387(7) 
N1 C6 1.361(5) C13 C14 1.493(6) 
N2 C7 1.470(6) C14 C15 1.398(6) 
N2 C8 1.489(5) C15 C16 1.379(6) 
N3 C9 1.490(6) Cl1 O1 1.425(3) 
N3 C10 1.464(6) Cl1 O2 1.445(4) 
N4 C11 1.355(5) Cl1 O3 1.446(4) 
N4 C16 1.346(6) Cl1 O4 1.450(3) 
C1 C2 1.378(6)    
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Table A.1.9 Bond Angles for Cu2. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 Cu1 N1 81.57(13) C2 C4 C3 121.4(4) 
N2 Cu1 N3 85.66(14) C5 C4 C2 117.5(4) 
N3 Cu1 N1 166.16(14) C5 C4 C3 121.2(4) 
N4 Cu1 N1 110.62(14) C6 C5 C4 120.4(4) 
N4 Cu1 N2 167.66(14) N1 C6 C5 121.7(4) 
N4 Cu1 N3 82.36(15) N1 C6 C7 116.0(4) 
O5 Cl2 O6 107.1(2) C5 C6 C7 122.3(4) 
O7 Cl2 O5 110.2(2) N2 C7 C6 107.8(3) 
O7 Cl2 O6 108.5(2) N2 C8 C9 106.6(4) 
O8 Cl2 O5 111.8(3) N3 C9 C8 106.5(3) 
O8 Cl2 O6 108.2(3) N3 C10 C11 108.7(3) 
O8 Cl2 O7 110.9(2) N4 C11 C10 115.8(4) 
C1 N1 Cu1 131.0(3) N4 C11 C12 121.3(4) 
C1 N1 C6 117.8(3) C12 C11 C10 122.9(4) 
C6 N1 Cu1 110.9(3) C14 C12 C11 120.4(4) 
C7 N2 Cu1 106.3(2) C12 C14 C13 121.9(4) 
C7 N2 C8 117.2(3) C12 C14 C15 117.3(4) 
C8 N2 Cu1 108.1(3) C15 C14 C13 120.8(4) 
C9 N3 Cu1 106.2(3) C16 C15 C14 119.8(4) 
C10 N3 Cu1 108.3(3) N4 C16 C15 122.6(4) 
C10 N3 C9 117.7(3) O1 Cl1 O2 109.0(2) 
C11 N4 Cu1 113.0(3) O1 Cl1 O3 110.3(3) 
C16 N4 Cu1 128.5(3) O1 Cl1 O4 110.5(2) 
C16 N4 C11 118.4(4) O2 Cl1 O3 109.4(3) 
N1 C1 C2 123.2(4) O2 Cl1 O4 108.2(2) 
C1 C2 C4 119.4(4) O3 Cl1 O4 109.3(2) 
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Table A.1.10 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for Cu2. 
Atom x y z U(eq) 
H2 4996 5715 7298 31 
H3 2350 4740 7058 34 
H1 4725 6148 5089 30 
H2A 5326 7436 4780 36 
H3A 6238 8920 5610 74 
H3B 5145 9270 5729 74 
H3C 5456 8937 5024 74 
H5 4928 8213 6663 37 
H7A 4642 7052 7516 34 
H7B 3518 6963 7268 34 
H8A 3069 5742 7880 35 
H8B 4103 5523 8229 35 
H9A 4230 4284 7604 35 
H9B 3180 4278 7976 35 
H10A 2442 3416 6791 39 
H10B 3624 3438 6699 39 
H12 2324 2805 5596 38 
H13A 2058 2352 4478 65 
H13B 2522 2897 3905 65 
H13C 1397 3037 4126 65 
H15 2581 4506 4138 36 
H16 3175 5447 4906 33 
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Table A.1.11 Cu4 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu4. Ueq is defined as 1/3 of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Cu2 6054.4(3) 5944.0(3) 2373.7(2) 11.22(13) 
Cu3 9066.0(3) 5875.1(3) 3109.1(3) 16.64(13) 
Cu1 7834.5(3) 8046.6(3) 4023.8(3) 17.69(14) 
N1 6476(2) 8166(2) 2565.4(18) 19.3(5) 
N2 7445(2) 9662(2) 3919.9(18) 19.9(5) 
N3 6914(2) 7948(2) 4803.0(19) 20.0(5) 
N4 8137(2) 6423(2) 4425.8(19) 19.7(5) 
N5 9070(2) 8360(2) 3635(2) 22.7(5) 
C1 5819(2) 7432(3) 2018(2) 19.8(6) 
C2 4994(3) 7689(3) 1189(2) 24.3(6) 
C3 4848(3) 8778(3) 932(2) 25.7(7) 
C4 5514(3) 9567(3) 1494(2) 22.3(6) 
C5 6319(3) 9228(3) 2309(2) 19.6(6) 
C6 7087(3) 10044(3) 2939(2) 21.8(6) 
C7 6619(3) 9839(3) 4347(2) 23.5(6) 
C8 6804(3) 9058(3) 5156(2) 22.5(6) 
C9 7377(3) 7123(3) 5539(2) 22.2(6) 
C10 7783(2) 6178(3) 5134(2) 21.2(6) 
C11 7809(3) 5122(3) 5477(3) 27.7(7) 
C12 8200(3) 4278(3) 5082(3) 33.2(8) 
C13 8572(3) 4513(3) 4370(3) 30.4(7) 
C14 8531(3) 5595(3) 4074(2) 23.9(6) 
C15 9890(3) 8483(3) 3588(2) 22.4(6) 
C16 10935(3) 8577(3) 3526(3) 27.6(7) 
Cl1 3783.4(6) 7878.9(6) 3548.5(5) 23.91(19) 
O1 3143(2) 7110(3) 3833(3) 47.2(8) 
O2 4739(2) 7312(3) 3569(2) 40.4(7) 
O3 4091(3) 8779(3) 4200(2) 46.4(8) 
O4 3220(3) 8276(3) 2633(2) 55.6(9) 
Cl2 10243.1(6) 8394.8(6) 6209.5(5) 20.50(18) 
O5 9267(2) 8933(2) 5633.8(19) 30.5(5) 
O6 10008(2) 7272(2) 6349(2) 31.0(5) 
O7 11010(2) 8436(2) 5739.9(17) 27.8(5) 
O8 10654(2) 8949(2) 7095.8(18) 29.7(6) 
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Table A.1.12 Anisotropic Displacement Parameters (Å2×103) for Cu4. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cu2 15.5(2) 7.33(19) 10.62(19) -1.87(10) 4.41(13) -4.74(11) 
Cu3 27.1(2) 11.4(2) 20.8(2) -3.54(12) 19.93(16) 0.12(12) 
Cu1 19.8(2) 17.4(2) 18.3(2) 0.28(13) 9.74(15) 0.95(13) 
N1 20.8(13) 22.0(12) 17.4(12) -0.7(10) 9.6(10) -1.4(10) 
N2 21.3(12) 18.7(12) 19.7(12) -1.1(10) 7.2(10) 0(1) 
N3 20.5(13) 20.8(13) 20.0(12) -1(1) 9(1) 1.3(10) 
N4 20.1(12) 20.5(13) 20.6(12) 0.3(10) 9.7(10) -0.1(10) 
N5 24.0(14) 21.5(13) 25.7(13) -0.3(10) 12.5(11) -0.6(10) 
C1 20.7(14) 22.3(15) 19.3(14) -1.2(11) 10.7(11) -2.6(11) 
C2 20.7(15) 28.4(16) 22.9(15) -4.4(13) 6.4(12) -5.4(12) 
C3 21.6(15) 32.8(18) 20.6(15) 1.6(13) 4.8(12) 1.4(13) 
C4 24.2(15) 23.0(15) 21.1(14) 1.3(12) 9.7(12) 1.8(12) 
C5 20.3(14) 21.4(14) 19.1(14) -1.4(11) 9.5(11) -0.8(11) 
C6 24.7(15) 20.3(14) 19.6(14) -0.1(11) 6.6(11) -2.4(12) 
C7 23.7(15) 24.2(15) 23.4(15) -0.6(12) 9.3(12) 4.6(12) 
C8 24.5(16) 25.1(16) 20.5(15) -3.0(11) 11.0(12) 3.0(12) 
C9 25.9(16) 23.9(15) 20.6(14) 2.2(12) 12.7(12) 1.6(12) 
C10 18.3(14) 24.3(15) 22.3(14) 0.8(12) 8.5(11) -0.5(12) 
C11 30.2(17) 27.7(17) 29.5(17) 7.9(13) 15.8(14) 1.6(13) 
C12 37(2) 22.2(16) 44(2) 10.8(15) 18.1(17) 4.2(14) 
C13 34.3(19) 21.2(16) 41(2) 0.9(14) 20.3(16) 4.9(14) 
C14 24.6(15) 22.9(15) 26.8(16) 0.5(12) 12.3(12) 0.8(12) 
C15 27.3(16) 18.9(14) 22.4(14) 0.8(11) 10.5(12) 1.7(12) 
C16 25.9(16) 29.0(17) 32.1(17) 2.6(13) 15.5(14) 0.0(13) 
Cl1 26.8(4) 22.5(4) 24.5(4) 1.5(3) 11.7(3) 2.5(3) 
O1 30.0(15) 49.6(19) 68(2) 19.1(16) 23.9(15) 0.9(13) 
O2 27.4(13) 38.0(15) 59.4(19) -15.8(14) 19.7(13) -2.6(12) 
O3 80(2) 27.3(14) 35.0(15) -4.3(12) 24.7(16) 10.3(15) 
O4 71(2) 50(2) 31.3(16) 9.7(14) 0.0(15) -1.5(17) 
Cl2 19.8(3) 22.0(4) 20.8(3) -1.1(3) 8.6(3) 0.2(3) 
O5 25.5(12) 34.2(14) 31.1(13) 2.8(10) 9.2(10) 7(1) 
O6 30.5(13) 24.5(12) 40.8(14) 0.3(11) 16.2(11) -2.2(10) 
O7 25.9(12) 35.4(13) 25.7(12) -1.9(10) 13.4(10) -1.8(10) 
O8 29.6(13) 38.2(14) 23.3(12) -7.5(10) 11.6(10) -5.6(10) 
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Table A.1.13 Bond Lengths for Cu4. 
Atom Atom Length/Å Atom Atom Length/Å 
Cu2 C1 1.893(3) C3 C4 1.390(5) 
Cu3 C14 1.889(3) C4 C5 1.395(5) 
Cu1 N1 2.338(3) C5 C6 1.514(4) 
Cu1 N2 2.036(3) C7 C8 1.514(5) 
Cu1 N3 2.002(3) C9 C10 1.502(5) 
Cu1 N4 2.076(3) C10 C11 1.391(5) 
Cu1 N5 1.989(3) C11 C12 1.390(5) 
N1 C1 1.329(4) C12 C13 1.379(5) 
N1 C5 1.352(4) C13 C14 1.394(5) 
N2 C6 1.481(4) C15 C16 1.446(5) 
N2 C7 1.491(4) Cl1 O1 1.442(3) 
N3 C8 1.487(4) Cl1 O2 1.451(3) 
N3 C9 1.476(4) Cl1 O3 1.444(3) 
N4 C10 1.362(4) Cl1 O4 1.423(3) 
N4 C14 1.340(4) Cl2 O5 1.455(3) 
N5 C15 1.141(5) Cl2 O6 1.442(3) 
C1 C2 1.396(5) Cl2 O7 1.451(3) 
C2 C3 1.383(5) Cl2 O8 1.441(3) 
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Table A.1.14 Bond Angles for Cu4. 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N2 Cu1 N1 76.83(10) N1 C5 C4 122.5(3) 
N2 Cu1 N4 165.83(11) N1 C5 C6 116.5(3) 
N3 Cu1 N1 97.65(10) C4 C5 C6 120.9(3) 
N3 Cu1 N2 84.79(11) N2 C6 C5 110.1(3) 
N3 Cu1 N4 82.17(11) N2 C7 C8 109.5(3) 
N4 Cu1 N1 110.38(10) N3 C8 C7 106.7(3) 
N5 Cu1 N1 99.01(11) N3 C9 C10 109.1(3) 
N5 Cu1 N2 90.48(11) N4 C10 C9 116.1(3) 
N5 Cu1 N3 161.15(12) N4 C10 C11 122.4(3) 
N5 Cu1 N4 100.11(11) C11 C10 C9 121.5(3) 
C1 N1 Cu1 133.0(2) C12 C11 C10 119.2(3) 
C1 N1 C5 117.7(3) C13 C12 C11 119.2(3) 
C5 N1 Cu1 109.1(2) C12 C13 C14 118.0(3) 
C6 N2 Cu1 111.59(19) N4 C14 Cu3 119.3(2) 
C6 N2 C7 111.8(3) N4 C14 C13 124.3(3) 
C7 N2 Cu1 108.5(2) C13 C14 Cu3 116.3(3) 
C8 N3 Cu1 108.9(2) N5 C15 C16 176.9(4) 
C9 N3 Cu1 108.24(19) O1 Cl1 O2 107.5(2) 
C9 N3 C8 114.6(3) O1 Cl1 O3 110.2(2) 
C10 N4 Cu1 111.0(2) O3 Cl1 O2 108.3(2) 
C14 N4 Cu1 131.9(2) O4 Cl1 O1 110.6(2) 
C14 N4 C10 116.8(3) O4 Cl1 O2 110.2(2) 
C15 N5 Cu1 166.6(3) O4 Cl1 O3 110.1(2) 
N1 C1 Cu2 117.5(2) O6 Cl2 O5 108.80(16) 
N1 C1 C2 124.0(3) O6 Cl2 O7 109.74(16) 
C2 C1 Cu2 118.4(2) O7 Cl2 O5 109.35(16) 
C3 C2 C1 117.6(3) O8 Cl2 O5 108.79(17) 
C2 C3 C4 119.8(3) O8 Cl2 O6 109.87(17) 
C3 C4 C5 118.3(3) O8 Cl2 O7 110.26(16) 
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Table A.1.14 Hydrogen Atom Coordinates (Å×104) and 
Isotropic Displacement Parameters (Å2×103) for Cu4. 
Atom x y z U(eq)  
H2 8079 10080 4280 24 
H3 6208 7696 4404 24 
H2A 4557 7147 823 29 
H3A 4306 8981 384 31 
H4 5425 10303 1332 27 
H6A 7696 10129 2745 26 
H6B 6743 10749 2889 26 
H7A 5919 9717 3883 28 
H7B 6652 10587 4566 28 
H8A 7445 9255 5670 27 
H8B 6209 9077 5375 27 
H9A 6840 6870 5781 27 
H9B 7954 7444 6050 27 
H11 7567 4981 5965 33 
H12 8211 3564 5294 40 
H13 8843 3965 4096 37 
H16A 10963 9218 3173 41 
H16B 11078 7941 3221 41 
H16C 11458 8633 4143 41 
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Table A.1.15 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu5(in). Ueq is defined as 1/3 of the trace of 
the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Cu1 3090.6(5) 5660.4(3) 6604.7(2) 20.93(17) 
Cl1 -1744.1(10) 7006.3(6) 5714.1(2) 24.5(2) 
O1 -1004(3) 6513(2) 6152.5(8) 31.4(5) 
O1W 6227(3) 5387.9(19) 6710.1(8) 27.8(5) 
O2 -2957(3) 7901(2) 5844.9(9) 32.7(5) 
O3 -196(3) 7392(2) 5425.9(9) 33.6(5) 
O4 -2785(4) 6185(2) 5456.9(10) 39.9(6) 
N1 3014(3) 7305.6(19) 6661.9(9) 21.4(5) 
N2 3302(3) 6027(2) 5931.6(8) 19.6(5) 
N3 2198(3) 4276(2) 6341.8(9) 22.6(5) 
N4 2626(4) 4849(2) 7228.2(9) 22.8(5) 
C1 2768(4) 7917(3) 7052.8(11) 25.0(6) 
C2 2560(5) 9045(3) 7024.7(12) 28.6(7) 
C3 2638(5) 9542(3) 6583.2(12) 27.3(6) 
C4 3074(5) 9463(2) 5687.6(11) 29.1(6) 
C5 2934(4) 8925(2) 6169(1) 22.7(6) 
C6 3098(4) 7794(2) 6227.2(10) 20.3(5) 
C7 3312(4) 7028(2) 5820.1(10) 19.7(5) 
C8 3364(4) 5073(2) 5615.8(10) 20.8(5) 
C9 2981(5) 5279(2) 5086.6(10) 24.8(6) 
C10 3038(5) 4191(3) 4821.1(10) 29.1(6) 
C11 1666(5) 3350(3) 5033.8(11) 31.6(7) 
C12 1999(5) 3168(2) 5569.6(11) 25.0(6) 
C13 1900(4) 4269(2) 5822.2(10) 21.7(5) 
C14 1902(4) 3503(2) 6635.3(10) 21.7(5) 
C15 2178(4) 3780(2) 7147.7(10) 21.1(6) 
C16 1554(5) 1847(2) 7416.9(12) 30.5(7) 
C17 1971(4) 3026(2) 7514.4(11) 23.8(6) 
C18 2224(4) 3399(3) 7984.2(11) 26.0(6) 
C19 2670(4) 4487(3) 8068.0(11) 26.9(6) 
C20 2880(4) 5179(2) 7679.2(11) 25.6(6) 
Cl2 6974.9(12) 2486.7(6) 6417.1(3) 29.2(2) 
O5 8548(4) 1742(2) 6391.8(10) 34.2(5) 
O6 6920(5) 3189(2) 6012.8(9) 42.0(6) 
O7 7262(7) 3170(3) 6835.9(10) 66.1(11) 
O8 5270(5) 1884(3) 6461(2) 83.8(17) 
 
 
123!!
Table A.1.16 Anisotropic Displacement Parameters (Å2×103) for Cu5(in). The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 
 
U23 U13 
U12 
Cu1 29.6(2) 18.5(2) 14.7(2) -0.94(12) 0.62(13) -3.03(14) 
Cl1 23.2(3) 29.0(4) 21.4(3) -0.4(3) 2.3(2) 0.7(3) 
O1 29.2(11) 36.6(12) 28.3(11) 5.8(10) 2.4(10) 3.2(10) 
O1W 29.9(10) 29.5(11) 24.1(10) 2.6(9) 0.1(8) 0.0(8) 
O2 30.4(11) 34.1(12) 33.8(12) 0(1) 1.7(10) 7.9(10) 
O3 27.5(11) 39.9(13) 33.5(12) 11(1) 7.2(9) 2.2(10) 
O4 34.6(13) 50.3(15) 34.8(13) -15.7(12) 2.1(10) -7.3(11) 
N1 25.1(11) 19.8(11) 19.4(11) -1.8(9) 1.5(10) -2.5(9) 
N2 21.2(10) 21.3(11) 16.3(10) -0.8(9) -0.2(9) -0.9(9) 
N3 27.6(11) 22.3(11) 17.9(11) -1.1(9) -0.1(9) -2.4(10) 
N4 27.7(12) 22.2(11) 18.4(11) -1.6(9) 0.1(9) -0.7(9) 
C1 31.8(14) 25.0(14) 18.1(13) -0.6(11) 2.6(11) -4.6(11) 
C2 35.5(16) 25.7(14) 24.6(15) -8.3(12) 6.0(12) -2.7(11) 
C3 35.0(15) 20.5(13) 26.5(15) -3.0(11) 2.4(12) 0.0(11) 
C4 40.6(16) 22.0(13) 24.9(15) 3.6(11) -0.4(12) 0.3(14) 
C5 25.1(13) 21.2(13) 21.9(13) -0.8(11) 1.4(11) -1.0(11) 
C6 19.8(11) 22.1(12) 18.9(12) -0.5(10) -1.7(10) -1.1(10) 
C7 18.9(11) 22.2(13) 18.0(12) -1(1) 0.5(10) 0.2(10) 
C8 25.8(13) 20.3(12) 16.3(12) -2.3(10) -1.2(10) -0.3(10) 
C9 33.2(14) 25.5(13) 15.7(13) 0(1) 0.9(11) 1.0(13) 
C10 44.1(17) 27.0(14) 16.1(13) -2.6(11) 1.5(12) -0.7(14) 
C11 46.1(19) 28.3(15) 20.4(14) -4.8(11) -2.5(13) -7.2(14) 
C12 36.6(15) 20.3(13) 18.0(13) -3.9(10) -0.6(12) -3.8(12) 
C13 27.6(13) 22.9(13) 14.7(12) -3.5(10) -1.4(10) -1.5(13) 
C14 26.0(13) 20.9(12) 18.2(13) -2.9(10) 2.0(11) -2.4(11) 
C15 23.1(13) 21.2(13) 19.1(13) -1.4(10) 0(1) -1(1) 
C16 42.2(17) 22.8(14) 26.4(15) 4.1(11) -2.1(13) -2.7(13) 
C17 26.9(13) 23.8(14) 20.7(13) 0.8(11) 0.8(11) -0.9(12) 
C18 30.6(15) 29.1(15) 18.4(13) 3.5(11) 0.6(11) 1.4(12) 
C19 33.2(15) 31.6(15) 16.0(13) -3.8(12) -1.6(10) 2.2(12) 
C20 31.3(15) 22.5(13) 23.0(13) -3.5(11) -0.9(12) 0.5(12) 
Cl2 35.6(4) 27.4(4) 24.5(4) 6.6(3) -0.3(3) 0.7(3) 
O5 35.8(12) 29.9(12) 36.8(12) 0.9(10) -1.4(10) -0.9(9) 
O6 67.2(17) 35.4(12) 23.4(11) 6.7(10) -3.9(13) 4.8(13) 
O7 125(3) 52.6(17) 21.1(13) -2.1(12) -5.4(17) 35(2) 
O8 35.6(15) 54.9(19) 161(5) 51(3) -1(2) -1.2(14) 
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Table A.1.17 Bond Lengths for Cu5(in). 
Atom Atom Length/Å Atom Atom Length/Å 
Cu1 O1W 2.263(2) C4 C5 1.505(4) 
Cu1 N1 2.026(2) C5 C6 1.402(4) 
Cu1 N2 1.944(2) C6 C7 1.486(4) 
Cu1 N3 1.956(3) C8 C9 1.528(4) 
Cu1 N4 2.037(3) C8 C13 1.543(4) 
Cl1 O1 1.466(2) C9 C10 1.529(4) 
Cl1 O2 1.441(2) C10 C11 1.536(5) 
Cl1 O3 1.440(2) C11 C12 1.535(4) 
Cl1 O4 1.441(3) C12 C13 1.527(4) 
N1 C1 1.339(4) C14 C15 1.487(4) 
N1 C6 1.359(4) C15 C17 1.390(4) 
N2 C7 1.267(4) C16 C17 1.501(4) 
N2 C8 1.469(3) C17 C18 1.405(4) 
N3 C13 1.471(4) C18 C19 1.392(5) 
N3 C14 1.273(4) C19 C20 1.389(5) 
N4 C15 1.369(4) Cl2 O5 1.442(3) 
N4 C20 1.339(4) Cl2 O6 1.424(3) 
C1 C2 1.394(5) Cl2 O7 1.456(3) 
C2 C3 1.380(5) Cl2 O8 1.420(4) 
C3 C5 1.401(4)    
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Table A.1.18 Bond Angles for Cu5(in). 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
N1 Cu1 O1W 99.39(9) C3 C5 C6 116.8(3) 
N1 Cu1 N4 114.54(10) C6 C5 C4 122.2(3) 
N2 Cu1 O1W 94.90(9) N1 C6 C5 122.5(2) 
N2 Cu1 N1 81.25(10) N1 C6 C7 114.4(2) 
N2 Cu1 N3 82.00(11) C5 C6 C7 123.1(3) 
N2 Cu1 N4 163.13(11) N2 C7 C6 115.1(3) 
N3 Cu1 O1W 103.73(10) N2 C8 C9 116.6(2) 
N3 Cu1 N1 152.43(10) N2 C8 C13 105.3(2) 
N3 Cu1 N4 81.14(11) C9 C8 C13 110.5(2) 
N4 Cu1 O1W 88.53(9) C8 C9 C10 108.8(2) 
O2 Cl1 O1 108.33(14) C9 C10 C11 112.4(3) 
O2 Cl1 O4 110.85(16) C12 C11 C10 112.3(3) 
O3 Cl1 O1 109.47(14) C13 C12 C11 108.5(2) 
O3 Cl1 O2 110.19(15) N3 C13 C8 105.7(2) 
O3 Cl1 O4 109.75(16) N3 C13 C12 117.2(2) 
O4 Cl1 O1 108.21(17) C12 C13 C8 111.2(2) 
C1 N1 Cu1 128.8(2) N3 C14 C15 115.5(3) 
C1 N1 C6 119.4(2) N4 C15 C14 114.1(3) 
C6 N1 Cu1 111.58(18) N4 C15 C17 122.7(3) 
C7 N2 Cu1 117.6(2) C17 C15 C14 123.1(3) 
C7 N2 C8 128.7(2) C15 C17 C16 121.9(3) 
C8 N2 Cu1 113.67(18) C15 C17 C18 117.5(3) 
C13 N3 Cu1 115.10(19) C18 C17 C16 120.7(3) 
C14 N3 Cu1 117.2(2) C19 C18 C17 120.0(3) 
C14 N3 C13 127.7(3) C20 C19 C18 118.6(3) 
C15 N4 Cu1 111.41(19) N4 C20 C19 122.7(3) 
C20 N4 Cu1 129.7(2) O5 Cl2 O7 107.3(2) 
C20 N4 C15 118.5(3) O6 Cl2 O5 111.45(18) 
N1 C1 C2 121.6(3) O6 Cl2 O7 107.18(18) 
C3 C2 C1 119.0(3) O8 Cl2 O5 109.24(18) 
C2 C3 C5 120.6(3) O8 Cl2 O6 111.2(2) 
C3 C5 C4 121.0(3) O8 Cl2 O7 110.4(3) 
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Table A.1.19 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for Cu5(in). 
Atom x y z U(eq)  
H1WA 6870 5651 6469 42  
H1WB 6495 4692 6702 42  
H1 2736 7582 7350 30  
H2 2372 9456 7300 34  
H3 2494 10293 6560 33  
H4A 4309 9338 5556 44  
H4B 2867 10232 5721 44  
H4C 2136 9162 5478 44  
H7 3444 7265 5507 24  
H8 4618 4740 5645 25  
H9A 3930 5767 4958 30  
H9B 1751 5616 5047 30  
H10A 4313 3901 4833 35  
H10B 2718 4311 4489 35  
H11A 379 3598 4985 38  
H11B 1815 2663 4867 38  
H12A 1043 2682 5697 30  
H12B 3229 2839 5621 30  
H13 643 4575 5761 26  
H14 1539 2811 6536 26  
H16A 2683 1491 7308 46  
H16B 595 1793 7176 46  
H16C 1118 1504 7705 46  
H18 2093 2920 8239 31  
H19 2824 4745 8378 32  
H20 3211 5901 7734 31  
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Table A.1.19 Cu6 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu6. Ueq is defined as 1/3 of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Cu1 3214.5(13) 3850.9(10) 3321.8(4) 63.8(5) 
O9 863(11) 4350(20) 3682(4) 168(9) 
N1 2568(8) 4177(7) 2664(3) 54.4(16) 
N2 2745(10) 2127(8) 3128(3) 65(2) 
N3 3575(8) 3140(6) 3960(2) 50.7(14) 
N4 4278(7) 5272(6) 3608(3) 48.9(14) 
C1 2834(11) 5176(9) 2398(4) 66(2) 
C2 2315(11) 5244(10) 1944(4) 67(2) 
C3 1542(10) 4284(9) 1760(3) 57.5(19) 
C4 427(15) 2167(11) 1820(3) 72(3) 
C5 1234(9) 3219(8) 2022(3) 52.4(17) 
C6 1803(10) 3225(8) 2475(3) 51.4(16) 
C7 1607(10) 2153(8) 2785(3) 56.8(19) 
C8 2489(9) 1407(6) 3549(3) 49.0(16) 
C9 2583(10) 38(7) 3458(3) 54.6(17) 
C10 2520(10) -673(7) 3910(3) 54.1(17) 
H011 -510(30) 4138(18) 3801(13) 175(14) 
C11 3787(11) -238(8) 4247(3) 58.4(19) 
C12 3639(10) 1117(8) 4347(3) 51.8(16) 
C13 3703(9) 1801(7) 3899(3) 46.2(15) 
C14 4960(10) 3702(7) 4158(3) 53.3(17) 
C15 5116(9) 5007(7) 3988(3) 52.7(17) 
C16 6915(17) 5489(12) 4630(4) 83(3) 
C17 6089(11) 5802(9) 4200(3) 61(2) 
C18 6233(10) 6962(9) 4012(3) 60(2) 
C19 5344(12) 7261(9) 3619(4) 65(2) 
C20 4380(11) 6411(8) 3436(4) 61(2) 
Cl1 3302(3) 4066(3) 5503.7(9) 75.7(8) 
O1 2638(16) 3650(12) 5911(3) 114(4) 
O2 3416(19) 5380(10) 5527(4) 115(4) 
O3 4786(13) 3600(19) 5412(4) 138(6) 
O4 2439(15) 3600(18) 5134(5) 152(7) 
Cl2 6722(3) 3717(2) 2739.1(7) 61.8(6) 
O5 6404(9) 4962(7) 2705(3) 69.1(17) 
O6 6103(10) 3218(8) 3145(3) 78(2) 
O7 5854(18) 3132(8) 2365(3) 109(4) 
O8 8233(14) 3436(14) 2647(5) 142(6) 
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Table A.1.19 Anisotropic Displacement Parameters (Å2×103) for Cu6. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cu1 54.0(7) 58.3(6) 79.3(8) 17.2(5) -27.4(5) -11.8(5) 
O9 51(4) 360(30) 94(6) -47(11) 23(5) -43(9) 
N1 37(3) 60(4) 66(4) 14(3) -7(3) 0(3) 
N2 57(4) 67(4) 72(4) 15(4) -23(4) -6(3) 
N3 46(3) 49(3) 57(3) 1(3) 0(3) 1(3) 
N4 33(3) 48(3) 65(4) 2(3) -1(3) 5(2) 
C1 51(5) 64(5) 83(6) 21(5) -15(4) -9(4) 
C2 55(5) 72(5) 73(5) 18(5) -5(4) 7(4) 
C3 49(4) 66(4) 58(4) 7(3) -8(3) 14(4) 
C4 75(6) 82(6) 58(4) -9(5) 3(5) -3(5) 
C5 43(4) 65(5) 50(4) -3(3) 0(3) 10(3) 
C6 41(3) 56(4) 58(4) 7(3) 8(3) 8(3) 
C7 48(4) 56(4) 66(5) 9(3) 5(4) 1(4) 
C8 45(4) 44(3) 57(4) 1(3) -4(3) 2(3) 
C9 49(4) 49(4) 66(4) 2(3) -3(4) -4(3) 
C10 51(4) 50(4) 61(4) 5(3) 4(4) 1(3) 
H011 107(12) 80(10) 340(40) -10(15) 97(19) -6(9) 
C11 59(5) 61(5) 55(4) 8(4) 1(4) 8(4) 
C12 49(4) 59(4) 48(3) 3(3) 2(3) 2(3) 
C13 41(3) 47(4) 51(4) 0(3) 5(3) 3(3) 
C14 53(4) 50(4) 57(4) 1(3) -6(3) -8(4) 
C15 44(4) 51(4) 64(4) -1(3) 3(3) -1(3) 
C16 86(8) 86(7) 79(6) -10(5) -24(6) -17(6) 
C17 53(4) 62(5) 68(5) -3(4) 3(4) -3(4) 
C18 44(4) 63(5) 74(5) -9(4) 5(4) -6(4) 
C19 60(5) 52(4) 81(6) 2(4) 16(5) -3(4) 
C20 50(4) 52(4) 82(5) 4(4) 4(4) 4(3) 
Cl1 56.7(12) 104.1(19) 66.4(12) -5.8(12) 1(1) -21.3(13) 
O1 130(9) 121(8) 89(6) -24(6) 28(6) -34(7) 
O2 149(11) 87(6) 109(7) -4(5) -15(8) 3(7) 
O3 70(6) 233(18) 109(7) -29(9) 18(5) -28(9) 
O4 94(7) 241(17) 122(8) -86(10) -2(7) -62(10) 
Cl2 61.3(12) 59.7(11) 64.4(11) -4.6(8) 18.0(9) -1.4(10) 
O5 67(4) 67(4) 73(4) 1(3) 13(3) -6(3) 
O6 76(5) 84(5) 76(4) 22(4) 23(4) 18(4) 
O7 186(12) 70(5) 70(4) -20(4) -35(6) 18(6) 
O8 89(7) 164(11) 174(11) 75(10) 75(8) 51(8) 
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Table A.1.20 Bond Lengths for Cu6. 
Atom Atom Length/Å Atom Atom Length/Å 
Cu1 O9 2.367(11) C8 C13 1.530(11) 
Cu1 N1 2.019(8) C9 C10 1.528(12) 
Cu1 N2 2.033(9) C10 C11 1.551(13) 
Cu1 N3 2.033(7) C11 C12 1.534(13) 
Cu1 N4 2.006(7) C12 C13 1.504(10) 
N1 C1 1.367(12) C14 C15 1.533(11) 
N1 C6 1.362(12) C15 C17 1.368(13) 
N2 C7 1.403(12) C16 C17 1.480(15) 
N2 C8 1.474(11) C17 C18 1.401(14) 
N3 C13 1.497(10) C18 C19 1.415(15) 
N3 C14 1.475(10) C19 C20 1.370(14) 
N4 C15 1.354(11) Cl1 O1 1.392(11) 
N4 C20 1.359(11) Cl1 O2 1.461(12) 
C1 C2 1.393(15) Cl1 O3 1.418(14) 
C2 C3 1.367(15) Cl1 O4 1.406(10) 
C3 C5 1.428(13) Cl2 O5 1.410(8) 
C4 C5 1.481(14) Cl2 O6 1.406(7) 
C5 C6 1.404(12) Cl2 O7 1.471(10) 
C6 C7 1.498(11) Cl2 O8 1.380(10) 
C8 C9 1.541(11)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
130!!
Table A.1.21 Bond Angles for Cu6. 
Atom Atom Atom  Angle/˚ Atom Atom Atom  Angle/˚ 
N1 Cu1 O9 97.6(4) N2 C8 C9 112.5(7) 
N1 Cu1 N2 81.4(3) N2 C8 C13 106.8(6) 
N1 Cu1 N3 165.9(3) C13 C8 C9 110.9(6) 
N2 Cu1 O9 99.7(6) C10 C9 C8 111.1(7) 
N3 Cu1 O9 79.9(5) C9 C10 C11 110.7(7) 
N3 Cu1 N2 85.3(3) C12 C11 C10 111.3(7) 
N4 Cu1 O9 91.9(5) C13 C12 C11 109.1(6) 
N4 Cu1 N1 112.2(3) N3 C13 C8 108.0(6) 
N4 Cu1 N2 160.9(3) N3 C13 C12 113.3(6) 
N4 Cu1 N3 81.8(3) C12 C13 C8 113.7(7) 
C1 N1 Cu1 128.9(7) N3 C14 C15 110.3(7) 
C6 N1 Cu1 112.1(5) N4 C15 C14 114.7(7) 
C6 N1 C1 118.9(8) N4 C15 C17 124.0(8) 
C7 N2 Cu1 108.6(6) C17 C15 C14 121.2(8) 
C7 N2 C8 119.3(7) C15 C17 C16 121.8(9) 
C8 N2 Cu1 108.1(6) C15 C17 C18 118.2(9) 
C13 N3 Cu1 106.8(5) C18 C17 C16 119.9(9) 
C14 N3 Cu1 108.4(5) C17 C18 C19 118.5(9) 
C14 N3 C13 113.7(6) C20 C19 C18 119.2(9) 
C15 N4 Cu1 114.5(5) N4 C20 C19 122.4(9) 
C15 N4 C20 117.6(8) O1 Cl1 O2 108.6(8) 
C20 N4 Cu1 127.4(6) O1 Cl1 O3 114.7(10) 
N1 C1 C2 121.3(9) O1 Cl1 O4 107.5(8) 
C3 C2 C1 119.1(9) O3 Cl1 O2 108.0(11) 
C2 C3 C5 121.9(8) O4 Cl1 O2 116.0(10) 
C3 C5 C4 122.0(8) O4 Cl1 O3 102.3(9) 
C6 C5 C3 115.2(8) O5 Cl2 O7 106.2(5) 
C6 C5 C4 122.7(8) O6 Cl2 O5 111.5(5) 
N1 C6 C5 123.5(8) O6 Cl2 O7 104.1(7) 
N1 C6 C7 115.5(7) O8 Cl2 O5 113.3(7) 
C5 C6 C7 121.0(8) O8 Cl2 O6 116.0(6) 
N2 C7 C6 111.0(8) O8 Cl2 O7 104.5(10) 
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Table A.1.22 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for Cu6. 
Atom x y  z U(eq) 
H1  3371 5823  2524 79 
H2  2493 5932  1768 80 
H3  1207 4326  1455 69 
H4A  1045 1456  1858 108 
H4B  250 2306  1497 108 
H4C  -537 2055  1974 108 
H7A  605 2185  2930 68 
H7B  1662 1420  2603 68 
H8  1472 1598  3673 59 
H9A  1737 -205  3261 65 
H9B  3532 -145  3298 65 
H10A  2658 -1525  3846 65 
H10B  1522 -567  4052 65 
H11A  3710 -685  4534 70 
H11B  4786 -400  4113 70 
H12A  2675 1277  4503 62 
H12B  4468 1375  4548 62 
H13  4708 1641  3760 55 
H14A  5859 3244  4068 64 
H14B  4894 3693  4492 64 
H16A  6187 5312  4869 125 
H16B  7545 6156  4723 125 
H16C  7549 4794  4576 125 
H18  6898 7523  4142 72 
H19  5413 8025  3488 77 
H20  3774 6621  3184 74 
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Table A.1.23 Cu6(in) Fractional Atomic Coordinates (×104) and Equivalent 
Isotropic Displacement Parameters (Å2×103) for Cu6(in). Ueq is defined as 1/3 of the 
trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
Cu1 6907.4(6) 4339.7(3) 3395.3(2) 25.07(19) 
O1W 3773(4) 4612(2) 3290.6(9) 31.7(6) 
N1 6982(4) 2698(2) 3336.6(10) 25.8(6) 
N2 6697(4) 3972(2) 4068.9(10) 23.5(6) 
N3 7802(4) 5722(2) 3659.0(11) 26.8(6) 
N4 7376(4) 5152(2) 2773.1(11) 26.9(6) 
C1 7224(5) 2083(3) 2947.5(13) 28.0(7) 
C2 7431(5) 956(3) 2976.6(14) 32.9(8) 
C3 7354(5) 458(3) 3417.3(15) 32.0(7) 
C4 6925(6) 538(3) 4310.1(14) 33.3(7) 
C5 7060(5) 1078(3) 3831.2(13) 27.4(7) 
C6 6904(5) 2205(3) 3772.9(12) 23.8(6) 
C7 6685(4) 2974(3) 4177.5(12) 23.7(6) 
C8 6635(5) 4927(3) 4384.8(12) 24.6(6) 
C9 7011(6) 4722(3) 4914.1(12) 29.1(7) 
C10 6959(6) 5809(3) 5178.9(13) 33.5(8) 
C11 8327(6) 6647(3) 4965.8(14) 36.7(8) 
C12 7995(6) 6831(3) 4432.9(13) 29.8(7) 
C13 8095(5) 5729(3) 4178.4(12) 25.9(6) 
C14 8097(5) 6496(3) 3365.5(12) 25.8(6) 
C15 7822(5) 6218(3) 2852.5(12) 25.1(7) 
C16 8450(6) 8152(3) 2583.9(15) 35.4(8) 
C17 8033(5) 6972(3) 2486.4(12) 28.1(7) 
C18 7779(5) 6601(3) 2016.4(13) 30.3(7) 
C19 7336(5) 5514(3) 1934.5(13) 31.3(7) 
C20 7123(5) 4821(3) 2320.4(13) 29.6(7) 
Cl1 11742.2(11) 2994.2(7) 4285.2(3) 29.0(2) 
O1 11005(4) 3488(2) 3848.2(10) 36.2(6) 
O2 10196(4) 2612(2) 4574.5(11) 39.0(6) 
O3 12777(4) 3816(3) 4542.6(12) 46.2(8) 
O4 12953(4) 2100(2) 4154.8(11) 37.6(6) 
Cl2 3023.5(14) 7512.5(7) 3583.4(3) 33.9(3) 
O5 1453(4) 8256(2) 3609.3(12) 39.5(6) 
O6 2735(8) 6829(3) 3168.4(13) 73.8(14) 
O7 3080(6) 6810(2) 3986.7(11) 47.2(7) 
O8 4725(6) 8116(4) 3539(3) 94(2) 
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Table A.1.24 Anisotropic Displacement Parameters (Å2×103) for Cu6(in). The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cu1 35.9(3) 21.6(2) 17.8(3) -0.97(14) 0.56(15) -3.38(16) 
O1W 35.9(12) 32.5(13) 26.7(14) 1.7(10) 0.2(9) 0.3(10) 
N1 30.7(13) 23.9(13) 22.7(14) -1.4(10) 1.7(12) -2.6(11) 
N2 27.3(12) 24.3(13) 19.1(14) -1.1(10) -0.6(10) -0.2(10) 
N3 33.8(13) 26.0(13) 20.7(15) -1.3(11) -1(1) -3.1(12) 
N4 32.7(14) 25.4(13) 22.6(15) -2.1(11) 0.4(10) -1.0(11) 
C1 37.1(17) 27.8(16) 19.1(16) -1.5(12) 2.6(13) -4.7(13) 
C2 42.0(19) 29.6(17) 27.0(19) -8.0(13) 6.6(14) -2.8(13) 
C3 42.5(18) 23.5(15) 30.1(19) -2.7(13) 3.5(14) 0.0(13) 
C4 46.2(19) 25.7(15) 28.0(19) 2.5(12) 0.4(14) -0.3(16) 
C5 29.8(15) 24.6(15) 27.7(18) -0.5(12) 1.2(13) -0.5(13) 
C6 25.6(13) 25.0(14) 20.8(15) -0.4(11) -2.3(12) -1.1(12) 
C7 23.5(13) 26.3(15) 21.3(16) -1.4(12) 0.8(11) 0.8(12) 
C8 31.9(15) 23.2(14) 18.6(16) -2.5(11) -0.8(12) -0.1(12) 
C9 39.7(17) 29.2(15) 18.4(17) 1.1(12) 1.1(13) 0.9(15) 
C10 52(2) 31.5(17) 17.4(17) -2.9(12) 1.6(14) 0.4(16) 
C11 52(2) 32.0(17) 26.2(19) -5.7(13) -2.7(16) -8.0(16) 
C12 42.7(17) 23.6(15) 23.2(17) -3.8(12) -1.0(15) -4.8(14) 
C13 33.6(15) 26.7(15) 17.5(16) -3.2(11) -1.4(12) -1.9(15) 
C14 31.8(15) 23.6(14) 22.1(17) -2.6(11) 2.1(13) -3.0(13) 
C15 28.5(16) 23.9(15) 22.9(18) -2.2(12) 0.7(12) -1.7(12) 
C16 49(2) 27.6(17) 29(2) 3.1(13) -2.6(15) -3.2(15) 
C17 33.2(15) 28.0(16) 23.1(17) 1.2(12) 0.7(13) -0.3(14) 
C18 36.0(17) 33.2(17) 21.7(18) 3.8(13) 0.8(13) 1.1(14) 
C19 38.9(17) 36.0(18) 18.9(17) -4.6(13) -1.5(12) 2.2(14) 
C20 38.2(17) 27.0(15) 23.7(17) -3.8(13) -1.5(13) 0.5(15) 
Cl1 28.6(4) 33.3(4) 25.2(4) -0.6(3) 2.6(3) 0.9(3) 
O1 34.8(12) 39.3(14) 34.5(15) 4.6(11) 4.1(11) 3.0(11) 
O2 33.9(13) 45.4(15) 37.6(15) 11.7(12) 8.2(11) 3.8(12) 
O3 40.7(15) 58.2(19) 39.7(18) -17.7(14) 2.6(12) -7.0(14) 
O4 36.7(13) 38.7(14) 37.3(15) 0.6(11) 1.6(12) 7.7(12) 
Cl2 42.4(5) 31.3(4) 28.0(5) 7.1(3) -0.7(3) 0.5(4) 
O5 42.5(15) 34.4(14) 41.7(16) 1.0(12) -1.7(12) -2.0(11) 
O6 138(4) 57(2) 26.2(18) -1.9(14) -6(2) 37(2) 
O7 76(2) 38.1(14) 27.2(15) 6.4(11) -3.9(15) 5.1(15) 
O8 41.9(18) 62(2) 179(6) 58(3) -3(2) -0.2(17) 
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Table A.1.25 Bond Lengths for Cu6(in). 
Atom Atom Length/Å   Atom Atom Length/Å 
Cu1 O1W 2.264(3)   C8 C13 1.541(5) 
Cu1 N1 2.025(3)   C9 C10 1.528(5) 
Cu1 N2 1.944(3)   C10 C11 1.534(6) 
Cu1 N3 1.957(3)   C11 C12 1.527(5) 
Cu1 N4 2.034(3)   C12 C13 1.532(4) 
N1 C1 1.336(4)   C14 C15 1.488(5) 
N1 C6 1.364(4)   C15 C17 1.390(5) 
N2 C7 1.264(4)   C16 C17 1.504(5) 
N2 C8 1.470(4)   C17 C18 1.404(5) 
N3 C13 1.468(5)   C18 C19 1.391(5) 
N3 C14 1.274(5)   C19 C20 1.384(5) 
N4 C15 1.366(5)   Cl1 O1 1.461(3) 
N4 C20 1.343(5)   Cl1 O2 1.440(3) 
C1 C2 1.396(5)   Cl1 O3 1.441(3) 
C2 C3 1.378(6)   Cl1 O4 1.440(3) 
C3 C5 1.402(5)   Cl2 O5 1.441(3) 
C4 C5 1.498(5)   Cl2 O6 1.448(4) 
C5 C6 1.399(5)   Cl2 O7 1.422(3) 
C6 C7 1.483(4)   Cl2 O8 1.420(4) 
C8 C9 1.526(5)         
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Table A.1.26 Bond Angles for Cu6(in). 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 Cu1 O1W 99.33(11)   N2 C8 C9 116.5(3) 
N1 Cu1 N4 114.52(12)   N2 C8 C13 105.4(3) 
N2 Cu1 O1W 94.85(11)   C9 C8 C13 110.6(3) 
N2 Cu1 N1 81.31(12)   C8 C9 C10 108.8(3) 
N2 Cu1 N3 82.02(12)   C9 C10 C11 112.5(3) 
N2 Cu1 N4 163.05(12)   C12 C11 C10 112.5(3) 
N3 Cu1 O1W 103.78(11)   C11 C12 C13 108.4(3) 
N3 Cu1 N1 152.47(12)   N3 C13 C8 105.8(3) 
N3 Cu1 N4 81.04(13)   N3 C13 C12 117.3(3) 
N4 Cu1 O1W 88.66(11)   C12 C13 C8 111.1(3) 
C1 N1 Cu1 129.2(2)   N3 C14 C15 115.4(3) 
C1 N1 C6 119.0(3)   N4 C15 C14 114.0(3) 
C6 N1 Cu1 111.6(2)   N4 C15 C17 123.0(3) 
C7 N2 Cu1 117.4(2)   C17 C15 C14 123.0(3) 
C7 N2 C8 129.1(3)   C15 C17 C16 122.0(3) 
C8 N2 Cu1 113.6(2)   C15 C17 C18 117.4(3) 
C13 N3 Cu1 115.1(2)   C18 C17 C16 120.5(3) 
C14 N3 Cu1 117.2(2)   C19 C18 C17 119.7(3) 
C14 N3 C13 127.7(3)   C20 C19 C18 119.2(3) 
C15 N4 Cu1 111.7(2)   N4 C20 C19 122.4(3) 
C20 N4 Cu1 129.6(2)   O2 Cl1 O1 109.52(17) 
C20 N4 C15 118.4(3)   O2 Cl1 O3 109.50(19) 
N1 C1 C2 121.8(3)   O3 Cl1 O1 108.0(2) 
C3 C2 C1 119.2(3)   O4 Cl1 O1 108.48(17) 
C2 C3 C5 120.3(3)   O4 Cl1 O2 110.27(18) 
C3 C5 C4 120.5(3)   O4 Cl1 O3 111.01(19) 
C6 C5 C3 116.9(3)   O5 Cl2 O6 107.4(2) 
C6 C5 C4 122.5(3)   O7 Cl2 O5 111.5(2) 
N1 C6 C5 122.7(3)   O7 Cl2 O6 106.8(2) 
N1 C6 C7 113.9(3)   O8 Cl2 O5 109.1(2) 
C5 C6 C7 123.3(3)   O8 Cl2 O6 110.7(4) 
N2 C7 C6 115.7(3)   O8 Cl2 O7 111.2(3)  
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Table A.1.27 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for Cu6(in). 
Atom x y z U(eq) 
H1WA 3482 5307 3311 48 
H1WB 3121 4320 3526 48 
H1 7256 2416 2649 34 
H2 7618 545 2702 39 
H3 7498 -292 3440 38 
H4A 7897 816 4516 50 
H4B 7082 -233 4273 50 
H4C 5711 686 4448 50 
H7 6547 2736 4491 28 
H8 5383 5259 4355 29 
H9A 8237 4383 4955 35 
H9B 6059 4236 5043 35 
H10A 7280 5690 5512 40 
H10B 5686 6099 5167 40 
H11A 8181 7332 5133 44 
H11B 9613 6398 5014 44 
H12A 8949 7318 4306 36 
H12B 6766 7160 4382 36 
H13 9351 5424 4240 31 
H14 8458 7187 3465 31 
H16A 8852 8499 2294 53 
H16B 9432 8206 2819 53 
H16C 7331 8503 2701 53 
H18 7905 7080 1761 36 
H19 7186 5256 1624 38 
H20 6792 4100 2264 36 
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Table A.1.28 Cu7 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for Cu7. Ueq is defined as 1/3 of the trace of the 
orthogonalised UIJ tensor. 
Atom x y z U(eq) 
Cu1 6263.0(7) 5303.6(6) 3604.3(4) 60.3(5) 
Cl2 3988.9(14) 4167.5(14) 3412.5(9) 68.2(7) 
O5 3113(4) 4054(4) 3790(3) 75.8(15) 
O6 4788(5) 4369(6) 3802(4) 108(2) 
O7 4043(9) 3686(9) 2879(6) 181(6) 
O8 3811(9) 4945(14) 3048(12) 242(11) 
N1 5692(4) 6362(4) 3958(3) 57.4(14) 
N2 5838(5) 5797(4) 2750(3) 65.4(16) 
N3 6869(6) 4402(5) 3045(3) 73.5(18) 
N4 6764(5) 4611(4) 4346(3) 61.4(15) 
C1 5424(5) 6546(5) 4586(3) 61.3(17) 
C2 5181(6) 7339(5) 4779(4) 70(2) 
C3 4095(9) 9071(8) 4541(7) 108(4) 
C4 5083(10) 8876(7) 4518(7) 112(4) 
C5 5264(7) 8001(6) 4319(5) 86(2) 
C6 5517(7) 7791(7) 3652(5) 82(2) 
C7 5688(5) 6954(5) 3501(3) 59.3(17) 
C8 5977(6) 6685(6) 2804(4) 72(2) 
C9 6366(6) 5356(7) 2204(4) 78(3) 
C10 6415(6) 4454(6) 2390(4) 71(2) 
C11 6840(7) 3659(7) 3389(5) 83(3) 
C12 6987(5) 3823(5) 4137(4) 63.8(18) 
C13 7290(6) 3231(5) 4595(4) 70(2) 
C14 7415(6) 3431(6) 5252(5) 78(2) 
C15 7172(8) 2809(6) 6384(4) 80(2) 
C16 7769(9) 2825(6) 5761(5) 95(3) 
C17 7209(7) 4242(5) 5428(4) 76(2) 
C18 6911(7) 4792(5) 4967(4) 72(2) 
Cl1 8750.9(15) 6190.7(15) 3447.3(11) 73.5(7) 
O1 8720(6) 6582(8) 2810(4) 127(3) 
O2 9547(5) 6569(6) 3764(4) 113(3) 
O3 8957(8) 5312(6) 3383(7) 132(4) 
O4 7853(6) 6268(5) 3776(4) 104(2) 
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Table A.1.29 Anisotropic Displacement Parameters (Å2×103) for Cu7. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
Cu1 60.9(7) 78.1(8) 41.8(6) -7.8(4) 1.2(3) 6.8(4) 
Cl2 53(1) 101.3(15) 50.3(10) 0.2(9) 1.8(7) -8.8(9) 
O5 59(3) 98(4) 70(3) 1(3) 11(3) -4(3) 
O6 69(4) 153(6) 101(5) -2(5) -14(4) -18(4) 
O7 156(9) 252(13) 136(8) -121(9) 74(7) -115(9) 
O8 116(9) 294(18) 320(20) 221(19) -45(10) -36(9) 
N1 48(3) 82(4) 42(3) -6(3) 0(2) 1(3) 
N2 65(4) 90(4) 42(3) -5(3) 8(3) 6(3) 
N3 79(4) 86(4) 55(4) -14(3) -4(3) 19(4) 
N4 62(4) 62(3) 60(4) -6(3) -6(3) 6(3) 
C1 55(4) 81(4) 48(3) -8(3) 0(3) 6(3) 
C2 66(4) 81(5) 65(4) -15(4) 2(4) 12(4) 
C3 98(8) 119(8) 106(8) -21(7) -36(7) 7(6) 
C4 100(8) 107(8) 128(10) -13(7) 5(7) 16(6) 
C5 79(6) 96(6) 84(6) -12(5) -2(5) 12(5) 
C6 68(5) 102(7) 75(5) 6(5) -5(4) 14(5) 
C7 52(4) 75(4) 51(4) 3(3) -1(3) 5(3) 
C8 63(4) 106(6) 46(4) 10(4) 2(3) 7(4) 
C9 62(5) 134(8) 39(4) -13(4) 7(3) -6(4) 
C10 61(4) 104(6) 49(4) -25(4) 4(3) 8(4) 
C11 62(5) 112(7) 75(5) -33(5) -4(4) 23(5) 
C12 54(4) 71(4) 66(4) -5(3) 5(3) 6(3) 
C13 65(4) 66(4) 81(5) -7(4) 8(4) 10(3) 
C14 67(5) 82(5) 84(6) 16(4) 11(4) 12(4) 
C15 91(6) 74(5) 75(6) 3(4) 3(4) 2(4) 
C16 107(7) 86(6) 91(7) 24(5) 33(6) 27(5) 
C17 91(6) 75(5) 64(5) -6(4) 2(4) 13(4) 
C18 81(5) 71(4) 64(5) -7(4) -9(4) 16(4) 
Cl1 61.5(12) 100.1(16) 59.0(11) -11.3(10) -1.8(8) -6.9(9) 
O1 98(6) 207(10) 76(5) 23(6) 6(4) -4(5) 
O2 70(4) 168(7) 100(5) -39(5) -10(4) -19(4) 
O3 108(7) 116(7) 172(10) -32(6) -6(7) -4(5) 
O4 89(5) 123(6) 99(5) -9(4) 10(4) -4(4) 
  
! !
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A.2. NMR Spectra 
!
A.2.1 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-diiminoethane, 
L1(in). 
!
1H!NMR!
13C NMR 
COSY 
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A.2.2 NMR spectra of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diiminoethane, 
L2(in). 
! !
1H!NMR!
13C!NMR 
COSY 
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A.2.3 NMR spectra of N,Nʹ-bis(5-chloro-2-pyridylmethyl)-1,2-diiminoethane, 
L3(in). 
!
1H!NMR!
13C!NMR!
COSY 
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A.2.4 NMR spectra of N,Nʹ-bis(6-bromo-2-pyridylmethyl)-1,2-diiminoethane, 
L4(in). 
1H NMR 
13C!NMR!
COSY 
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A.2.5 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-R’R’-1,2-
diiminocyclohexane, L5(in). 
!
1H NMR 
13C!NMR!
COSY 
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A.2.6 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-S’S’-1,2-
diiminocyclohexane, L6(in). 
1H NMR 
13C!NMR!
COSY 
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A.2.7 NMR spectra of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diiminoethane, 
L7(in)  
! !
1H!NMR!
13C!NMR!
COSY 
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A.2.8 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1,2-diaminoethane, L1.   
! !
1H!NMR!
13C!NMR!
COSY 
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A.2.9 NMR spectra of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diaminoethane, L2. 
! !
1H!NMR!
13C NMR 
COSY 
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A.2.10 NMR spectra of N,Nʹ-bis(5-chloro-2-pyridylmethyl)-1,2-diaminoethane L3. 
! !
1H!NMR!
13C!NMR!
COSY 
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A.2.11 NMR spectra of N,Nʹ-bis(6-bromo-2-pyridylmethyl)-1,2-diaminoethane, L4.   
! !
1H!NMR!
13C!NMR!
COSY 
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A.2.12 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1R,2R-
diaminocyclohexane, L5.  !
!
1H!NMR!
13C!NMR!
COSY 
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A.2.13 NMR spectra of N,Nʹ-bis(3-methyl-2-pyridylmethyl)-1S,2S-
diaminocyclohexane, L6. 
! !
1H!NMR!
13C!NMR!
COSY 
152!!
A.2.14 NMR spectra of N,Nʹ-bis(4-methyl-2-pyridylmethyl)-1,2-diaminoethane, L7.  
! !
1H!NMR!
13C!NMR!
COSY 
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!
A.3. U.V Spectroscopy 
A.3.1 UV spectrum of L1(in), in chloroform. 
A.3.2 UV spectrum of L2(in), in chloroform. 
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A.3.3 UV spectrum of L3(in), in chloroform. 
A.3.4 UV spectrum of L4(in), in chloroform. 
!
!
!
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!
A.3.5 UV spectrum of L5(in), in chloroform. 
!
!
A.3.6. UV spectrum of L6(in), in chloroform.     
  
!
!
!
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!
!
!
A.3.7. UV spectrum of L7(in), in chloroform. 
A.3.8. UV spectrum of L1, in chloroform. 
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!!
!
!
!
!
!
!
!
!
!
!
!
A.3.9. UV spectrum of L2, in chloroform. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.3.10. UV spectrum of L3, in chloroform. 
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!
A.3.11. UV spectrum of L4, in chloroform. 
!
A.3.12. UV spectrum of L5, in chloroform. 
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!
A.3.13. UV spectrum of L6, in chloroform. 
 
 
A.3.14. UV spectrum of L7, in chloroform. 
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A.3.15. UV spectrum of Cu1(in), in acetonitrile. 
 
 
A.3.16. UV spectrum of Cu2(in), in acetonitrile. 
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A.3.17. UV spectrum of Cu3(in), in acetonitrile. 
 
 
 
A.3.18. UV spectrum of Cu4(in), in acetonitrile. 
! !
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A.3.19. UV spectrum of Cu5(in), in acetonitrile. 
A.3.20. UV spectrum of Cu6(in), in acetonitrile. 
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A.3.21. UV spectrum of Cu7(in), in acetonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.3.22. UV spectrum of Cu1, in acetonitrile. 
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A.3.23. UV spectrum of Cu2, in acetonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.3.24. UV spectrum of Cu3, in acetonitrile. 
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!
A.3.25. UV spectrum of Cu4, in acetonitrile. 
!
A.3.26. UV Spectrum of Cu5, in acetonitrile. 
! !
166!!
 
A.3.27. UV spectrum of Cu6, in acetonitrile.  
!!
A.3.28. UV spectrum of Cu7, in acetonitrile. 
! !
Extinction Coefficient: 
7.3 x 103 + 0.1 !
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A.4. CD Spectra  
 
A.4.1 CD Spectra of L5(in) (black)and L6(in) (red), in acetonitrile. 
 
 
A.4.2 CD Spectra of L5 (black)and L6 (red), in acetonitrile. 
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A.4.3 CD Spectra of Cu5(in) (black)and Cu6(in) (red), in acetonitrile. 
 
 
A.4.4 CD Spectra of Cu5 (black)and Cu6 (red), in acetonitrile. 
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A.5. ESI-MS Spectra 
A.5.1$Mass$$spectrometry$analysis$of$copper(II)$complexes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex Name Molecular Weight (g/mol) Base Peak Molecular Ion (m/z) Abundance of m/z (%) 
Cu1(in) 329.08 133.08 329.08 [M] 95 
Cu2(in) 329.08 133.08 328.07 [M-1H] 75 
Cu3(in) 370.97 153.02 369.97 [M-1H] 30 
Cu4(in) 459.63 198.97 458.87 [M-1H] 28 
Cu5(in) 383.13 382.12 382.12[M-1H] 100 
Cu6(in) 383.13 482.08 382.12[M-1H] 98 
Cu7(in) 357.11 147.09 356.11[M-1H] 20 
Cu1 331.10 332.10 332.10 [M+1H] 100 
Cu2 331.10 332.10 332.10 [M+1H] 100 
Cu3 372.99 373.99 373.99 [M+1H] 100 
Cu4 461.64 262.91 462.90 [M+1H] 52 
Cu5 385.15 317.07 386.15 [M+1H] 40 
Cu6 385.15 106.06 386.15 [M+1H] 91 
Cu7 359.13 211.03 358.12 [M+1H] 45 
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!
A.5.2. Mass spectra of Cu1(in). 
A.5.3. Mass spectra of Cu2(in).
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!
 
A.5.4. Mass spectra of Cu3(in). 
A.5.5. Mass spectra of Cu4(in).
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!
A.5.6. Mass spectra of Cu5(in). 
!
!
A.5.7. Mass spectra of Cu6(in).
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A.5.8. Mass spectra of Cu7(in). 
 
A.5.9. Mass spectra of Cu1. 
!
!
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!A.5.10. Mass spectra of Cu2. 
!
A.5.11. Mass spectra of Cu3. 
!
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A.5.12. Mass spectra of Cu4. 
!
A.5.13. Mass spectra of Cu5
176$$
 
A.5.14. Mass spectra of Cu6. 
!
A.5.15. Mass spectra of Cu7.
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A.6. MIC Testing  
A.6.1. MIC of Cu1-Cu3(in) against S. aureus. 
!
A.6.2. MIC of Cu4(in)-Cu7(in), ampicillin, streptomycin and 5-fluorocytosine 
against S. aureus.!
! !
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A.6.3. MIC of Cu1-Cu3(in) against K. pneumoniae. 
!
A.6.4. MIC of Cu4(in)-Cu7(in), ampicillin, streptomycin and 5-fluorocytosine 
against K. pneumoniae. 
!
!
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A.6.5. MIC of Cu1-Cu3(in) against C. krusei. 
!
!
!
A.6.6. MIC of Cu4(in)-Cu7(in), ampicillin, streptomycin and 5-fluorocytosine 
against C. krusei. 
! !
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
Cu1 Cu2 Cu3 Cu4 Cu5 Cu6 Cu1(in) Cu2(in) 3(in) Blank
O
D
 a
t 5
95
 n
m
Samples
C. krusei 
2μg/mL
4μg/mL
8μg/mL
16μg/mL
32μg/mL
64μg/mL
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
O
D
 a
t 5
95
 n
m
Samples
C. krusei
2μg/mL
4μg/mL
8μg/mL
16μg/mL
32μg/mL
64μg/mL
180$$
A.7. Cytotoxicity Assays 
!
A.7.1: Single concentration (30µM) assay of copper(II) complexes and hydrogenated 
ligands. 
 
A.7.2: Table of A2780 cell growth inhibition (%) to obtain IC50 values. 
  30 µM 10 µM 3.33 µM 1.11 µM 0.37 µM 0.12 µM 0.04 µM 
Cu1 80% 96% 94% 101% 93% 96% 101% 
Cu2 13% 68% 67% 72% 74% 74% 83% 
Cu3 1% 2% 28% 69% 74% 73% 85% 
Cu5 3% 9% 51% 71% 68% 68% 79% 
Cu6 3% 19% 61% 69% 68% 67% 78% 
Cu7 2% 20% 84% 90% 88% 82% 94% 
Cu1(in) 67% 81% 75% 83% 84% 87% 89% 
Cu2(in) 12% 58% 58% 62% 63% 66% 71% 
Cu3(in) 1% 2% 26% 64% 66% 66% 74% 
Cu5(in) 3% 9% 50% 68% 67% 71% 80% 
Cu6(in) 3% 18% 59% 66% 66% 66% 78% 
Cu7(in) 3% 21% 80% 85% 88% 80% 94% 
Cisplatin 4% 14% 34% 61% 71% 74% 76% 
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A.8. ESI-MS QDNA Binding Studies 
 
 
 
 
 
 
 
 
 
 
 
A.8.1: 1:1 and 1:3 binding of Cu5(in) to QDNA 1XAV and 1:3 binding of Cu6 to 
QDNA 1XAV (top to bottom). =1XAV 5- + Cu2+; = 1XAV 5- + 2 Cu2+. 
 
 
